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Angiogenesis is one of the limiting steps in tumor progression and metastasis. 
Anti-angiogenesis has become a promising therapeutic strategy for the treatment of 
various malignances. Isthmin (ISM) is a secreted 60 kDa endogenous angiogenesis 
inhibitor potently inducing endothelial cell (EC) apoptosis and suppressing EC 
tube-like structure formation. However, the physiological or pathological significance 
of ISM remains unclear. It is also undetermined whether recombinant ISM can function 
as an effective anticancer agent to suppress tumor growth when delivered systemically. 
In addition, although αvβ5 integrin is important for ISM's pro-apoptotic function, 
whether a cell-surface high-affinity receptor exists for ISM and mediates its function 
remain to be determined.  
First, I demonstrated that systemic delivery of rISM potently suppresses tumor 
growth in B16 melanoma and 4T1 breast carcinoma in syngeneic mouse models. ISM 
triggers apoptosis in both tumor cells and tumor associated endothelial cells (ECs). 
These results indicated that rISM has therapeutic potential in cancer treatment.  
Secondly, ISM induces distinct responses from adherent ECs under different 
physical conditions. Immobilized ISM can provide positive signals that promote ECs 
survival. On the other hand, soluble ISM can induce ECs apoptosis. To understand the 
functional disparity of ISM under different physical status, I hypothesized that soluble 
but not the immobilized ISM can be internalized into cells and only when ISM gets 
internalized it can cause apoptosis. To test this hypothesis, ISM internalization was 
investigated. Indeed, only soluble ISM can be internalized into cells through 
clathrin-dependent endocytosis. Selective internalization of soluble ISM is the reason 
that only soluble ISM is antiangiogenic. These data explained why immobilized and 
soluble ISM exert pro-survival and death-promoting effects on EC respectively and 
shed light on the functional mechanism of an angiogenesis inhibitor exerting opposite 
actions under different physical status. 
Thirdly, a search for cell surface receptors of ISM was conducted by pull down 
assay combined with Mass Spectrometry (MS). In this study, glucose-regulated protein 
 ix 
 
78 (GRP78) was identified as a novel high affinity cell surface receptor of ISM, 
mediating ISM internalization through clathrin-dependent endocytosis.  
Once inside the cell, GRP78 co-targets with ISM to mitochondria. Inside 
mitochondria, ISM interacts with ADP/ATP carriers (AACs) on the inner membrane 
and blocks ATP transport from mitochondria to cytosol thus causing apoptosis. Given 
that cell-surface GRP78 has emerged as an important regulator for cancer/angiogenesis 
signaling and survival, ISM is a promising dual targeting anticancer agent, targeting 
cancer cells as well as cancer ECs. 
I demonstrated that GRP78 and αvβ5 integrin function as independent cell-surface 
receptors for ISM and mediate EC apoptosis through distinct signaling pathways. 
Taken together, this work identifies the importance of cell-surface GRP78 as a 
receptor mediating the antiangiogenic and anti-cancer function of ISM. It also 
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Angiogenesis is the fundamental process of new blood vessel formation from 
the pre-existing vasculatures (Folkman, 1972). It is important in both 
physiological and pathological conditions. In physiological process, 
angiogenesis plays an essential role in growth and development, as well as in 
reproduction and in wound healing. In pathological process, angiogenesis is 
regarded as a hallmark in cancer and various inflammatory and ischemic 
diseases (Carmeliet & Jain, 2000). Under these conditions, angiogenesis is 
influenced by the microenvironment and modulated by a multitude of pro- and 
antiangiogenic factors.  
In all vertebrates, the vascular system formed by blood vessels is crucial 
because it provides cells, tissues and organs a transportation route to supply 
oxygen and nutrients and to discard waste products. And due to the limitation of 
oxygen diffusion (1 mm to 2 mm), a hierarchically branched network of blood 
vessels covers the entire body (Fraisl et al, 2009). Both angiogenesis and 
vasculogenesis contribute to the construction of vascular system. Different from 
angiogenesis, vasculogenesis denotes the de novo blood vessel formation from 
endothelial progenitor cells (Heinke et al, 2012). Angiogensis and 
vasculogenesis can be distinguished by whether there is an established 
vasculature or not. During the embryonic development, vasculogenesis forms 
the primary vascular plexus by endothelial cells (ECs) differentiated from 
mesodermal angioblast precursor cells, after which angiogenesis progressively 
prunes and extends the vascular tree (Risau, 1997). However, angiogenesis is 





Fig. 1.1 Schematic illustration of vasculogenesis and angiogenesis 
During vasculogenesis, the haemangioblasts differentiated from mesodermal cells 
further develop into angioblasts, the precursors of ECs. ECs differentiated from these 
angioblast cells form a primitive vascular plexus. Angiogenesis further remodel and 
expand these pre-existing vessels generated by vasculogenesis. In sprouting 
angiogenesis, endothelial stalk cells proliferate behind the tip cell of a growing sprout 
in response to angiogenic stimulators and form a vascular lumen. Intussusceptive 
angiogenesis includes splitting by the formation of trans-capillary pillars and growing 
of vessels. Recruitment of smooth muscle cells (SMCs) or pericytes is required by both 
forms of angiogenesis to facilitate functional maturation of the nascent vessels. 
(Adopted from (Heinke et al, 2012)) 
 
Generally, angiogenesis can be divided into two principal mechanisms - 
sprouting angiogenesis (true sprouting of capillaries from the vessel of origin) 
and non-sprouting or intussusceptive angiogenesis (capillaries are generated by 
splitting of the vessel of origin) (Heinke et al, 2012). During sprouting 
angiogenesis, ECs on a pre-existing blood vessel are activated by angiogenic 
stimulators such as vascular endothelial growth factor (VEGF) and cytokines. 
Upon stimulation, activated ECs secret protease such as members of the matrix 
metalloproteinase (MMP) family to degrade the extracellular matrix (ECM) 
surrounding the cells for facilitating its migration. Within a capillary, the 
leading ECs in the growing sprout are defined as tip cells. The tip cells integrate 
attractive and chemotactic directional cues presented by local environment and 
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decide on the route for sprout growth (Gerhardt et al, 2003). The highly 
proliferative endothelial stalk cells following the tip cells can establish adherent 
and tight junction to maintain the stability of the new sprout, and form a nascent 
vascular lumen. Finally, supporting cells such as pericytes and smooth muscle 
cells can assist in the maturation of newly formed blood vessels.  
Different from sprouting angiogenesis, ECs in non-sprouting angiogenesis 
invaginate into existing vessels and create a contact zone within the two 
opposing capillary walls. In the following steps, the endothelial bilayer turns 
perforated and an interstitial pillar is formed. Invading pericytes and their 
secreted collagen fibers further stabilize vessel division (Frontczak-Baniewicz 
& Walski, 2002) (Fig. 1.1). These two parallel vessels eventually separate from 
each other through insertion of tissue pillars. This process leads to expansion of 
vessels (Djonov & Makanya, 2005). 
1.2 Angiogenesis in physiology and pathology 
Angiogenesis and vasculogenesis occur primarily and dominantly during the 
embryonic development and endothelial cells turn into quiescent by adulthood. 
In adult physiology, angiogenesis is restricted to reproductive cycle and wound 
healing (Carmeliet, 2005). Under normal physiological processes, angiogenesis 
is tightly regulated by a delicate local balance between proangiogenic and 
antiangiogenic substances. Disturbance of the balance between positive and 
negative regulators can lead to several illnesses. Angiogenesis has been 
reported to be involved in more than 70 disorders so far, and the list is still 
expanding (Carmeliet, 2005). Both insufficient and excessive angiogenesis is 
pernicious (Folkman, 1995). Insufficient angiogenesis results in a variety of 
disorders such as chronic wound (Tonnesen et al, 2000), hair loss (Yano et al, 
2001), ulceration (Jenkinson et al, 2002), ischemia (Friehs et al, 2004; Ye et al, 
2004), Alzheimer’s disease (Zlokovic, 2005), stroke (Slevin et al, 2006), 
hypertension (Sica, 2006) etc. For excessive angiogenesis, the best known 
condition is malignant tumor (Carmeliet, 2005). Many additional processes are 
also affected by abnormal and excessive angiogenesis, such as asthma (Bai & 
Knight, 2005), atherosclerosis (Slevin et al, 2009), endometriosis (Taylor et al, 
2009), psoriasis (Heidenreich et al, 2009), age related macular degeneration 
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(Bressler, 2009), rheumatoid arthritis (Marrelli et al, 2011) and diabetic 
retinopathy (Antonetti et al, 2012), 
1.3 Angiogenesis regulators 
Angiogenesis, as a tightly regulated process, is believed to be modulated by a 
local balance of proangiogenic and antiangiogenic factors. Angiogenic 
stimulators and inhibitors acting in multiple complementary, overlapping and 
independent cellular signaling pathways form a complex network to regulate 
angiogenesis (Quesada et al, 2007). Therefore, a comprehensive understanding 
of the regulatory network of angiogenesis can help to elucidate the mechanism 
of angiogenesis. 
1.3.1 Pro-angiogenic factors 
A variety of angiogenesis stimulators have been reported. Based on 
biological characteristics, they are defined as heparin binding or non-heparin 
binding peptide growth factors, inflammatory mediators, cell adhesion 
molecules, hormones, enzymes, oligosaccharides, hematopoietic factors and 
others (Table 1.1) (Liekens et al, 2001; Otrock et al, 2007). Selected key 
proangiogenic factors are introduced below. 
Table 1.1 Overview of endogenous angiogenesis inducers 
Angiogenic inducers References 
Heparin binding peptide growth factors 
Vascular endothelial growth factor (VEGF) (Lohela et al, 2009) 
Fibroblast growth factor 1 and 2 (FGF-1 
and FGF-2) 
(Beenken & Mohammadi, 
2009) 
Platelet derived growth factor (PDGF) (Andrae et al, 2008) 
Placenta growth factor (PlGF) (Ribatti, 2008) 
Pleiotrophin (PTN) (Perez-Pinera et al, 2008) 
Non-heparin binding peptide growth factors 
Transforming growth factor - α (TGF-α) (Leker et al, 2009) 
Transforming growth factor - β (TGF-β) (Massague, 2012; ten 
Dijke & Arthur, 2007) 




Tumor necrosis factor (TNF)  (Sainson et al, 2008) 
Prostaglandin E2 (Wang & DuBois, 2004) 
Interleukin 3 (IL-3) (Dentelli et al, 1999) 
Interleukin 8 (IL-8)  (Li et al, 2003) 
Cell adhesion molecules 
Integrins (Avraamides et al, 2008) 
Vascular cell adhesion molecule 1 
(VCAM-1) 
(Dong et al, 2011a) 
E-selectin (Koch et al, 1995) 
Vascular endothelial cadherin 
(VE-cadherin) 
(Carmeliet & Collen, 
2000) 
Enzymes 
Cycloxygenase (COX-2) (Toomey et al, 2009) 
Angiogenin (ANG) (Gao & Xu, 2008) 
Matrix metalloproteinases (MMPs) (van Hinsbergh & 
Koolwijk, 2008) 
Oligosaccharides 
Hyaluronan Oligo’s (Savani et al, 2001) 
Other factors 
Nitric oxide (Donnini & Ziche, 2002) 
MicroRNAs (miR-27b, -126, -130a, -210, 
-296, -378 and -17~92 cluster)  
(Suarez & Sessa, 2009) 
1.3.1.1 Vascular endothelial growth factor (VEGF) 
VEGFs are the most important players that are involved in angiogenic 
regulation. VEGF is a subfamily of the platelet-derived growth factor (PDGF) 
family. They are heparin-binding disulfide bond linked homodimeric 
glycoproteins with a molecular weight of approximate 45 kDa (Ferrara & 
Henzel, 1989). VEGFs are predominantly secreted by endothelial, stromal and 
hematopoietic cells in response to hypoxia or stimulation of other growth 
factors, such as interleukins, transforming growth factors and platelet-derived 
growth factors (Cebe-Suarez et al, 2006). At least 7 members of VEGF family 
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have been reported. They are VEGF-A, -B, -C, -D, -E, -F and placenta growth 
factor (PlGF) (Shibuya, 2008; Suto et al, 2005).  
The biological functions of VEGFs are mainly mediated upon binding to 3 
tyrosine kinase receptors (VEGFR-1, -2 and -3) on the cell surface 
(Cebe-Suarez et al, 2006). Among them, VEGFR-2 is the most important 
receptor in VEGF-induced mitogenesis and permeability. VEGF receptors have 
seven immunoglobulin domains in the extracellular portion, a single 
transmembrane domain and an intracellular portion of conserved tyrosine kinase 
sequence (Terman et al, 1991). The interaction between VEGFs and VEGFRs 
leads to receptor dimerization and activation through transphosphorylation in 
the cytoplasmic domain. These receptors are expressed on the cell surface of 
several bone-marrow-derived cells such as endothelial cells (Ferrara & 
Davis-Smyth, 1997), macrophages and hematopoietic cells (Kabrun et al, 1997), 
on vascular smooth muscle cells (Ishida et al, 2001) and on some malignant 
cancer cells (Bellamy, 2002). 
VEGF is important in physiological angiogenesis. vegf gene knockout in 
mice lead to embryonic lethality due to severe developmental anomalies 
including impaired vascular system (Carmeliet et al, 1996; Ferrara et al, 1996). 
In addition, growth arrest and kidney failure were observed in mice under 
systemic administration of soluble VEGFR1 to block the function of VEGFs, 
indicating the role of VEGF in renal development (Gerber et al, 1999). During 
the process of wound healing, VEGF-A reduces barrier properties between 
adjacent endothelial cells and enhances the supply of proteins and cells needed 
to accelerate the formation of granulation tissue in wound edge (Dai et al, 2004; 
Dvorak et al, 1995). During female reproductive cycle, neutralization of 
VEGF-A during the early luteal phase hampers the development of the normally 
extensive capillary bed (Fraser & Lunn, 2000).  
VEGF also plays prominent role in pathological conditions (Ferrara, 2001). 
Considerable evidence shows that VEGF is a major factor in tumor 
angiogenesis (Carmeliet, 2003). VEGF mRNA is significantly up-regulated in a 
large number of tumor types (Ferrara & Davis-Smyth, 1997). In tumor stroma, 
VEGF-A induces the formation of interendothelial junctions, caveolae and 
fenestrations, which facilitate hyperpermeability and transvascular transport of 
macromolecules (Hobbs et al, 1998; Monsky et al, 1999). Tumor cells 
 7 
 
constitutively produce VEGFs that makes tumors the wounds that never heal. 
Elevated level of VEGF and hence enhanced vascular permeability has also 
been reported in other pathological conditions, such as diabetic retinopathy, 
psoriasis, edema and other kinds of inflammations (Aiello et al, 1994; Dvorak et 
al, 1995).  
Several VEGF inhibitors have already been approved by the US Food and 
Drug Administration for the treatment of tumors and neo-vascular 
diseases. They are antibodies or small molecules blocking the function of either 
VEGF/VEGFR2 or downstream events (Carmeliet & Jain, 2011). Avastin, also 
known as Bevacizumab, is a humanized anti-VEGF-A monoclonal antibody, 
which has been demonstrated as an anti-cancer agent (Ferrara et al, 2004; Presta 
et al, 1997).  It has been approved for treating metastatic colorectal cancer 
(Hurwitz et al, 2004), nonsquamous non-small-cell lung cancer (NSCLC) 
(Sandler et al, 2006), recurrent glioblastoma multiforme, metastatic breast 
cancer and metastatic renal cell carcinoma (RCC) in combinatorial 
chemotherapy (Carmeliet & Jain, 2011). In addition to Avastin, small molecules 
targeting VEGFRs have also been proved to have efficacy in cancer therapy. 
Sunitinib and Sorafenib are the most advanced drugs within this group. 
Sunitinib blocks the tyrosine phosphorylation of VEGFRs (Smith et al, 2004) 
and has shown therapeutic promise in imatinib-resistant gastrointestinal stromal 
tumor (Morgan et al, 2005). FDA has approved it for the treatment of both 
gastrointestinal stromal tumor and metastatic renal carcinoma (Motzer et al, 
2007). In the case of Sorafenib, its treatment leads to a remarkable increase in 
progression-free survival in advanced renal cell carcinoma patients (Escudier et 
al, 2007). In 2006, Sorafenib was also approved by the FDA for treating 
metastatic renal cell carcinoma. In addition to these achievements, novel VEGF 
inhibitors are still under investigation.  
1.3.1.2 Fibroblast growth factor (FGF) 
Fibroblast growth factors (FGFs) constitute a large family of polypeptide 
growth and differentiation factors (Ornitz & Itoh, 2001). FGFs possess a high 
binding affinity for heparan sulfate proteoglycans and require heparan sulfate to 
activate their cell-surface FGF receptors (Shing et al, 1984). To date, 23 
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members of FGF family have been reported in human (Beenken & Mohammadi, 
2009; Itoh & Ornitz, 2004). FGF-2 (bFGF) is one of the most well studied and 
effective angiogenic inducers in the FGF family (Dow & deVere White, 2000).  
FGFs exert their cellular functions through binding and activating the 
fibroblast growth factor receptor (FGFR) family of tyrosine kinase receptors in 
a heparan sulfate glycosaminoglycans (HSGAGs)-dependent manner 
(Vlodavsky et al, 1991). To date, four FGFRs (FGFR-1, -2, -3 and -4) have been 
reported. They consist of three extracellular immunoglobulin domains (D1–D3), 
a single transmembrane domain and a cytoplasmic tyrosine kinase domain 
(Mohammadi et al, 2005). Upon activation, FGFRs trigger the cytoplasmic 
downstream signaling pathways resulting in endothelial cell proliferation, 
differentiation, migration, protease production and angiogenesis (Liekens et al, 
2001; Sorensen et al, 2006). 
FGFs play important role in both physiological and pathological conditions 
(Bikfalvi et al, 1997; Liekens et al, 2001). During developmental processes, 
FGFs participate in brain patterning, branching morphogenesis and limb 
development (Beenken & Mohammadi, 2009). In  addition, FGFs are involved 
in adult physiological conditions, such as hematopoiesis (Bruno et al, 1993; 
Harada et al, 1994) and wound healing (Ashton et al, 1995; Liekens et al, 2001; 
Ortega et al, 1998). However, FGFs signaling pathway also acts as a key driver 
of several illnesses, especially tumor growth and progression through the 
dysfunction of cell proliferation, differentiation and angiogenesis in numerous 
tumor types (Carmeliet, 2005; Carmeliet & Jain, 2000). It may underlie the 
mechanism of resistance to anti-vascular endothelial growth factor targeted 
therapy.  
Several agents through inhibiting or modulating FGFs signaling pathways 
are in various stages of development. At first, direct inhibition of FGFRs by 
small molecules has been proved to be of clinical value. Sunitinib is the FDA 
proved receptor tyrosine inhibitor for the treatment of renal cell carcinoma and 
gastrointestinal stromal tumors, which functioning through both VEGFRs and 
FGFRs inhibition (Chow & Eckhardt, 2007). Small-molecule FGFRs 
inhibitors-PD173074, Su5402 and nordihydroguaiaretic acid also show efficacy 
in several myeloma cell lines with abnormal FGFR-3 expression (Grand et al, 
2004; Meyer et al, 2008). Besides small-molecule inhibitors, antibodies against 
 9 
 
FGFR-3 have been reported to effectively induce apoptosis in mouse models of 
multiple myeloma and bladder cancer (Martinez-Torrecuadrada et al, 2008; 
Trudel et al, 2006). 
1.3.2 Angiogenesis inhibitors 
In 1970s, Dr. Judah Folkman first proposed that angiogenesis is a key player 
in tumor progression (Folkman, 1971). Till now, several endogenous 
angiogenic inhibitors were discovered and the list is still expanding (Table 1.2). 
They can be divided into three groups, namely, gene products, natural 
proteolytic fragments and other factors. Selective antiangiogenic agents are 
reviewed below. 
Table 1.2 List of endogenous angiogenesis inhibitors 




A Disintegrin and 
metalloproteinase with 
thrombospondin motifs -1, -2, -5, -8, 
-9 and -12 (ADAMTS-1, -2, -5, -8, -9 
and -12) 
(Dubail et al, 2010; Koo et al, 2010; 
Kumar et al, 2012; Llamazares et al, 2007; 
Vazquez et al, 1999)  
Chondromodulin (Hiraki et al, 1997) 
Interferons (Sidky & Borden, 1987) 
Interleukin-10 and -18 (Cao et al, 1999; Silvestre et al, 2000) 
Isthmin (Xiang et al, 2011; Zhang et al, 2011) 
Maspin (Zhang et al, 2000) 
Pigment epithelial derived factor (Dawson et al, 1999) 
Platelet factor-4 (Hagedorn et al, 2001) 
Thrombospondin-1 and -2 (Good et al, 1990) 
Tissue inhibitors of 
metalloproteinases-1, -2 and -3 
(Ikenaka et al, 2003; Qi et al, 2003; Seo 
et al, 2003) 
Troponin Ⅰ (Moses et al, 1999) 
Vascular endothelial growth 
inhibitor 
(Zhai et al, 1999) 
Vasohibin-1 (Watanabe et al, 2004) 
Natural proteolytic fragments: 
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Angiostatin (Kringles 1~4) (O'Reilly et al, 1994b) 
Arrestin (Colorado et al, 2000) 
Canstatin (Kamphaus et al, 2000) 
Endostatin (O'Reilly et al, 1997) 
Kringle 5 (Cao et al, 1997; Davidson et al, 
2005) 
 
Parstatin (Duncan & Kalluri, 2009) 
Pex (Ribatti, 2009) 
Prolactin fragment (Galfione et al, 2003) 
Tumstatin (Maeshima et al, 2000) 
Vasostatin (Pike et al, 1998) 
Other factors: 
2-methoxyestradiol (Pribluda et al, 2000) 
MicroRNAs (miR-15, -16, -221 
and -222) 
(Suarez & Sessa, 2009) 
1.3.2.1 Gene products 
Thrombospondins (TSPs): The thrombospondins are a family of 
multifunctional proteins that are widely distributed in the ECM of numerous 
tissues. This family comprises a group of 5 members (TSP-1, -2, -3, -4 and -5) 
(de Fraipont et al, 2001). Only TSP-1 and TSP-2 function as angiogenic 
inhibitors. TSP-1 and TSP-2 are homotrimers sharing a similar structural 
organization. Each monomer is comprised of a globular N-terminal 
heparin-binding domain, a linker domain possessing two cysteine residues 
involved in trimerization, a procollagen domain, three thrombospondins type 1 
repeats (TSR), three EGF-like type II repeats and seven calcium-binding type 
III repeats followed by a globular C-terminal end (Fig. 1.2). Expression patterns 
of the TSP family members are different. During developmental processes, 
TSP-1 is mainly expressed in liver, gut and kidney and TSP-2 is dominantly 
observed in connective tissues (Iruela-Arispe et al, 1993). In adult, TSP-1 and 
TSP-2 are expressed in several organs with overlapping but distinct patterns. 
Other members of TSP family are particularly enriched in cartilage and bone 
tissues (Corless et al, 1992; Danik et al, 1999; Kyriakides et al, 1998). 
The regulatory functions of TSPs in cell adhesion, migration, proliferation 
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and protease activation have been intensely studied since 1980s (Chen et al, 
2000; Rastinejad et al, 1989). For TSP-1, both positive and negative regulation 
of EC adhesion, motility, and growth has been observed. This should not be 
surprising considering that a variety of cellular receptors have been identified to 
recognize specific peptide domains of TSP-1 and mediate its biological 
functions, including CD36, integrins (αvβ3, α3β1 and αIIbβ3), HSPG, and 
integrin-associated protein (IAP or CD47) (Fig. 1.2).  Among these receptors, 
the antiangiogenic function of TSP-1 on ECs is mediated mainly through CD36 
(Dawson et al, 1997a). The thrombospondins type 1 repeats (TSR) in TSP-1 are 
the key sites for this interaction. Upon activation, CD36 stimulates the 
cytoplasmic protein tyrosine-kinase p59fyn. This kinase in turn activates 
downstream molecules such as caspase-3-like proteases, which switches on p38 
mitogen-activated protein kinase. Then phosphorylated form of p38 
mitogen-activated protein kinase translocates into the nucleus and induces 
further expression of caspase-3, which results in endothelial cell apoptosis. (de 
Fraipont et al, 2001; Jimenez et al, 2000). 
 
 
Fig. 1.2 Cell surface receptors recognizing TSP-1(Adapted from (de Fraipont et 
al, 2001)) 
 
However, it has been reported that TSP-1 exerts dual function on ECs in a 
context and conformation dependent manner (Iruela-Arispe et al, 2004).  
Soluble TSP-1 peptide inhibits EC proliferation and angiogenesis, whereas the 
same molecule stimulates EC proliferation when immobilized 
(Chandrasekaran et al, 2000).  
Several synthetic peptides derived from TSR sequence have been shown to 
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function as antiangiogenic agents both in vitro and in vivo (Iruela-Arispe et al, 
1999; Tolsma et al, 1993). For example, CSVTCG sequence in TSP-1 is the 
binding site for CD36 and is proved to inhibit VEGF or FGF mediated 
angiogenesis (Iruela-Arispe et al, 1999). In addition, WSPWSHW sequence in 
TSP-1 is also known for inhibiting FGF mediated angiogenesis (Guo et al, 
1997a). The efficacies of TSP-1 and its derived peptides in several tumor types 
highlight their potential usages in developing antiangiogenic and 
anti-tumorigenic strategies (Bocci et al, 2003; Lawler & Detmar, 2004).  
Pigment epithelial derived factor (PEDF): PEDF is a 50 kDa secreted 
protein first identified in the medium of cultured pigment epithelial cells of the 
human fetal retina (Steele et al, 1993). It is a non-inhibitory member of the 
serpin superfamily of serine/theronine kinases inhibitors. PEDF is a 
multifunctional protein with antiangiogenic, anti-tumorigenic and 
neurotrophic properties. It exerts the antiangiogenic effect in ocular 
compartments (Volpert et al, 2002) and plays a negative role in regulating 
neovascularization in retina induced by ischemia (Stellmach et al, 2001). In 
addition, PEDF is also known for contributing to growth, survival and 
maturation of neurons both in central nervous system and retina (Tombran-Tink 
& Barnstable, 2003). Moreover, PEDF inhibits tumor growth through 
angio-static function (Crawford et al, 2001; Mahtabifard et al, 2003). The 
feature that the antiangiogenic function of PEDF is only limited to the 
proliferating ECs but not the pre-existing vessels makes PEDF an attractive 
candidate for cancer therapy (Bouck, 2002).  
Vasohibin-1 (VASH1): VASH1 is the first characterized angiogenic 
inhibitor as a negative feedback regulator upon angiogenic stimulation by 
VEGF (Abe & Sato, 2001). VASH1 is a 42 kDa protein produced by ECs. Its 
expression is enhanced during angiogenesis, which in turn terminates 
angiogenesis in an autocrine manner. It has been shown that VASH1 is 
antiangiogenic in vitro through inducing EC apoptosis and inhibiting of EC 
proliferation (Watanabe et al, 2004). VASH1 is dominantly expressed by ECs 
during developmental processes (Shibuya et al, 2006) (Nimmagadda et al, 2007) 
and becomes undetectable in adult stages except for certain cell types such as 
bone marrow hematopoietic stem cells (Naito et al, 2009). 
As an angiogenic inhibitor, VASH1 facilitates the maturation of newly 
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formed vasculatures. Hence tumors implanted into VASH1-/- null mice was 
suppressed due to lack of vessel maturation (Hosaka et al, 2009). Exogenous 
expression of VASH1 disrupts angiogenesis in the sprouting region but not in 
the termination area of the vessels (Heishi et al, 2010). In addition, VASH1 also 
plays a role in inhibiting tumoral lymphangiogenesis (Heishi et al, 2010).  
1.3.2.2 Natural proteolytic fragments 
In general, vascular basement membrane components play important roles in 
angiogenic regulation through modulating EC behavior and providing 
structural and functional support (Darland & D'Amore, 1999). Numerous 
natural proteolytic fragments with antiangiogenic function are produced by 
ECM and basement membrane proteins (Nyberg et al, 2005). As the most 
abundant component of ECM, collagen functions as the raw material source of 
several well-known angiogenic inhibitors. For example, arrestin, canstatin and 
tumstatin are proteolytic fragments originated from the α1, α2 and α3 chain of 
type IV collagen in ECM respectively. They perform their antiangiogenic 
activities through inhibiting EC proliferation, migration and capillary network 
formation (Colorado et al, 2000; Kamphaus et al, 2000; Ribatti, 2009). Another 
example of this group is endostatin. It is a potent antiangiogenic factor derived 
from collagen XVIII, which can efficiently inhibit angiogenesis and suppress 
tumor growth in animal models with no observed side effects (Boehm et al, 
1997; O'Reilly et al, 1997). 
Besides protein fragments originated from ECM, non-ECM components can 
also be the source of angiogenic inhibitors. For example, some antiangiogenic 
fragments are derived from blood coagulation factors. The most well studied 
antiangiogenic regulator of this group is angiostatin, which selectively targets 
and suppresses ECs under active proliferation (Ribatti, 2009). In addition, Pex, 
derived from MMP-2, can suppress tumor growth through angiogenic 
inhibition (Ribatti, 2009). Another example is a 16 kDa fragment of prolactin, 
which can efficiently block the proangiogenic function of VEGF and FGF2 
(D'Angelo et al, 1995). 
In the following section, a few examples of natural proteolytic fragments 
function as angiogenic inhibitors are introduced: 
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Angiostatin: Angiostatin has been proved as one of the most potent 
angiogenic inhibitors, which was originally discovered in 1994 by Folkman 
and coworkers (Wu et al, 1997). It was identified according to its antitumor 
effects in mice and later was proved to be a potent inhibitor of angiogenesis. As 
an internal fragment of plasminogen, angiostatin may contain first three (K1-K3) 
or four (K1-K4) kringle domains that are known to be lysine-binding (Liu et al, 
2000).  These fragments, as well as the individual kringle modules, exert 
inhibitory function toward endothelial cell migration and proliferation. To date, 
at least three cell surface receptors for angiostatin have been reported, namely, 
adenosine triphosphate (ATP) synthase (Moser et al, 1999), angiomotin 
(Troyanovsky et al, 2001) and integrin αvβ3 (Tarui et al, 2001). It is surprising 
to find a typical mitochondrial enzyme protein- ATP synthase presenting on the 
surface of ECs to function as a receptor of angiogenic inhibitor (Wahl & Grant, 
2000). And recent study has shown that angiostatin can be internalized into 
ECs through binding to ATP synthase and ultimately target mitochondrial 
compartment to induce EC apoptosis. This discovery suggests mitochondrion 
as a novel target for antiangiogenic therapy (Lee et al, 2009). Through those 
specific ligand-receptor interactions, angiostatin functions as an 
antiangiogenic and anti-tumorigenic factor both in vitro and in vivo. In vitro, 
angiostatin selectively targeting tumor ECs and inhibits their proliferation, 
migration and tube formation (Moser et al, 1999). It has also been published 
that angiostatin can inhibit proliferation and migration of smooth muscle cells, 
which play important roles in neo-vascular maturation (Walter & Sane, 1999).  
In vivo, angiostatin inhibits tumor growth and primary tumor metastasis in 
mice ((O'Reilly et al, 1994a; O'Reilly et al, 1994b) and vascular proliferation 
in the chick chorioallantoic membrane assay (Gately et al, 1996). 
Kringle5: As above mentioned, proteolytic processing of human 
plasminogen produces potent antiangiogenic peptides such as angiostatin. 
However, the plasminogen kringle5 (K5) domain, which is distinct from 
angiostatin, also possesses efficient angiogenic inhibitory properties on its 
own (Cao et al, 1997). Similar to angiostatin, kringle5 fragment of 
plasminogen is a specific inhibitor for EC and tumor growth (Davidson et al, 
2005).  It even appears to be more potent than angiostatin on inhibiting EC 
proliferation stimulated by FGFs. Further investigation has shown that 
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kringle5 blocks tumor progression through both antiangiogenic and 
proinflammatory pathways (Perri et al, 2007). Kringle5 has been shown to 
interact with cell surface glucose-regulated protein 78 (GRP78) (Davidson et 
al, 2005) and is functionally associated with low-density lipoprotein 
receptor-related protein 1 (LRP1) (McFarland et al, 2009). GRP78 is found at 
the cell surface in a wide variety of cancer cells, which makes it a promising 
anti-cancer target (Delie et al, 2012). The peptide region around the 
lysine-binding pocket of kringle5 is responsible for binding with GRP78 and 
mediating its antiangiogenic function, particularly the peptide PRKLYDY, 
which is meaningful in anti-cancer agent development (Davidson et al, 2005). 
Canstatin: Canstatin is an endogenous 24 kDa basement membrane 
derived-inhibitor of angiogenesis and tumor growth (Colorado et al, 2000). It is 
the proteolytic product of α2 chain of type IV collagen. In vitro, canstatin is 
shown to inhibit EC tube formation and induce EC apoptosis (Colorado et al, 
2000). In vivo, canstatin has been shown to inhibit tumor growth and tumor 
angiogenesis (Petitclerc et al, 2000). It has been reported that Canstatin interacts 
with cell surface integrin αvβ3 and αvβ5 (Magnon et al, 2005). Their interaction 
may lead to crucial mitochondrial apoptotic mechanism through procaspase-9 
cleavage in both endothelial and tumor cells.  
Endostatin: As one of the most potent and well studied angiogenesis 
inhibitors, endostatin was originally discovered by O’Reilly in Judah 
Folkman’s laboratory in 1997. It is a 20 kDa cleaved product of the 
carboxyl-terminal domain of collagen XVIII that was first found in conditioned 
medium from a murine endothelial tumor cell line (O'Reilly et al, 1997). 
Endostatin directly exerts its antiangiogenic function through inhibiting EC 
proliferation, migration and inducing EC apoptosis (Dhanabal et al, 1999a; 
Dhanabal et al, 1999b). It also indirectly inhibits angiogenesis by disrupting 
interaction between VEGF and VEGFR and inhibiting activity of matrix 
metalloproteinase 2 (MMP-2) (Kim et al, 2002; Kim et al, 2000). In vivo, 
endostatin inhibits tumor growth in various cancers (Boehm et al, 1997; Sund 
et al, 2005) and impairs blood vessel maturation in wound healing (Bloch et al, 
2000). Endostatin plays important roles in EC adhesion and cytoskeletal 
organization (Dixelius et al, 2002). It has been reported that cell surface 
integrins containing α5 or αv subunit (Rehn et al, 2001), nucleolin (Shi et al, 
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2007), VE-cadherin (Nemoto & Kubota, 2011) and glypican (Karumanchi et al, 
2001) are involved in mediating biological functions of endostatin. 
 1.3.2.3 Other angiogenesis regulators 
MicroRNAs: MicroRNAs are a group of small non-coding RNAs 
functioning in regulation of gene expression through base-pairing with 
complementary sequence within mRNA (Pillai et al, 2007). Members of this 
family have been shown to participate in almost every cellular process studied 
so far. It is not surprising to notice that accumulating evidence suggests a role 
of miRNAs in the regulation of angiogenesis. Knockdown of two key enzymes 
- Dicer and Drosha involved in processing miRNAs disrupts 
angiogenesis-related molecules, which first implies the link between 
angiogenesis and microRNAs (Kuehbacher et al, 2007; Poliseno et al, 2006; 
Yang et al, 2005). As shown in Table 1.2, many antiangiogenic microRNAs 
have been discovered and the list is still expanding. Therefore microRNAs are 
important players and regulators of angiogenic processes, making them 
promising targets for potential therapeutics 
2-methoxyestradiol: This is a biologically active metabolite of estradiol that 
appears to inhibit key pathways regarding cell replication (Dubey & Jackson, 
2009). It has been shown to exert potent inhibitory effect of EC proliferation 
and migration as well as angiogenesis in vitro (Fotsis et al, 1994). As the first 
steroid to have high antiangiogenic activity by itself, 2-methoxyestradiol may 
possess therapeutic potential in cancer and other angiogenic diseases. 
1.4 Tumor angiogenesis 
Tumorigenesis is literally the creation of cancer. It is a multi-step process 
governing the transition from normal cells to neoplasm and malignancy. 
Cancer is a complicated disease driven by genomic alterations, including point 
mutation, deletions, insertions, translocations, genomic rearrangements and 
genomic copy number alterations (Futreal et al, 2004). Till now, at least 10 
hallmarks for cancer have been characterized that denote cancer progression, 
invasion and metastasis (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 
2011). They are: i) self-stimulated growth, ii) resistance to anti-growth signals, 
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iii) escaping from apoptosis, iv) infinite cell proliferation, v) inducing 
angiogenesis, vi) ability to invade and metastasize, vii) abnormal metabolic 
pathways, viii) evading the immune system, ix) genome instability and 
mutation and x) prolonged inflammation.  
Among them, tumor angiogenesis is one of the most important characters of 
cancer (Hanahan & Weinberg, 2011). Due to abnormally-high metabolic level 
and cell division rate, tumor cells possess greater demand than normal cells for 
blood vessels to supply nutrients, oxygen, remove carbon dioxide and waste, 
even provide route for metastasis. This demand drives transition from 
pre-vascular hyperplasia tumors to highly-vascularized and progressively 
growing ones. And this transition is denoted as the “angiogenic switch” 
(Bergers & Benjamin, 2003; Ribatti et al, 2007). As mentioned before, 
angiogenesis is largely quiescent during adulthood and is only transiently 
reactivated under certain circumstances such as wound healing or 
menstruation. However, during the process of tumor progression, the 
“angiogenic switch” is permanently turned on to meet the needs raised by fast- 
growing tumor cells. 
Although oncogenic events might allow tumor cells to enhance survival and 
escape from surveillance, the growth rate of tumor cells is restricted due to 
lack of vascular system. To achieve this blood supply, tumor cells can increase 
activator gene expression, elevate the bio-availability of the inducer proteins 
and reduce the amount of endogenous inhibitors. During this “angiogenic 
switch”, the balance between angiogenic promoters and inhibitors is flipped in 
favor of angiogenic stimulation to drive vascular growth through attracting and 
activating cells within tumor microenvironment (Hanahan & Weinberg, 2008). 
The tumor microenvironment is composed of a variety of cells involved in the 
angiogenic response to a tumor. Tumor cells govern their microenvironment 
by secreting cytokines and growth factors to activate surrounding quiescent 
normal cells and trigger a cascade of events. For example, tumor cell 
released-VEGFs stimulate EC sprouting and proliferation. However, the 
newly-formed vessels can only scramble to provide tumors more oxygen and 
nutrients due to its leaky and tortuous feature. Then neighboring platelets are 
recruited and activated by basal lamina exposed during vascular leakage. 
Upon activation, platelets release proangiogenic factors and permeability 
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inducers into the local environment to further enhance the angiogenic response. 
Later, this blood supply system can be further polished by recruitment of 
perivascular cells responding to the stimulation of platelet-derived PDGF and 
activated ECs (Weis & Cheresh, 2005). In addition, this angiogenic response is 
further escalated by tumor associated fibroblasts, which abnormally deposit 
ECM protein and secrete angiogenic stimulators (Franco et al, 2010). 
The magnitude and quality of “angiogenic switch” depends on the sum of 
pro- and antiangiogenic clues and, more specifically, their unique activities on 
multiple cell types. In addition, the switch may also be a result of total effects of 
several mediators besides angiogenic regulators such as integrins, proteases 
and other factors altered during the vascular formation (Baeriswyl & 
Christofori, 2009). Based on the variety of signals and cell types involved, 
there are several aspects in angiogenesis that can be targeted therapeutically. 
However, targeting one aspect of vascular remodeling process may only 
provide a short-term effect. Suppressing one pathway may stimulate another 
one. Therefore, understanding how these various players are cooperated and 
which steps and components of this process are the most suitable targets for 
cancer therapy is important. The most effective treatment may probably be 
drugs that target multiple cell types and angiogenic factors with improved 
efficiency of delivery into the leaky and poorly perfused tumor 
microenvironment. 
1.5 Antiangiogenic cancer therapy  
Tumors construct their own private vascular system to deliver oxygen and 
nourishment for tumor cells. By cutting off tumor blood supply, antiangiogenic 
therapy may starve tumor cells, and suppress their growth and spread. It is 
reasonable to hypothesize that antiangiogenic agent can be useful when 
combined with conventional chemotherapy or radiation therapy to attack tumor 
cells via different strategies simultaneously using "multiple warheads". 
Comparing to conventional cancer treatment, antiangiogenic cancer therapy 
has its own advantage through selectively targeting tumor ECs and tumor 
associated angiogenic factors. At first, in contrast to tumor cells housing 
non-homogeneous and aneuploidy genome, tumor associated ECs are assumed 
 19 
 
to be genetically normal and are therefore originally considered to be ideal 
therapeutic targets for cancer (Carmeliet, 2005). In addition, tumor associated 
ECs are activated by environmental clues and express specific markers such as 
integrins, especially integrin αvβ3 and αvβ5, E-selectin, Tie-2 and VEGF 
receptors (Wu & Li, 2008). They are valuable for the development of novel 
cancer targeting therapies. Moreover, tumor associated ECs would be the most 
approachable targets for antiangiogenic and anti-tumorigenic agents 
administered through systemic delivery (Gasparini, 1999).  
There are a variety of approaches for the antiangiogenic cancer treatment  
(Carmeliet, 2005). Firstly, tumor angiogenesis can be inhibited through 
directly targeting tumor associated ECs. The best characterized angiogenic 
inhibitors of this group are the VEGF antagonists. They can be either 
anti-VEGF/VEGFR antibodies or small molecules targeting VEGF family 
members or their receptors. This group of angioinhibitory agents can not only 
arrest ECs proliferation but also can induce ECs apoptosis.  
Secondly, tumor angiogenesis can be influenced by antiangiogenic drugs 
targeting stromal cells in tumor. It has been reported that tumor stroma is an 
active contributor facilitating tumor progression rather than simply an 
innocent bystander (Langley & Fidler, 2011). In contrast to normal tissue, 
tumor has a dense desmoplastic stroma with fibrotic connective tissue, which 
leads to a microenvironment with hypoxia and low blood perfusion, 
functioning as a barrier to obstruct the delivery of anticancer drugs and 
provoking aggressive tumor cell behavior (Neesse et al, 2011). Enzymatic 
targeting of tumor stroma combined with conventional chemotherapy can 
ablate this physical barrier and action on tumor cells with a better delivery and 
perfusion of anti-tumorigenic and antiangiogenic agents (Provenzano et al, 
2012). Inhibiting stromal-cell-derived factor (SDF) such as SDF-1α can also 
inhibit both tumor growth and tumor angiogenesis (Orimo et al, 2005).  
Thirdly, tumor angiogenesis can be interrupted through targeting vascular 
mural cells. Tumor vessels are covered by pericytes, which promote vessel 
stabilization. The recruitment of pericytes to tumor vessels is dominantly 
controlled by PDGFs pathway. Administration of PDGFRβ inhibitors exerts 
antiangiogenic effect in tumors (Bergers et al, 2003). In addition, tumor 
angiogenesis can be restrained by targeting haematopoietic cells. Tumor cells 
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release several cytokines and chemokines to attract haematopoietic cells, such 
as macrophages, monocytes, platetlets, T cells, dendritic cells, mast cells and 
haematopoietic progenitor cells (Carmeliet, 2005). It has been shown that 
inflammatory cells can promote tumor progression and induce tumor 
angiogenesis by producing proangiogenic factors (Coussens & Werb, 2002; 
De Palma et al, 2005). Antagonists of angiogenic stimulators can offset these 
effects. In other cases, they also can function as endothelial progenitors to give 
rise to new blood vessels. In response to PlGF secreted by tumor cells, they 
can even migrate to tumor specific premetastatic niches and then turn back to 
guide tumor cells to the new habitats (Kaplan et al, 2005). Therefore, 
interfering with PlGF is one approach to reduce tumor angiogenesis, 
progression and even metastasis. Moreover, tumor angiogenesis also can be 
suppressed by targeting neoplastic cells. As tumor cells function as the 
structural support for its vascular system and the major resource of 
proangiogenic regulators, traditional regimens using radiation, chemotherapy 
or biological targeting agents to destroy tumor cells can decompose tumoral 
blood vessels. And tumor cells usually express receptors of angiogenic 
stimulators, such as VEGFR, PFGFR, FGFR and EGFR. So antiangiogenic 
drugs can directly effect on both tumor cells and tumor associated ECs. For 
example, one broad spectrum receptor tyrosine kinase inhibitor (RTKI) – 
Sorafenib can inhibit division of both ECs and tumor cells (Kim et al, 2007). 
The first anti-angiogenesis agent approved by FDA for cancer treatment was 
bevacizumab (Avastin), the humanized monoclonal antibody against VEGF, in 
2004 (Mass et al, 2004). It is now used in combination with chemotherapy to 
treat some types of cancer. To date, as shown in Table 1.3, several 
anti-angiogenesis drugs have been approved for clinical use. Potential 
compounds modulating angiogenesis are currently under intense pre-clinical 
studies. 
Table 1.3 List of anti-angiogenesis drugs approved for clinical use (Modified from 
(Ribatti, 2010)) 
Drug Target Targeted cancer type 
Avastin 
(Bevacizumab) 
VEGF mCRC (metastatic colorectal cancer), 
NSCLC (non-small cell lung 
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carcinoma), Advanced breast cancer 
Lucentis 
(Ranibizumab) 
VEGF Wet age-related macular regeneration 
Erbitux 
(Cetuximab) 










PDGFR & Raf 





PDGFR & c-kit 
Advanced RCC&GIST 
(gastrointestinal stromal tumor ) 
Dasatinib 
(Sprycel) 
























Although the majority of pre-clinical investigations show a vast progress in 
the discovery and characterization of angiogenesis inhibitors with therapeutic 
promise in mouse models and certain human cancers, clinical benefits of 
antiangiogenic drugs in cancer therapy are relatively modest and transitory 
(Ribatti, 2010). Tumor progression or metastasis is merely slowed down and 
the life span of patients is prolonged by only a few months. In cancer, the 
process of tumor progression is contributed by multiple sources and modes of 
vascular remodeling. Targeting one aspect of this process may act for a 
short-term, but inhibiting one pathway may promote another. The diversity 
and redundancy by which blood vessels can rearrange may lead to the poor 
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efficacy or acquired resistance observed in antiangiogenic cancer therapies. 
Another hurdle is that angiogenic inhibition may cause endothelial 
dysfunction and vessel collapse in normal tissue. This adverse effect can be 
dangerous for fragile cancer patients. Improving the therapeutic efficacy 
demands a comprehensive consideration of numerous signaling pathways that 
regulate the various cell types involved in the tumor vascular system. 
Therefore, better understanding of the regulatory network of tumor 
angiogenesis is important for developing effective strategies for cancer therapy 
with minimum side effects. Identification of novel angiogenic inhibitors and 
clarification of their downstream signaling hubs could provide new therapeutic 
strategies in suppressing angiogenesis and tumor progression. In addition, 
screening for candidate markers that are selectively expressed on tumor cells, 
stromal cells or haematopoietic cells that potentiate the angiogenic response is 
meaningful for designing drugs specifically targeting tumors. Future direction 
for cancer treatment would be the combinatorial approaches including both 
antiangiogenic therapy and conventional radiation or chemo therapy.    
1.6 Potential targets for antiangiogenic cancer therapy 
A lot of the angiogenic regulators are proteins or peptides presenting at the 
ECM. Their biological functions on ECs are mediated by cell surface receptors. 
It has been reported that the gene expression patterns of endothelial cells 
derived from normal and tumor tissues are distinct (Wu & Li, 2008). Tumor 
angiogenesis is often associated with up-regulation of several EC surface 
receptors. Many of these receptors, such as VEGFR (Smith et al, 2010), FGFR 
(Ahmad et al, 2012), integrins (Cox et al, 2010; Desgrosellier & Cheresh, 
2010) and glucose-regulated protein of 78 kDa (GRP78) (Virrey et al, 2008), 
are functionally important for tumor angiogenesis, proliferation and 
progression. Therefore, they can be taken as promising targets for 
antiangiogenic cancer therapy. As the functions of VEGFR and FGFR in 
tumor angiogenesis have been introduced in the previous part, the current 
knowledge regarding integrins and GRP78 in tumor angiogenesis will be 




Integrin is the major cell surface receptor family mediating cell adhesion to 
ECM molecules and playing important roles in various cellular processes 
including transcriptional control, cell proliferation, migration and even cell 
death  (Silva et al, 2008). Members of this family are non-covalently associated 
transmembrane heterodimers comprising an α-subunit and a β-subunit (Hynes, 
1992). In mammals, at least 24 integrins formed by 18 α and 8 β subunits have 
been reported  (Alghisi & Ruegg, 2006). Both α and β subunits consist of a 
large extracellular region, a single transmembrane domain and a small 
cytoplasmic tail containing about 40~70 amino acid residues (Nermut et al, 
1988). The cytoplasmic tails bind to cellular cytoskeletal elements such as 
actin filaments and play essential roles in mediating the function of integrins. 
The extracellular domains of α and β subunits are capable to directly bind with 
ECM components, such as collagen, vitronectin, fibronectin, and laminin, to 
provide the traction necessary for cell motility and invasion. In addition, they 
can also function in a co-receptor manner with other proteins on the cell 
surface, including cadherins, syndecans and selectins. Moreover, 
environmental clues can be further amplified through the clustering of 
integrins (Giancotti & Ruoslahti, 1999). 
The ligand specificity of integrins is mainly determined by the combination 
of their subunits. Hence members of integrin family possess overlapping but 
distinct ligand binding patterns. For example, some integrins, such as α5β1 
integrin, primarily interact with only one ligand. However, some others, 
including αvβ3 integrin, can bind with multiple ligands. Based on ligand 
binding properties, integrins can be simply divided into two groups, 
RGD-binding integrins and non-RGD-binding integrins. The RGD-binding 
integrins are integrins containing αv or β1 subunit which can selectively 
recognize Arg-Gly-Asp (RGD) tripeptide motif in various ECM proteins 
including vitronectin, fibronectin, fibrinogen and thrombospondin (Plow et al, 
2000). In the meantime, non-RGD-binding integrins may recognize alternative 
short amino acid sequences, such as Arg-Glu-Asp-Val (REDV) and 
Glu-Ile-Leu-Asp-Val (EILDV) (Komoriya et al, 1991).  
Upon ligand-integrin binding, survival signals can be provided through 
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several mechanisms, including focal adhesion kinase (FAK), 
phosphatidylinositol 3 kinase (PI3K)/protein kinase B (PKB), rho-family 
GTPases, nuclear factor- κB (NF-κB) and ras-mitogen-activated protein kinase 
(MAPK) (Alghisi & Ruegg, 2006; Eliceiri, 2001; Martin et al, 2002; Smyth & 
Patterson, 2002). Besides the pro-survival effects of integrins, in the cases of 
integrin-mediated death (IMD) and anoikis, unligated or antagonized integrins 
may initiate pro-apoptotic signals (Desgrosellier & Cheresh, 2010). Here 
anoikis denotes the apoptosis that occurs in response to the detachment from 
ECM (Frisch & Screaton, 2001). Different from anoikis, IMD is apoptotic cell 
death triggered by recruitment and activation of caspase8 by unligated or 
antagonized integrins (Stupack et al, 2001). 
Integrin expression profiles in cells of normal and tumor tissues are distinct. 
Integrins expressed in tumor cells facilitate tumor progression and metastasis 
through increasing proliferation, migration and invasion. Expression levels of 
α4β1, α5β1, α6β4, αvβ3, αvβ5 and αvβ6 integrins in tumor cells are correlated 
with disease progression in various tumor types (Desgrosellier & Cheresh, 
2010). In the case of tumor-associated ECs, as they are anchorage-dependent 
cells, integrins function as hooks to bond ECs with ECM and remodel ECs 
based on environmental clues. It has been reported that ECs express up to ten 
members of integrins: α1β1, α2β1, α3β1, α4β1, α5β1, α6β1, α6β4, αvβ3, αvβ5 
and αvβ8 (Serini et al, 2006). Pathological angiogenesis is often related to the 
up-regulation of certain integrins. There is evidence indicating that vascular 
integrins are important regulators of tumor angiogenesis (Ruegg et al, 2002). In 
particular, αvβ3 and αvβ5 integrins are implicated in neovascularization and 
tumor-induced angiogenesis (Mizejewski, 1999). In addition to the 
involvement of integrins in tumor cells and tumor associated ECs, recent 
studies have demonstrated that integrins also influence the response of other 
host cells, including pericytes, inflammatory cells (such as neutrophil and 
leucocytes) and fibroblasts, to facilitate tumor progression and angiogenesis 




Fig. 1.3 Integrins expressed on multiple cell types contribute to angiogenesis and 
tumor progression (Adopted from (Weis & Cheresh, 2011)) 
 
Since integrin signaling pathways modulate the behavior of multiple cell 
types involved in angiogenesis and cancer, integrin antagonists may possess 
two fold of actions through targeting both tumor cells and tumor 
microenvironment and provide novel approaches to significantly curtail tumor 
progression. To date, several integrin antagonists, such as monoclonal 
antibodies, peptide inhibitors and antisense oligonucleotides, have been 
reported to suppress tumor angiogenesis and tumor progression in many 
preclinical tumor models (Desgrosellier & Cheresh, 2010). And it is 
encouraging to notice that a cyclic RGD containing pentapeptide - Cilengitide, 
as the inhibitor of both αvβ3 and αvβ5 integrins, is currently being tested in a 
Phase III clinical trial in patients with glioblastoma (Mas-Moruno et al, 2010).  
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1.6.2 Glucose-regulated protein of 78 kDa (GRP78) 
Glucose-regulated protein of 78 kDa (GRP78), also referred to as binding 
immunoglobulin protein (BiP) or heat shock 70 kDa protein 5 (HSPA5), is a 
member of heat shock protein 70 kDa (HSP70) family (Li & Lee, 2006). 
GRP78 gets its name from the property that it can be up-regulated in response 
to glucose deprivation and other cellular stresses, such as hypoxia and acidosis 
(Lee, 2007). It is traditionally regarded as a central endoplasmic reticulum (ER) 
chaperon facilitating protein folding and assembly, recruiting mis-folded 
proteins for degradation and serving as an ER stress sensor (Hendershot, 2004; 
Lee, 2005).  
Recent studies showed that the existence of GRP78 is not limited to ER. As 
shown in Figure 1.4, GRP78 can localize to multiple subcellular locations 
including cell surface, mitochondria, nucleus, cytoplasm and extracellular 
space as a secreted protein to mediate distinct cellular functions (Ni et al, 
2011). Among them, cell surface GRP78 has emerged as an important 
regulator in tumor cell growth, progression, metastasis, angiogenesis and 
resistance to cancer therapy (Lee, 2007). The presence of GRP78 on the cell 
surface of tumor cells and tumor-associated ECs but not normal cells provides 
a novel opportunity for cancer-specific targeting in antiangiogenic and 




Fig. 1.4 Summary of GRP78 functions in different subcellular locations. 
GRP78 is traditionally regarded as a major ER chaperone facilitating protein 
maturation and degradation, calcium binding and regulating ER stress signalling. 
However, it also exists in other subcellular compartments and acts in multifaceted 
cellular processes. For example, ER stress induces cell-surface expression of GRP78 
and generates a cytoplasmic isoform through alternative splicing. Cell surface GRP78 
emerges as an important regulator in cell signal transduction, viability and 
cancer-specific therapy. The cytoplasmic GRP78 is a newly characterized regulator of 
the ER stress signalling pathway. Beyond the ER, the secreted, mitochondrial and 
nuclear forms of GRP78 are involved in cellular homoeostasis and therapeutic 
resistance. C, cytoplasm; M, mitochondrion; N, nucleus. (Adopted from (Ni et al, 
2011)) 
 
As a major ER chaperone, GRP78 has a typical N-terminal ER signal 
peptide and a C-terminus KDEL-ER retention motif. In addition, it contains an 
ATPase domain and a peptide binding domain. These domains are highly 
conserved among HSP70 family members and are mediating classical 
chaperone functions (Daugaard et al, 2007) (Fig. 1.5A). Although best known 
as an ER luminal protein, a subpopulation of GRP78 can exist as an ER 
transmembrane protein interacting with cytoplasmic procaspase-7 and 
preventing cell from apoptosis (Reddy et al, 2003).  This discovery is 
consistent with the potential transmembrane configuration predicted by 
hydrophobicity plot (Fig. 1.5B) (Reddy et al, 2003). For the cell surface 
GRP78, recent study shows that there are at least three domains of GRP78 (N, 
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middle and C) exposed on the cell surface, making GRP78 an appealing target 
for cancer-specific therapy (Fig. 1.5C) (Zhang et al, 2010).  
 
 
A, domain illustration of human GRP78. The numbers below refer to the amino acid 
residues. B, schematic presentation of human GRP78 with potential transmembrane 
domains (I–IV) predicted by TMPred (ExPasy tools) shown in green. The numbers below 
refer to the amino acid residues. C, GRP78 is multiple-times transmembrane protein on 
cell surface. Here shows the proposed topology model of cell surface GRP78. The 
putative transmembrane domains are indicated in green and the extracellular sequences 
recognized by the antibodies used for FACS analysis are labeled by orange star. The ER 
signal sequence is indicated as an asterisk. (Modified from (Zhang et al, 2010)) 
 
GRP78 has been well established as the central regulator of ER functions. 
ER is the cellular site for synthesizing secretory and membrane proteins, 
where proteins must be properly folded and post-translationally modified. 
These processes require the assistance of molecular chaperone proteins under 
a conductive ER environment. As a major ER chaperone, GRP78 locates in the 
lumen of ER and plays essential roles in protein folding, assembly, quality 
control, calcium binding and regulation of ER stress response (Ni et al, 2011).  
Different from the properly folded proteins, misfolded proteins are disposed 
of by ER-associated protein degradation (ERAD) to maintain the ER 
homeostasis (Yoshida, 2007). When ER is under stress, the amount of protein 
load exceeds the protein folding capacity of ER. Then cells may initiate a 
defense mechanism denoted the unfolded protein response (UPR) to allow cell 
to conquer the stress targeted to ER. To decrease the burden on ER, UPR can 
Fig. 1.5 Schematic illustration of human GRP78. 
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induce the expression of ER chaperones, in particular GRP78, and ERAD 
components to accelerate protein folding and enhance the degradation of 
misfolded proteins (Wang et al, 2010). Therefore, GRP78 is also an essential 
player in the UPR. Except for severe ER stress, the UPR modulated by GRP78 
is protective through activation of pro-survival, adaptive and anti-apoptotic 
pathways (Lai et al, 2007).  
As an essential protein for cell survival, GRP78 plays important roles in 
both physiological and pathological conditions. During embryonic 
development, GRP78 is required for cell proliferation and protecting cells 
from apoptosis. Homozygous disruption of the Grp78 allele in mouse leads to 
early embryonic lethality (Luo et al, 2006). Transcription of Grp78 can be 
detected as early as the two-cell stage mouse embryo and is necessary for both 
proliferation and survival of the pluripotent stem cells. In addition, it has been 
reported that Grp78 transcription is strongly elevated in early embryonic heart, 
which consumes glucose as the major energy source (Mao et al, 2006).  
In normal adult tissues, GRP78 is constitutively expressed and its 
expression is maintained at basal level to exert the fundamental biological 
functions. However, under pathological conditions, especially cancer, its 
expression can be strongly induced (Lee, 2001; Lee, 2007). In the case of 
cancer, tumors undergo ER stress due to both extrinsic and intrinsic factors (Li 
& Lee, 2006). Comparing with normal cells, tumor cells and tumor-associated 
ECs exhibit elevated glucose metabolism with enhanced glycolytic activity 
and often grow faster than their blood supply, which leads to a 
glucose-deprived, hypoxic and acidosic tumor microenvironment. All these 
factors contribute to the accumulation of under-glycosylated and misfolded 
protein in ER, which may activate the UPR and ultimately increase the 
expression level of GRP78 in tumor cells (Lee, 2007).  
GRP78 functions as a key factor for the survival and progression of tumor 
cells. Firstly, it has been reported that GRP78+/- mice with 50% of GRP78 
expression level are comparable to wild type mice in growth and development 
(Luo et al, 2006). However, tumor progression in GRP78+/- mice was 
significantly impeded as demonstrated by a prolonged latency period, reduced 
tumor size, and elevated tumor apoptosis (Virrey et al, 2008). These evidences 
support that GRP78 is more critically required for the survival of stressed 
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cancer cells. In addition, GRP78 has been shown to play a protective role 
against tumor cell death induced by cytotoxic T cells and tumor necrosis factor 
α. Molecular inhibition of GRP78 induction in xenograft model causes a 
dramatic increase in tumor cell apoptosis (Jamora et al, 1996). Moreover, 
accumulating evidence shows that GRP78 is involved in tumor metastasis. For 
example, GRP78 expression level is up-regulated in metastatic cancer cell 
lines (Ramsay et al, 2005; Sun et al, 2012) and lymph node metastasis (Zhang 
et al, 2006a). Knocking down of GRP78 impedes tumor cell metastasis both in 
vitro and in vivo (Dong et al, 2011b).  
As one of the major contributors for cell adaptation and oncogenic survival, 
GRP78 also mediates the resistance of antiangiogenic and anti-tumorigenic 
therapies in cancers. It has been noticed that using therapeutic agents that 
target the tumor vasculatures to deprive tumor from essential nutrients  
unintendedly leads to GRP78 induction in tumor cells (Dong et al, 2005). 
These tumor cells with induced GRP78 expression are highly chemoresistant.  
In various tumor types, such as lung, breast, stomach, bladder, gastric and 
epidermoid carcinoma, GRP78 induction is correlated with the resistance to 
multiple chemotherapeutic agents. Knocking down of GRP78 reverse the 
tumor cells to be sensitive to drug treatment again (Li & Lee, 2006).  
GRP78-mediated drug resistance not only exists in proliferating tumor cells, 
but is also detectable in dormant tumor cells and tumor-associated ECs. It has 
been reported that knocking down of GRP78 in growth-arrested tumor cells 
induces strong killing effect upon drug treatment, indicating that dormant 
tumor cells also rely on GRP78 for drug resistance (Zhang et al, 2006b). 
Similarly, in tumor-associated ECs, targeting GRP78 again greatly enhances 
their drug sensitivity (Virrey et al, 2008). These findings suggest that 
therapeutic drugs against GRP78 with the ability to overcome drug resistance 
may possess potent efficacy to eradicate tumors (Fig. 1.6). 
Based on the important role of GRP78 in tumor cell survival, it represents a 
promising target for anticancer agents. Anti-cancer agents functioning through 
inhibiting either the expression or the activity of GRP78 have been 
characterized from multiple sources, including plants, microbes, bacteria and 
immune cells (Fig. 1.6) (Lee, 2007). For the naturally occurring compounds, 
they can be isolated from soy (genistein)(Zhou & Lee, 1998), green tea 
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((-)-epigallocatechin gallate-EGCG) (Ermakova et al, 2006) or other plants 
(salicyclic acid) (Deng et al, 2001). Through a screening of compounds from 
microbes, versipelostatin has been identified to specifically suppress the 
activation of the GRP78 promoter and inhibit induction of GRP78 upon 
glucose starvation (Park et al, 2004). In bacteria, a highly lethal AB5 subtilase 
cytoxin selectively cleaves GRP78, making it a promising candidate in 
anticancer therapy (Montecucco & Molinari, 2006). In addition, melanoma 
differentiation-associated gene-7/interleukin 24 (MDA7/IL-24) secreted by 
immune cells can target intracellular GRP78 to arrest growth and induce 
apoptosis in multiple human cancers (Dent et al, 2005). These observations 
indicate the potential of GRP78 inhibitors in cancer therapy.  
 
 
Fig. 1.6 Therapeutic implications of GRP78 in cancer. 
Both extrinsic and intrinsic factors result in the induction of GRP78 and its cell surface 
expression in tumor cells. Through anti-apoptotic effect, GRP78 facilitates tumor 
growth, progression, metastasis and drug resistance. Dormant tumor cells and 
tumor-associated ECs also rely on GRP78 to immunise chemotherapy. Anticancer 
drugs functioning through either inhibiting the stress induction of GRP78 or 
suppressing its catalytic function have been identified from multiple sources. When 
used in combinatory therapy, they should increase drug effect, revest sensitivity and 
facilitate tumor removal. GRP78 has also been reported as a cell surface receptor for 
Kringle 5 and the activated α2-macroglobulin. Because cell surface GRP78 is absent in 
normal cells, it is a potential conduit for cancer-specific delivery of therapeutic agents. 
It also can serve as a novel biomarker in stratifying patients for tumor behavior and 
responsiveness to treatment. C, cytoplasm; ER, endoplasmic reticulum; N, nucleus. 




Since the first discovery of cell surface-located GRP78 in 1997, 
accumulating evidence indicates that GRP78 is a specific cell surface receptor 
of cells under stress, in particular tumor cells and tumor-associated ECs 
(Berger et al, 1997; Ni et al, 2011). However, the mechanism of how GRP78 
translocates to the cell surface remains unclear, which may result from 
oversaturation of the ER retention receptors, co-trafficking with other cell 
surface proteins, cycling of ER transmembrane GRP78 to the cell surface, or 
unknown processes adapted by tumor cells. So far, several ligands of cell 
surface GRP78 have been characterized, including activated α2-macroglobulin 
(α2M*) (Misra et al, 2006), Kringle 5 (Davidson et al, 2005), Par-4 
(Burikhanov et al, 2009) and cell-surface anchored proteins-Cripto (Shani et al, 
2008) and T-cadherin (Philippova et al, 2008) (Fig. 1.7). Through specific 
ligand-receptor interaction, GRP78 plays multiple roles in cellular signal 
transduction, inducing both pro-survival and pro-apoptotic pathways. 
  
 
Fig. 1.7 Summary of known ligands of cell surface GRP78 and their role in 
cellular signaling. 
Cell-surface GRP78 functions as the receptor of a variety of extracellular ligands, 
including activated α2-macroglobulin (α2M*), Kringle 5 and Par-4 and cell-surface 
anchored proteins (Cripto and T-cadherin) in tumor and ECs, leading to pro-survival or 
pro-apoptotic pathways. In addition, it interacts with integral membrane protein (tissue 
factor) to initiate coagulation cascade. It also facilitates fungal and viral internalization 




For example, α2M* is a proteinase inhibitor interacting with cell surface 
GRP78 to promote proliferation, progression and metastasis of prostate cancer 
cells through activation of downstream PI3K/AKT pathways (Misra et al, 
2006). Another example is that GRP78 can function as the cell surface 
receptor mediating the antiangiogenic and anti-tumorigenic effects of a potent 
angiogenic inhibitor-kringle 5 (Davidson et al, 2005). Kringle 5 binds to cell 
surface GRP78 and then is endocytosed into cells. Inside cells, it functions as 
an inhibitor of the stress response pathway through disrupting the 
GRP78-procaspase-7 complex, which leads to the apoptosis of both 
activated-ECs and tumor cells. In the case of cell-surface proteins, taking 
T-cadherin as the example, it associates with GRP78 on the surface of 
tumor-associated ECs to provide positive signal for cell survival (Philippova et 
al, 2008). In addition, GRP78 is also involved in host-pathogen interactions. 
Emerging evidences show that GRP78-meidated internalization serves as an 
important path for the entry of virus into host cells (Jindadamrongwech et al, 
2004; Triantafilou et al, 2002). Similarly, GRP78 has been identified as the 
host receptor that mediates invasion and damage of ECs by Mucorales (Liu et 
al, 2010). Patients with diabetic ketoacidosis (DKA) have a unique 
predisposition to mucorale infection (Spellberg et al, 2005), which may be due 
to the induced EC surface GRP78 under acidosis condition. GRP78-specific 
immune serum can protect DKA mice from mucormycosis, suggesting a novel 
therapeutic intervention against diseases associated with up-regulated 
expression level of cell surface GRP78.  
The exciting idea that GRP78 may serve as a functional molecular target for 
cancer-specific therapy has already been utilized in preclinical research. 
GRP78 targeting molecules can be linked to chemotherapeutic drugs to serve 
as a conduit for cancer-specific delivery of cytotoxic agents and decrease the 
toxicities caused by treatment. It has been reported that systemic 
administration of synthetic chimeric peptides, containing a GRP78 binding 
motif and an apoptosis-inducing sequence, can suppress tumor growth without 
injuring normal tissues (Arap et al, 2004). Similarly, another GRP78 targeting 
peptide fused with taxol, an anti-cancer compound, triggers apoptosis in the 
targeted tumor cells (Kim et al, 2006). In addition, Dr. Robin L. Anderson’s 
group conjugated a tumor-homing GRP78-targeting peptide to a cell death 
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inducing domain, which can selectively kill breast cancer cells that express 
cell surface GRP78. Using preclinical metastasis models, they showed that this 
conjugated compound can inhibit primary tumor growth as well as reduce the 
established lung and bone micrometastases (Miao et al, 2013). These 
encouraging results prompt for investigation of potent and specific GRP78 
targeting antagonists that may function as both tracker and killer of tumor cells 
and tumor-associated ECs. However, to date, very few endogenous 
pro-apoptotic ligands of cell surface GRP78 have been characterized. There is 
an urgency to identify and study novel cell-surface GRP78 antagonists for 
cancer therapeutics development. In future, combinatory strategies including 
both compounds against GRP78 and traditional anti-cancer agents can be used 
together to eradicate tumors. These treatments may possess enhanced efficacy 
through smashing drug resistance and reducing toxicity. 
1.7 Isthmin (ISM) 
Isthmin (ISM) is a recently characterized endogenous angiogenesis inhibitor 
(Xiang et al, 2011). It is a 60 kDa secreted protein first indentified in Xenopus 
(Pera et al, 2002). ISM is named from its high expression level in the isthmus 
organizer, the signaling center located at the midbrain-hindbrain boundary 
(MHB), during neuronal stage with unknown function (Pera et al, 2002). 
Additional expression is detectable in neural folds and the paraxial mesoderm 
in tail bud stage, as well as in notochord and neuronal stage (Pera et al, 2002). 
Moreover, the expression of xIsm is associated with xFgf-8 at multiple sites, 
such as MHB, notochord, neural plate and neural crest. Their overlapped 
expression patterns in Xenopus indicate that ISM and FGF8 may be involved 
in the same biological process (Niehrs & Pollet, 1999). Besides Xenopus, 
orthologous Ism genes also present in other vertebrates, including zebrafish, 
mouse and human. In zebrafish, the expression of ism can be induced by 
over-expression of Wnt8 or be suppressed by Wnt/β-catenin inhibitors, 
suggesting its involvement in Wnt signaling pathways during embryonic 





Fig. 1.8 Domain structure of ISM 
 
As shown in Figure 1.8, ISM contains an N-terminal signal peptide, a 
centrally located thrombospondin type I repeat (TSR) domain and a C-terminal 
adhesion-associated domain in MUC4 and other proteins (AMOP). The 
function of the N-terminal unstructured region of 210 amino acids is unclear.  
The TSR domain is initially identified in the endogenous angiogenesis 
inhibitor TSP-1 and plays a main role in the antiangiogenic function of TSP-1 
(Guo et al, 1997b; Iruela-Arispe et al, 1999). TSR domain contains 
approximately 60 amino acid residues, of which 12 are highly conserved. It has 
been demonstrated to be an ancient protein domain which emerged before the 
evolutionary separation of nematodes and chordates in the analysis of the 
adhesion molecules in C. elegans (Hutter et al, 2000). Structural study of TSR 
domain in TSP-1 shows an antiparallel, three-stranded fold with alternatively 
stacked layers of arginine and tryptophan residues from respective strands, 
encapsulated by disulfide bonds on each end (Tan et al, 2002). A right-handed 
spiral, positively charged groove located at the front face of TSR domain 
might function as the recognition site mediating the interaction between its 
various ligands. Several conserved amino acid motifs have been proposed to 
mediate the antiangiogenic properties of TSR domain. For example, it has 
been reported that the CSVTCG sequence is the binding site of TSP-1 for 
CD36, which is a major scavenger receptor on ECs mediating the 
antiangiogenic effect of TSP-1 (Dawson et al, 1997). Besides TSPs, TSR 
domain has been identified in multiple protein families, including ADAMTS, 
semaphorin 5 and F-spondin (Adams & Tucker, 2000). The copy number of 
TSR domain varies from 1 to 18. TSR-containing proteins are either secreted 
proteins or transmembrane proteins, in which TSRs are always exposed to the 
ECM. TSR domain is responsible for the antiangiogenic function of several 
TSR-containing proteins, such as ADAMTS5 (Kumar et al, 2012; 
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Sharghi-Namini et al, 2008), F-spondin (Terai et al, 2001) and Brain-specific 
angiogenic inhibitor 1 (BAI1) (Koh et al, 2004). Given the idea that various 
TSR-containing proteins are naturally occurring inhibitors of angiogenesis, 
TSR domain may serve as an indicator for the implication of a certain protein 
in angiogenic inhibition. This is the underlying reason driving the functional 
study of ISM in angiogenic process. 
Another important domain of ISM is the C-terminal AMOP domain, which 
is initially a computer predicted domain hypothesized to be involved in cell 
adhesion (Ciccarelli et al, 2002). Sequence analysis shows that AMOP domain 
contains 100 amino acid residues, of which a pattern of 8 cysteines is highly 
conserved. These conserved cysteines may form disulfide bonds to maintain 
the structural and biological functions of AMOP domain. This domain is 
discovered in the extracellular portion of cell adhesion molecules, including 
MUC4 and sushi domain containing 2 (SUSD2). The presence of AMOP 
domain indicates the potential role of ISM in mediating cell adhesion. 
As mentioned above, according to its domain contents, ISM is speculated to 
be involved in cell attachment and angiogenesis. Indeed, ECs can attach to 
recombinant ISM (rISM) coated surface in a dose-dependent manner. In 
addition, ISM potently inhibited angiogenesis both in vitro and in vivo (Xiang 
et al, 2011). In vitro, rISM inhibits VEGF-stimulated EC proliferation, and EC 
capillary tube formation on Matrigel. It also induces EC apoptosis in the 
presence of VEGF. As shown in Table 1.4, structure-functional study indicates 
that the C-terminal AMOP domain plays an important role in the antiangiogenic 
effect of ISM. Although the N-terminal region of ISM inhibits 
VEGF-stimulated EC proliferation, it has no effect in EC capillary network 
formation. Unexpectedly, the TSR domain alone of ISM possesses no 
antiangiogenic activity. In vivo, Ism functions in both pathological and 
physiological angiogenesis (Xiang et al, 2011). Over-expression of ISM in B16 
melanoma inhibits tumor growth and angiogenesis in mice. Knockdown of ism 
in zebrafish embryos leads to abnormal intersegmental vessel formation in the 
trunk. 
Mechanism study shows that ISM selectively binds to integrin αvβ5 on the 
ECs surface (Xiang et al, 2011). Through the interaction with integrin αvβ5, 
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ISM induces EC apoptosis through integrin mediated death (IMD) by direct 
recruitment and activation of caspase-8 without generating anoikis (Xiang et al, 
2011).  
Table 1.4 Summary of the functional disparity of ISM and its various domains in 








ISM ↓↓ ↓↓ ↑↑ ↑↑ 
ISM-N - ↓ - - 
ISM-C ↓↓ ↓ - ↑↑ 
ISM-TSR - - - - 
‘-’, no effect; ↓↓, stron g inhibitory effect; ↓, inhibitory effect; ↑ ↑, strong 
stimulatory effect.  
1.8 Gaps of knowledge in the functional mechanisms of ISM 
As mentioned above, ISM is a secreted 60 kDa endogenous angiogenesis 
inhibitor potently inducing endothelial cell (EC) apoptosis and suppressing EC 
tube-like structure formation. However, the physiological or pathological 
significance of ISM remains unclear. It is also undetermined whether rISM can 
function as an effective anticancer agent to suppress tumor growth when 
delivered systemically.  
In addition, ISM induces distinct responses from adherent ECs under 
different physical conditions. Immobilized ISM can provide positive signals 
that mediate ECs attachment and promote ECs survival. On the other hand, 
soluble ISM in medium can induce ECs apoptosis. How the same ligand could 
induce completely different cell signaling pathways in adherent cells when 
present in soluble or immobilized conditions is still unknown. 
Prior to this thesis work, only one low-affinity cell surface receptor of ISM, 
αvβ5 integrin, had been identified. Although αvβ5 integrin is important for 
ISM's pro-apoptotic function, whether additional receptors exist for ISM and 
mediate its antiangiogenic functions remains to be determined.  
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1.9 Aim and objectives of this study 
The aim of my project is to unveil the functional mechanism of ISM in 
angiogenic inhibition and provide novel approaches for the development of 
drugs for cancer therapy. 
Specific objectives would be as follows: 
1) To determine if systemically delivered rISM suppresses tumor growth in 
mouse subcutaneous B16 melanoma and 4T1 breast carcinoma models. 
2) To unravel the mechanism of the functional disparity of ISM under 
different physical conditions. 





2 MATERIALS AND METHODS 
2.1 Cell lines and culture conditions 
2.1.1 Isolation of Human Umbilical Vein Endothelial Cells (HUVECs) 
HUVECs used in this work were isolated from the freshly obtained human 
umbilical cord (Jaffe et al, 1973). Umbilical cords were provided by consented 
maternal ward patients at the National University Hospital of Singapore 
according to the protocol (DSRB C/00/553) issued by the Singapore National 
University Health care Group’s Domain Specific Review Board (DSRB) ethics 
approval committee. Umbilical cord was stored at 4ºC in 1× Phosphate buffered 
saline (PBS) (8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4, 0.24 g/L KH2PO4, 
pH 7.4) after being collected from the placenta soon after birth. HUVECs were 
immediately isolated within 24 h.  Briefly, the cord was placed inside the 
sterile biosafety cabinet. Both the ends of it were cut transversely to make a 
clear view to insert adaptors into the vein. Then the adaptors were tightly 
sealed by sterile suture threads. One adaptor was linked to a 50 ml syringe 
(Terumo, Philippines) for the intake of fluid. The umbilical vein was washed 3 
times with 50 ml PBS to remove blood clot. Filter-sterilized 20 ml of 0.2% 
collagenase (Sigma-Aldrich, USA) in PBS was injected into the vein. Both ends 
were clamped using clamping scissors on the rubber portions of two adaptors. 
The whole umbilical cord was incubated for 15 min at room temperature (RT) 
for the enzymatic digestion. After that, the cord was kneaded gentlely to 
accelerate cell detachment. The HUVECs along with the collagenase was 
collected into a sterile 50 ml falcon tube. The umbilical vein was rinsed by 20 
ml of PBS once more to flush all the residual HUVECs. The cells were spun 
down at 500 g for 3 min. The cells were resuspended in 5 ml of Endogro-LS 
complete media (Millipore, Singapore) or CSC complete medium (Cell System 
Corporation, USA) supplemented with 1% Gentamicin (Sigma-Aldrich, USA) 
and transferred into a T-25 culture flask (NUNC, Denmark) pre-coated with 0.2% 
gelatin (Sigma-Aldrich, USA) in PBS. HUVECs were cultured at 37ºC in an 
incubator with 5% CO2. After 2 h, HUVECs were able to attach to the plastic 
 40 
 
surface of the culture flask. Then medium was replaced with fresh one and 
HUVECs were cultured for future use.  
2.1.2 HUVEC culture  
The HUVECs were cultured in EndoGRO-LS complete media or CSC 
complete medium supplemented with 1% Gentamicin in a 0.2% gelatin  
coated T-25/T-75 culture flask (Corning, USA) or 10 cm dishes (NUNC, 
Denmark) pre-coated with 0.2% gelatin in PBS at 37ºC in a humidified 
incubator (Thermo Scientific, Singapore) with 5% CO2. Cell culture medium 
was changed once every other day. When they reach around 80-90% 
confluence, HUVECs were washed once with PBS and rinsed by 
Trypsin-EDTA solution (Sigma-Aldrich, USA). The dish/flask was incubated at 
37ºC incubator for 2-3 min till the cells have detached from the plastic surface. 
The trypsin-EDTA was neutralized using complete media. The cells were split 
into new gelatin pre-coated dishes/flasks at the passage ratio of 1:2 and 
cultured at 37ºC in a humidified incubator with 5% CO2. HUVECs within 
passage 3 to passage 8 were used for all the experiments after which they may 
differentiate.  
2.1.3 Tumor cell culture  
In this study, several mouse and human cancer cell lines were obtained from 
American type culture collection (ATCC) – B16F10 (mouse melanoma), 4T1 
(mouse mammary carcinoma), NIH3T3 (mouse embryo fibroblast), SWISS3T3 
(mouse embryo fibroblast), 786-O (human kidney carcinoma). LS174T and 
LS-LM6 (human colon carcinoma) were obtained from Dr. Toshiaki Yoshioka 
(Department of Molecular Pathology and Tumor Pathology, Akita University 
Graduate School of Medicine, Akita, Japan) (Yoshioka et al, 2010). These cell 
lines were incubated in Dulbecco’s minimal essential medium (DMEM) 
(Sigma-Aldrich, USA) with 10% Fetal bovine serum (FBS) (Biowest, France) 
and 1% Penicillin-Streptomycin (PS) antibiotic solution (Life technologies, 
USA). The cells were cultured at 37ºC in a humidified CO2 incubator with 5% 
CO2.  Once reaching around 80-90% confluence, cells were trypsinized as 
explained before with 0.25% Trypsin (Life technologies, USA) and passaged at 
the ratio of 1:4 for further maintenance. 
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2.1.4 Cell number quantification 
HUVEC or cancer cell lines were trypsinized and resuspended in a minimum 
volume of 1-5 ml culture medium. The quantification of cell number was done 
by using Nucleocounter NC-100 (Chemometec, Denmark). The cell suspension 
was mixed with an equal volume of Reagent A (Cell lysis buffer) and Reagent B 
(Stabilization buffer) in a 1.7 ml microcentrifuge tube (Axygen, USA). The 
lysate solution was vortexed and loaded into a nucleocassette by immersing its 
tip into the solution and pressing the piston. The nucleocassette was later 
inserted into the instrument slot. Then the program was run to calculate the cell 
number in the nucleocassette. Later, the cell number displayed on the screen 
was multiplied by 3 to obtain the cell number per ml in cell suspension.  
2.1.5 Cryopreservation and recovery of cell lines 
HUVECs or the cancer cell lines at 80-90% confluence were trypsinized as 
mentioned before and were spun down at 500 g for 3 min. The cell pellets 
were resuspended in their culture medium containing 5-10% Dimethyl 
sulfoxide (DMSO) (Freshney, 1994). Around 2×106 cells were transferred into a 
1 ml cryovial. Cryovials were sealed tightly and placed in Mr. Frosty (Thermo 
Scientific, USA) which provides the critical -1ºC/min cooling rate required for 
successful cell cryopreservation and recovery. Then the Mr. Frosty was placed 
in -80ºC freezer (Sanyo, Japan) for 24 h before transferring inside cryovials into 
liquid nitrogen tank (Thermo Scientific, USA). Cell thawing and recovery was 
performed with rapid thawing by submerging cryovials in a 37ºC water bath 
(Memmert, Germany). The cells were centrifuged at 500 g for 3 min to remove 
DMSO and resuspended in fresh culture medium. After that, the cells were 
seeded onto a T-25 flask/10 cm dish for further incubation. 
2.2 DNA cloning techniques 
2.2.1 Polymerase Chain Reaction (PCR) 
To obtain the desired DNA sequence, PCR was conducted by using high 
fidelity Taq DNA polymerase - Advantage®-HF 2 cDNA PCR polymerase 
(Clontech, USA) with specific primer pairs (Table 2.1) in DNA thermal cycler 
model 480 and 9600 (Biometra, Germany). Each reaction was set in a 0.5 ml 
PCR tube (Axygen, USA). The components of a 50 µl reaction are as follows: 
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5 µl of 5× Reaction buffer, 5 µl of 50× dNTP mix, 25 ng DNA template, 1 µl 
of 10 µM sense primer, 1 µl of 10 µM anti-sense primer, 1 µl of HF- taq 
polymerase and top up to 50 µl with RNase free water. A typical cycling 
parameter used for the PCR consists of the following steps: initial denaturation 
at 94ºC for 2 min, followed by 35-40 cycles of denaturation at 94ºC for 30 sec, 
annealing and extension at 68ºC for 1-3 min (1 min per kb) and final extension 
at 68ºC for 10 min.  
2.2.2 Agarose gel electrophoresis  
Typical DNA electrophoresis was performed in 0.8-1% (w/v) agarose gel. 
The agarose powder (Vivantis Inc, USA) was dissolved in Tris-acetate 
Ethylene di-amine tetra acetic acid (EDTA) (TAE) buffer within a 100 ml 
conical flask and was melted in a microwave (National, Singapore) by 3 min 
heating. The whole flask was cooled by tap water. SYBR safe DNA gel stain 
(Life technologies, USA) was added into the agarose solution at the ratio of 
1:10,000. After mixation, the agarose solution was poured into the gel cast tray 
mounted with comb. The agarose gel was allowed to cool and solidify at RT. 
Once the gel hardened, it was transferred to the electrophoresis reservoir tray 
(Bio-Rad, USA) and submerged under TAE buffer. The comb was carefully 
pulled out. PCR product was mixed with 10× DNA loading dye (3.9 ml glycerol, 
500 μl 10% (w/v) SDS, 200 μl 0.5 M EDTA, 0.025 g bromophenol blue, 0.025 g 
xylene cyanol in 10 ml total volume with H2O) and loaded into the well. 
Appropriate 100 bp or 1 kb DNA ladder (Generuler, USA) was loaded in the 
adjacent well. The electrophoresis apparatus was connected to a power pack 
(Bio-Rad, USA) which applies a voltage of 5 V/cm during the electrophoresis. 
After running for 20 – 30 min, the gel was visualized using UV-transilluminator 
Gel Doc XR (Bio-Rad, USA). 
2.2.3 Gel extraction 
A gel extraction kit (Qiagen, USA) was used to isolate the desired DNA 
product. The DNA sample was separated according to size by electrophoresis 
as above mentioned with minor modifications. Instead of SYBR safe DNA 
gel stain, crystal violet (0.001%) was applied to visualize DNA (Yang et al, 
2001). After the running, the desired band in agarose gel was in brown color 
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and visible for naked eye. Then it was excised using a clean sharp scalpel. 
After that, a typical gel extraction was conducted following the manufacturer’s 
protocol. Briefly, 1 volume of the gel was mixed with 3 volumes of buffer QG 
and incubated at 50ºC on a heat block (Techne, UK) for 10 min with occasional 
mixation to dissolve the gel product. If the desired DNA sample was greater 
than 4 kb or smaller than 500 bp, additional 1 volume of isopropanol was 
added into the mixture. Then the mixture was transferred into a QIAquick 
column and spun at 13,000 rpm in a bench top centrifuge (Eppendorf, USA) for 
1 min. The column was washed with 0.75 ml of buffer PE and spun at 13,000 
rpm for 1 min. The empty column was centrifuged for an additional 2 min to 
remove any residual ethanol. 30-50 µl of RNase free water (pre-heated to 60ºC) 
was carefully added on the column membrane and kept for 2 min to 
disassociate the adhered DNA product. After that, the column was placed into 
a clean 1.7 ml micro centrifuge tube (Axygen, USA) and the desired DNA 
product was spun down by centrifugation at 13,000 rpm for 1 min.  
2.2.4 Quantification of DNA concentration 
Measurement of DNA concentration is performed by NanoDrop ND-1000 
Spectrophotometer (NanoDrop technologies, USA). Firstly, 1 µl of MilliQ 
water was applied on the NanoDrop pedestal to initialize the software. After 
that, the pedestal was gentlely cleaned by Kimwipes (Kimtech science, USA). 
Then 1 µl of appropriate solution (water or buffer used to dissolve DNA) was 
added on the pedestal as the blank. Again the residual solution was wiped 
away. DNA sample of 1 µl was loaded and its concentration was measured at 
the wavelength of 260 nm and printed on the screen of the attached computer.  
2.2.5 Restriction endonuclease digestion 
Digestion of DNA with restriction endonucleases (REs) was performed to 
sub-clone the gene of interest. All the REs used for this study were either from 
New England Biolabs (UK) or from Promega (USA). The plasmid used as the 
backbone, plasmid containing the insert of interest or PCR product of 3 μl was 
restriction digested in a 20 µl reaction containing 2 µl of 10× specific buffer for 
enzyme reaction, 0.5 µl of enzyme (5 Units), 0.2 µl of 100× BSA and made up 
to 20 µl with MilliQ H2O. The mixture was incubated at 37ºC for 4 h. After that, 
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the restriction digested product was separated by agarose gel electrophoresis 
and gel extracted as explained above.    
2.2.6 Ligation 
The desired DNA insert and vector was gel purified as mentioned above and 
each ligation reaction was set up following the manufacturer’s instruction 
(Promega, USA). In a 10 µl reaction, 1 µl of 10× DNA ligase buffer (300 mM 
Tris-HCl at pH 7.8, 100 mM MgCl2, 100 mM DTT and 10 mM ATP), 0.5 µl of 
T4 DNA ligase (1 Weiss units), 50 ng vector and corresponding amount of 
DNA insert, was added into a fresh 0.6 ml microcentrifuge tube (Axygen, USA) 
and made up with RNase free water. The molar ratio between vector and DNA 
insert was 1:3. Ligation reaction was incubated at 4ºC overnight.  
2.2.7 Transformation  
The standard transformation was performed using calcium chloride based 
chemically competent E.Coli DH5α cells (Seidman et al, 2001). The aliquot (50 
µl) of bacterial stock was thaw on ice for 10 min. After that, 1 ng of desired 
plasmid or 5 µl of ligation product was added into the competent cells and 
mixed by gentlely pippeting. The mixture was incubated on ice for 30 min. 
Heat shock was conducted by rapidly dipping the tube into 42ºC water bath 
(Bio Laboratories, Singapore) for 90 s. The tube was cooled on ice for 2 min. 
Then 1 ml of Luria-Bertani (LB) media (5 g yeast extract, 10 g tryptone and 10 
g of NaCl in 1 L of H2O) (Life technologies, USA) was added into the mixture 
of bacteria and plasmid and incubated for 1 h at 37ºC in a bacterial shaker 
swaying at 250 rpm (Thermo Scientific, USA). The cells were spun down,  
spread on a LB plate with 50 µg/ml ampicillin or other appropriate antibiotics 
and incubated at 37ºC for 16 h. For the pGEM-T vector containing LacZ 
cassette, blue-white screening was applied based on the principle of 
α-complimentation. Specially pre-treated LB plate was used in this case. LB 
plate containing 50 µg/ml ampicillin was spread with 20 µl of 50 mg/ml X-gal 
(Promega, USA) and 100 µl of 100 mM Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) (Promega, USA) and incubated at 37ºC for 1 h prior to use. Then the 
transformation was performed as mentioned before. Cells transformed with 
vectors containing recombinant DNA insert produced white colonies. Cells 
transformed with non-recombinant plasmids grew into blue colonies 
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2.2.8 Colony PCR screening 
Colony PCR is used to screen the presence of the desired DNA insert and its 
orientation in the vector. The colonies on the LB plate is picked by a 0.1-10 µl 
pipette tip and resuspended in 4 µl of sterile H2O, 1 µl of which is used as the 
DNA template source. The ideal primer pair consists of one primer generated 
from the sequence of the vector and another primer obtained from the 
sequence of the DNA insert. The 20 µl PCR reaction (KAPA Biosystems, South 
Africa) contains 2 µl of 10× Buffer A, 0.4 µl of 10 mM dNTP, 0.4 µl of 10 µM 
forward primer, 0.4 µl of 10 µM reverse primer and made upto 20 µl with 
sterile H2O. The PCR parameters were – initial denaturation at 95ºC for 3 min, 
followed by 35 cycles of denaturation at 95ºC for 30 s, annealing at the lowest 
Tm of the used primers minus 5ºC for 30 s, extension at 72ºC for 1-3 min (1 
min per kb) and final extension of 72ºC for 10 min. The size of the PCR 
product was visualized by agarose gel electrophoresis as explained earlier and 
positive colonies were picked and expanded for plasmid isolation.  
2.2.9 Plasmid isolation  
The bacterial colony containing the vector of interest was picked from a 
freshly streaked LB plate and inoculated into 6 ml of LB medium with 50 
µg/ml ampicillin or appropriate antibiotics in round bottom bacterial culture 
tubes (BD Biosciences, USA). The tubes were cultured at 37ºC for 16 h with 
vigorous shaking at 250 rpm in a bacterial shaker (Thermo Scientific, USA). 
The plasmid mini prep was conducted based on manufacturer’s instructions 
(Omega bio-tek, USA). Briefly, the bacterial culture was spun down at 13,000 
rpm for 1 min in a 1.7 ml microcentrifuge tube and resuspended in 250 µl of 
Solution I with RNase by vortex. Another 250 µl of Solution II (lysis buffer) 
was added into the bacterial solution and mixed gentlely by inverting 10 times. 
The mixture was incubated at RT for 2-3 min. Then 350 µl of Solution III was 
added and mixed carefully by inverting the tube several times to precipitate the 
protein and genomic DNA. The solution was spun down at 13,000 rpm for 10 
min at RT. At the same time, a HiBind DNA mini column with a 2 ml collection 
tube was pre-equilibrated with 100 µl of equilibration buffer. The supernatant 
was carefully transferred into the column and bond to its membrane by 
centrifugation. The column membrane was washed by 500 µl of HB buffer and 
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700 µl of DNA wash buffer. Empty column was centrifuged to remove residual 
ethanol. Elution was done by addition of 30-50 µl of 60ºC sterile H2O and 
plasmid was quantified using NanoDrop as described before (NanoDrop 
technologies, USA).  
2.2.10 DNA sequencing 
DNA sequencing was performed by BigDye® terminator (Applied 
Biosystems Inc., USA). The components for a 10 µl sequencing PCR are as 
follows: around 300 ng DNA template, 0.4 µl of 10 µM forward primer, 4 µl of 
the BigDye premix containing buffer, dNTP, ddNTPs and DNA Taq polymerase 
(Applied Biosystems Inc., USA) and made upto 10 µl with sterile H2O. The 
PCR conditions include 96ºC for 30 s, 25 cycles of 50ºC for 15 s and 60ºC for 1 
min. The PCR product was purified by ethanol precipitation. Briefly, the 10 µl 
PCR product was transferred into a 1.7 ml micro centrifuge tube (Axygen, USA) 
containing 62.5 µl of ethanol, 3 µl of 3 M sodium acetate and 24.5 µl sterile 
H2O. The reaction was mixed and incubated at RT for 10 min and then spun 
down at 10,000 g for 15 min. The supernatant was carefully discarded and 
pellet washed twice with 1 ml 70% ethanol and centrifuged at 10,000 g for 10 
min. The pellet was air-dried at 60ºC for 20 min and resuspended in 15 µl of 
ABI HiDi formamide buffer (Applied Biosystems Inc., USA). The solution was 
loaded into a 96 well reaction plate and sequencing was performed using the 
377 ABI PRISM automated DNA sequencer (Applied Biosystems Inc., USA).  
2.2.11 Total RNA isolation  
HUVECs within P4 were cultured to reach 90% confluence in T75 flask. 
The cells were washed twice by PBS. TRIzol reagent (Invitrogen, USA) of 1 
ml was directly added into the flask. The cells were homogenized and scraped 
down by a cell scraper (SPL Life Science, Korea). The solution was 
transferred to a 1.7 ml micro centrifuge tube and incubated at RT for 5 min. 
0.2 ml of chloroform was added into the homogenate, vortexed for 15 s and 
incubated at RT for 3 min. The mixture was subjected to phase separation by 
centrifugation at 12,000 g for 15 min at 4ºC. The aqueous phase containing 
RNA at the top was transferred to a new 1.7 ml tube and was precipitated by 
adding 0.5 ml of isopropanol. After 10 min incubation at RT, the mixture was 
centrifuged at 12,000 g for 10 min at 4ºC. Precipitated RNA was washed once 
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with 70% ethanol and air-dried at 60ºC for 20 min. The RNA pellet was 
dissolved in RNAase-free water and kept at -80ºC until further use. Quantity 
and purity of RNA samples were determined by NanoDrop and gel 
electrophoresis as described before. 
2.2.12 Two-step Reverse Transcription-PCR (RT-PCR) 
In the two-step RT-PCR, the first step was to synthesize the first strand 
cDNA using oligo dT primer and the second step was to amplify the gene of 
interest with the specific primer pair. The first strand of cDNA was 
synthesized in a 20 µl reaction using SuperScript III Reverse transcriptase (RT) 
(Life technologies, USA) following the manufacturer’s recommendation. 
Briefly, 1 µg of total RNA and 1µl of 50 µM oligo(dT)20 were mixed and 
heated to 70ºC for 5 min and incubated on ice for 1 min. Then 5 µl of 4× 
First-Strand Buffer, 1 µl of 0.1 M DTT, 1 µl of Protector RNase Inhibitor (40 
units/µl) (Roche, Germany), 1 µl of SuperScript III RT (200 units/µl) and 
RNase free water were added to the reaction solution. The reaction was 
incubated at 50ºC for 60 min and inactivated at 70ºC for 15 min. First-strand 
cDNA of 1 µl was used as the template to amplify desired gene using 
Advantage®-HF 2 cDNA PCR polymerase (Clontech, USA) with specific 
primer pairs as described before . 
2.2.13 Construction of plasmids 
2.2.13.1 Construction of pSecTag2B_mISM-EGFP plasmid and its control 
pSecTag2B_EGFP plasmid  
The pSecTag2B_mISM-EGFP plasmid was created to detect the subcellular 
location of ISM. The pSecTag2B_mISM plasmid was created previously in the 
lab by cloning the CDS of mouse ISM into pSecTag2B between BamH1 and 
Xho1. It was used as the template to generate all the expression constructs of 
ISM. Proteins expressed from pSecTag2A, B, C (Invitrogen, USA) are fused 
at the N-terminus to the murine Igκ-chain leader sequence for secretion and at 
the C-terminus to a sequence of c-myc epitope and six tandem histidine 
residues for detection and purification (Fig. 2.1). 
Firstly, the pSecTag2B_EGFP was constructed as the control. To create this 
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plasmid, the CDS of EGFP was inserted into pSecTag2B vector between the 
Xho1 and Apa1 sites. To add Xho1 site at the 5’ arm and Apa1 site at the 3’ 
arm, ‘EGFP F Xho1’ and ‘EGFP R Apa1’ primers were used to amplify the 
CDS of EGFP from pEGFP-N1 (Fig.2.2) (Clontech, USA). After Xho1 and 
Apa1 digestion, EGFP was ligased into pSectag2B between these two 
restriction enzyme sites to get pSecTag2B_EGFP (Fig. 2.3). 
Secondly, the CDS of mouse ISM was released from pSecTag2B_mISM by 
BamH1 and Xho1 digestion, and cloned into pSecTag2B_EGFP between these 
two restriction enzyme sites to get pSecTag2B_mISM-EGFP (Fig. 2.4). 
 




Fig. 2.2 pEGFP-N1 vector map (Adopted from Clontech) 
 
 





Fig. 2.4 pSecTag2B_mISM-EGFP map 
2.2.13.2 Construction of pXJ40_mCherry-hGRP78 plasmid and 
pXJ40_mCherry-hAAC2 plasmid 
To visualize the subcellular location of GRP78 and AAC2, the constructs of 
pXJ40_mCherry-hGRP78 and pXJ40_mCherry-hAAC2 were built. The CDSs 
of human GRP78 and human AAC2 (or SLC25A5) were amplified from 
cDNAs of HUVECs obtained as described before and inserted into 
pXJ40_mCherry vector (Fig. 2.5) (obtained from Dr Low Boon Chuan, NUS, 
Singapore) between the Xho1 and Kpn1 sites. To add Xho1 site at the 5’ arm 
and Kpn1 site at the 3’ arm, ‘GRP78 F Xho1’ and ‘GRP78 STOP R’ primers 
were used to amplify the CDS of GRP78 from cDNAs of HUVECs. Similarly, 
‘SLC25A5 F XhoI’ and ‘SLC25A5 STOP R’ primers were used to amplify the 
CDS of AAC2 from cDNAs of HUVECs. After Xho1 and Apa1 digestion, the 
human CDSs of GRP78 and AAC2 were ligased into pXJ40_mCherry 
between these two restriction enzyme sites to get pXJ40_mCherry-hGRP78 




Fig. 2.5 pXJ40_mCherry vector map 
 
Fig. 2.6 pXJ40_mCherry-hGRP78 plasmid map 
 
Fig. 2.7 pXJ40_mCherry-hAAC2 plasmid map 
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2.2.13.3 Construction of pXJ40_HA-hGRP78, pXJ40_FLAG-hITGAV 
and pXJ40_FLAG-hITGB5 
To study the contribution of GRP78 and αvβ5 integrin to the antiangiogenic 
function of ISM, the constructs of pXJ40_HA-hGRP78, 
pXJ40_FLAG-hITGAV and pXJ40_FLAG-hITGB5 were built to over express 
human GRP78 and αvβ5 integrin in cells.  
The CDS of human GRP78 was released from pXJ40_mCherry-hGRP78 by 
Xho1 and Kpn1 digestion and ligased into pXJ40_HA vector (Fig. 2.8) 
(obtained from Dr Low Boon Chuan, NUS, Singapore) between the Xho1 and 
Kpn1 sites to obtain pXJ40_HA-hGRP78 (Fig. 2.9). The CDS of human αv 
integrin subunit (hITGAV) in pGEM-T vector (Fig. 2.10) (Sino Biological Inc. 
China) was amplified and inserted into pXJ40_FLAG vector (Fig. 2.12) 
(obtained from Dr Low Boon Chuan, NUS, Singapore) between the Not1 and 
Kpn1 sites. To add Not1 site at the 5’ arm and Kpn1 site at the 3’ arm, ‘ITGAV 
F NotI2’ and ‘ITGAV R KpnI2’ primers were used to amplify the CDS of 
hITGAV in pGEM-T vector. After Not1 and Kpn1 digestion, the CDS of 
hITGAV was ligased into pXJ40_FLAG vector between these two restriction 
enzyme sites to get pXJ40_FLAG-hITGAV (Fig. 2.13).  
 




Fig. 2.9 pXJ40_mCherry-hGRP78 plasmid map 
 
Similarly, the CDS of human β5 integrin subunit (ITGB5) in pMD18-T 
Simple vector (Fig. 2.11) (Sino Biological Inc. China) was amplified and 
inserted into pXJ40_FLAG vector between the Hind3 and Not1 sites. To add 
Hind3 site at the 5’ arm and Not1 site at the 3’ arm, ‘ITGB5 F HindIII’ and 
‘ITGB5 R NotI’ primers were used to amplify the CDS of hITGB5 in 
pMD18-T Simple vector. After Hind3 and Not1 digestion, the CDS of hITGB5 
was ligased into pXJ40_FLAG vector between these two restriction enzyme 
sites to get pXJ40_FLAG-hITGB5 (Fig. 2.14). 
 




Fig. 2.11 pMD18-T Simple vector map (Adopted from Sino Biological Inc.) 
 




Fig. 2.13 pXJ40_FLAG-hITGAV plasmid map 
 
Fig. 2.14 pXJ40_FLAG-hITGB5 plasmid map 
2.2.14 List of primers 
All the primers used in the study were listed in Table 2.1 below with a brief 
description of their purpose and the corresponding annealing temperature for 
the PCR. 















EGFP F Xho1  GCTCGAGGAGTGAGCAAGGGCGAGGAG 
67ºC 
Cloning of EGFP cDNA in pEGFP-N1 
vector into pSecTag2B vector. EGFP R Apa1 GAGGGCCCCTTGTACAGCTCGTCCAT 
2 
GRP78 F XhoI TCTCGAGATGAAGCTCTCCCTGGTG 
62ºC 
Cloning of human GRP78 from 
HUVEC cDNAs into pXJ40_mCherry 
vector. GRP78 STOP R CTGGTACCGCTACAACTCATCTTTTTCTGC 
3 
SLC25A5 F XhoI TCTCGAGATGACAGATGCCGCTGTG 
57ºC 
Cloning of human AAC2 (SLC25A5) 
from HUVEC cDNAs into 
pXJ40_mCherry vector. SLC25A5 STOP R CTGGTACCGTTATGTGTACTTCTTGATTTC 
4 




Cloning of the CDS of human αv 
integrin subunit (hITGAV) from 
pGEM-T vector into pXJ40_FLAG 
vector. 




ITGB5 F HindIII TCCAAGCTTATGCCGCGGGCCCCGGCG 
68ºC 
Cloning of the CDS of human β5 
integrin subunit (ITGB5) in pMD18-T 
Simple vector into pXJ40_FLAG 
vector. ITGB5 R NotI CCGGGCGGCCGCTCATTCCACAGTGCCATT 
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6 ITGAV SEQ F650 CTTATTTCGGATCAAGTGG 50ºC 
Primers used for sequencing PCR  
7 ITGAV SEQ F1324 AATGAAAGGAGCCACAGA 50ºC 
8 ITGAV SEQ F2081 AATGAAGCCTTAGCAAGA 50ºC 
9 ITGAV SEQ F2679 AGCGGGATCTTGCCCTCAG 50ºC 
10 ITGB5 SEQ F656 GGTTCCGCCATCTGCTGCCTCT 50ºC 
11 ITGB5 SEQ F1436 GCAACGGGAGCGGGACCTAT 50ºC 
12 ITGB5 SEQ F2034 TGACCAGGAGGCTGTGCT 50 ºC 
13 T7  TAATACGACTCACTATAGGG 50ºC 
Primers used for sequencing or colony 
PCR 
14 SP6 ATTTAGGTGACACTATAG 50ºC 
15 BGH reverse primer TAGAAGGCACAGTCGAGG 50ºC 
16 oligodT TTTTTTTTTTTTTTTTTTTT 50ºC 





2.3 Transient transfection of cells 
Branched polyethylenimine (bPEI) (Sigma-Aldrich, USA) was used to transient 
transfect cell types that are easy to reach high efficiency, such as HEK293T cells and 
o-786 cells, with desired plasmids. The cells were seeded in a 10 cm dish or a 6-well 
plate (Greiner bio-one, Germany). Once reaching 70-80% confluence, the cells were 
washed with PBS once and changed into fresh complete medium. The transfection mix 
possesses 10% of the volume of the culture medium (1 ml for 10 cm dish and 200 µl 
for 6-well plate). It was comprised of DNA: bPEI in a ratio of 3:4 in PBS. Endotoxin 
free plasmid DNA of 10 µg or 2 µg was used for transfection for 10 cm dish or 6-well 
plate respectively. The 1 mg/ml bPEI working solution in sterile MilliQ H2O was stored 
in -20ºC and thawed before use. This transfection mix was vortexed and incubated at 
37ºC for 20 min before adding onto the cells dropwisely.  
Besides bPEI, electroporation was used for cell types that are difficult to obtain 
high efficiency in transient transfection, such as HUVECs and LS174T. Cells were 
grown to 90% confluence and trypsinized. A 6-well plate was prepared by filling 1.5 
ml of appropriate complete culture medium. 5×105 Cells were centrifuged and 
resuspended in 100 µl of the Ingenio electroporation buffer (Mirus, USA). The cell 
suspension was combined with 0.5-5 µg plasmid or 30 nM-300 nM siRNA (3-30 
pmol/sample). The mix was transferred into a 0.2 cm cap Ingenio cuvette (Mirus, 
USA). The cuvette was inserted into the NucleofectorTM II (Amaxa Biosystems, 
Germany) cuvette holder and applied the selected program (U-001 or A034 for 
HUVECs, T-020 for LS174T). The cuvette was taken out of the holder once the 
program was finished. Complete culture medium of 500 µl was added into the cuvette. 
The mix was gently transferred into the 6-well plate. 
After transient transfection, the cells were incubated overnight and replaced with 
fresh serum free medium for 48 h to harvest the conditioned medium (CM) or changed 
with complete medium for 48 h to detect the expression of reporter gene. 
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2.4 Concentration of conditioned medium 
The conditioned medium (CM) was harvested after transfection and incubation with 
serum free medium for 48 h. Two distinct methods were applied for the concentration 
of CM according to the downstream application. For functional tests, Amicon Ultra-15 
Centrifugal Filter Units (Millipore, USA) with appropriate molecular weight cut off 
membrane was used for the CM concentration and buffer exchange. CM in the filter 
unit was centrifuged at 4,500 rpm for 15 min (Beckman Coulter, USA) to obtain a 75× 
concentrated CM (200 µl). This filter unit can be re-filled with MilliQ H2O and 
centrifuged for another three times to desalt the protein solution. The obtained protein 
was quantified and stored in -80ºC till further use.  
For assays that do not require intact protein such as western blotting (WB), the CM 
concentration was performed by acetone precipitation. -20ºC pre-cooled acetone with 
4 times of the sample volume was added into the CM, mixed and kept at -80ºC for 2 h 
to overnight. The precipitated total protein was spun down at 4,500 rpm for 15 min. 
The protein pellet was air-dried to remove residual acetone at RT for 30 min and 
dissolved in 200 µl of 2× SDS-loading dye (100 mM Tris-Cl (pH 6.8), 20% (v/v) 
glycerol, 4% (w/v) SDS (sodium dodecyl sulfate), 200 mM β-mercaptoethanol and 0.2% 
(w/v) bromophenol blue). Then the sample was boiled at 100ºC on a heat block 
(Techne, Germany) for 5 min and analyzed by WB.    
2.5 Quantification of protein concentration 
Protein concentration was quantified by Bradford protein assay. BSA standard (10 
mg/ml) was prepared prior to the assay. A serial of BSA standard dilutions were 
prepared between 0-500 µg/ml. Standard dilutions and protein sample (20 µl) were 
added into 96 well plate in triplicate (Nunc, Denmark) and mixed with 180 µl of the 
filtered 1×Bradford reagent (Bio-Rad, USA). The absorbance at 595 nm was measured 
by a microplate reader (Bio-Rad, USA). Based on the standard curve, the protein 
concentration was automatically calculated.  
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2.6 Cell lysis 
Briefly, cells were rinsed twice with PBS. Then RIPA lysis buffer containing 50 
mM Tris-HCl pH7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Triton X-100, 
0.1% sodium dodecyl sulfate, 5 mM EDTA and 1× protease inhibitor cocktail solution 
(Roche, Germany) was added dropwisely on the cells. The cells were immediately 
harvested by cell scraper (SPL Life Science, Korea), transferred into a 1.7 ml tube and 
incubated on a nutator (Labnet International, USA) at 4ºC for 30 min. The 
undissolving cell debris was removed by centrifugation at 13,000 rpm at 4ºC for 10 
min. For WB analysis, the supernatant was quantified, mixed with SDS-loading dye 
and boiled as above described. 
2.7 Western Blotting 
2.7.1 Sodium dodecyl sulfate - Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
8-15% polyacrylamide gel was used according to the molecular weight of the protein 
band and was manually casted in Mini-PROTEAN 3 Cell (Bio-Rad, USA) 
SDS-PAGE apparatus following the manufacturer’s instruction. Briefly, the clean glass 
cassette sandwich with a 1.5 mm spacer was secured in a casting frame. Resolving gel 
was prepared by mixing 1.5 M Tris-Cl (pH 8.8) and 30% acrylamide/bisacrylamide 
solution (37.5:1, acrylamide/bis; Bio-Rad, USA) in different proportion based on the 
percentage of the gel, 150 µl of 10% (w/v) SDS solution and 150 µl of 10% (w/v) 
ammonium per sulfate (APS) and making upto 15 ml with MilliQ H2O. Then the mix 
was completed by adding 8 µl of TEMED and poured into the gel cassette. MilliQ H2O 
was added on the top of resolving gel to produce a smooth surface. Once the gel is 
solidified, the MilliQ H2O was decanted and 5% stacking gel was poured. 8 ml stacking 
gel contained 5.5 ml H2O, 1.3 ml of 30% acrylamide/bisacrylamide solution, 1 ml 0.5 
M Tris.Cl (pH 6.8), 80 μl of 10% SDS, 80 μl of 10% APS, and 8 μl TEMED. The comb 
was inserted into the stacking gel and allowed to solidify. The settled gel cassette was 
carefully removed from the casting frame and placed into the Mini-PROTEAN 3 
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electrophoresis module assembly. The SDS-running buffer (15 g/L Tris base, 72 g/L 
Glycine, pH 8.3, SDS 5 g) was filled into the inner and outer chamber of the tank. The 
comb in the gel was gently removed. The protein marker (Bio-Rad, USA) and samples 
were loaded into the wells. The electrical leads were connected to a power pack and run 
at 100 V for 1.6 h. 
 To visualize protein bands, the resolving gel was carefully transferred into a 20 cm 
culture dish and stained with filtered Coomassie blue staining solution (0.1% 
Coomassie R250, 10% acetic acid, 40% ethanol in 1 L of H2O) for 1 h with vigorous 
shaking (GFL, Germany). The gel was immersed in destaining solution (10% acetic 
acid, 5% ethanol) with 2 knotted Kimwipes and shaken for 1 h. After that, the 
destining buffer was replaced with fresh one and the gel was destained overnight till 
the protein bands are clear. The gel was placed on a gel illuminator (Hoefer, USA) and 
its photo was taken by a digital camera (Cannon, Japan). 
2.7.2 Gel transfer 
Proteins separated by SDS-PAGE were transferred into the nitrocellulose 
membrane (Bio-Rad, USA) by wet electroblotting transfer system (Bio-Rad, USA). 
Briefly, the nitrocellulose membrane, 6 sheets of chromatography papers (Whatman, 
UK) and foam pads were pre-soaked in transfer buffer (48 mM Tris, 39 mM glycine, 
0.04% SDS, 20% methanol). Gel covered by the membrane was sandwiched between 
3 chromatography papers on each side followed by a foam pad in the plastic holder. 
Care was taken to avoid any bubble in this step. Then the holder was inserted into the 
cassette placed inside the electrophoresis system. It was made sure that the membrane 
faced the positive electrode. A bio-ice cooling unit was placed into the tank. After that, 
the transfer buffer was poured into the tank. The protein transfer was performed at 
100V for 1 h.  
2.7.3 Immunoblotting  
The nitrocellulose membrane with transferred protein was placed in a plastic box 
and blocked by 10 ml of 1% BSA in 1× Tris buffered saline (50 mM Tris-Cl, 150 mM 
NaCl, pH to 7.6) with 1% Tween-20 (TBST) at RT with gentle shaking for 2 h. The 
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blocking solution was replaced by the primary antibody with appropriate dilution 
prepared in 1% BSA in 1× TBST with 0.2% sodium azide and incubated overnight at 
4ºC with shaking. After incubation, the primary antibody solution can be collected and 
reused for the next WB. The membrane was washed for three times with TBST for 10 
min each on a shaker. The matching secondary antibody conjugated with horse radish 
peroxidase (HRP) in 1% BSA in TBST was added to the membrane and incubated at 
RT with shaking for 1 h. This was followed by three times washes with TBST for 10 
min each on a shaker.  
2.7.4 Chemiluminescent detection 
After immunoblotting, the HRP activity was detected by enhanced 
chemiluminescent substrate (Thermo Scientific, USA). In a red light dark room, equal 
volumes of the luminol/enhancer and the peroxide buffer were mixed and added 
dropwisely on the membrane. After 5 min incubation, the membrane was transferred 
into the developing cassette and covered with a plastic sheet. An X-ray film (Kodak, 
USA) was placed on the plastic sheet and exposed for appropriate time. The film was 
developed by an automated X-ray film processor (Kodak, USA).  
2.7.5 Stripping and re-probing 
The immunoblotting on the nitrocellulose membrane was removed by washing the 
membrane in the stripping buffer (1.5% glycine, 0.1% SDS, pH 2.2) with shaking at RT 
for 15 min. The membrane was further washed thrice with 1×TBST before blocking 
with 1% BSA in TBST. The re-probing with desired antibodies was done as described 
above.  
2.8 Expression and purification of recombinant ISM protein in E. coli 
The recombinant ISM protein with C-terminal 6×His tag was expressed by the 
pETm-ISM plasmid (Xiang et al, 2011) upon isopropyl-beta-D-thiogalactoside (IPTG) 
induction in E.coli BL21 (DE3). Then His-tagged recombinant ISM (rISM) was 
purified by Ni-NTA affinity chromatography in 6 M urea according to the 
manufacturers’ protocol (Promega, USA). After that, rISM was further purified by 
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reverse-phase high-performance liquid chromatography (HPLC) using a Phenomenex 
Jupiter 300 C18 column. Protein purity was estimated by SDS-PAGE combined with 
Coomassie blue staining. Endotoxin content of rISM was measured using Limulus 
Amebocyte Lysate PYROGENT kit (Cambrex, USA) following the manufacturer’s 
instructions.  
2.9 Isolation of the plasma membrane fraction of cells  
2.9.1 Isolation of the plasma membrane fraction of cells through 
ultracentrifugation 
To search for the cell surface receptor of ISM, the plasma membrane fraction was 
isolated from HUVECs through ultracentrifugation. Briefly, after PBS wash, HUVECs 
were directly scraped down into ice-cold hypotonic buffer containing 10 mM Tris-HCl 
of pH 7.9, 0.5 mM DTT and 1× protease inhibitor cocktail solution (Roche, Germany). 
The cells were homogenized by a tight-fitting Dounce homogenizer (Wheaton, USA) 
with 50 strokes. The homogenate was centrifuged to remove the nuclei and 
mitochondria at 8,000 g for 10 min at 4Cº. Then the supernatant was centrifuged at 
100,000g (Beckman Coulter, USA) for 45 min at 4ºC. The obtained pellet containing 
plasma membrane proteins was dissolved in hypotonic buffer containing 1% Triton 
X-100 and processed for pull-down and spectrometry. 
2.9.2 Isolation of the plasma membrane fraction of cells through phase 
partitioning 
For WB analysis, the plasma membrane fraction of cells was isolated by Mem-PER 
Eukaryotic Membrane Protein Extraction Reagent Kit following the manufacturer’s 
instructions with slight modification (Thermo-Scientific, USA). The cell lysate 
without the nuclei and mitochondria was prepared as above mentioned. Diluted 
reagent C (a detergent to separate the hydrophobic and hydrophilic proteins) was 
made by mixing 300 µl reagent C with 150 µl reagent B at 4ºC and added into 150 µl 
cell lysate. The mix was incubated on ice for 30 min with vortex every 5 min. Then 
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the tube was centrifuged at 10,000 g for 3 min at 4ºC. The supernatant was transferred 
to a new tube and incubated in 37ºC water bath for 20 min to separate the protein 
fraction. The tube was centrifuged at 10,000 g for 2 min at RT to isolate the 
hydrophobic fraction from the hydrophilic fraction. The hydrophobic plasma 
membrane fraction in the bottom was diluted 2-fold by 4-fold H2O diluted reagent B 
and processed for WB analysis. 
2.10 Isolation of mitochondrial and cytosolic fractions of cells 
The isolation of mitochondrial and cytosolic fractions of HUVECs and HEK293T 
were conducted by the Mitochondria Isolation Kit for Cultured Cells (Pierce, USA). 
Briefly, 2×107 HUVECs or HEK293T cells post 48 h transient transfection by 
pSecTag-ISM plasmid or 24 h 1µM ISM treatment were trypsinized and harvested by 
centrifugation in a 2 ml tube at 500 g for 3 min. The pellet was resuspended in 800 µl 
of reagent A and incubated on ice for 2 min. Then 10 µl of reagent B for breaking the 
cells was added into the mix. The tube was vortexed at maximum speed for 5 s and 
incubated on ice for 5 min with vortex every min. Reagent C of 800 µl was added into 
the cell solution and mixed by gentle invert. The undissolving cell debris and nuclei 
were spun down at 700 g for 10 min at 4Cº. The supernatant was transferred into a 
new 2.0 ml tube and centrifuged at 3,000 g for 15 min at 4Cº to separate the cytosolic 
fraction (the supernatant) and the mitochondrial fraction (the pellet). The 
mitochondrial pellet was washed once by 500 µl reagent C and spun down at 12,000 g 
for 5 min at 4ºC. These two fractions were saved for further analysis such as WB, 
pull-down, spectrometry and ATP colorimetric assay. 
2.11 Pull-down and Mass Spectrometry 
2.11.1 Identification of the cell surface receptor of ISM 
ISM-Ni-NTA affinity beads were prepared with 1 mg rISM and 1 ml Ni-NTA beads 
(Promega, USA). ISM-Ni-NTA affinity beads of 1 ml were incubated with 10 mg 
plasma membrane proteins isolated from HUVECs as above described at 4°C 
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overnight. Ni-NTA beads without binding ISM were used as the control. The affinity 
beads or the control beads were extensively washed with ice-cold PBS. The beads were 
boiled with 2× SDS loading buffer and applied for SDS-PAGE and Coomassie blue 
staining as mentioned before. The specific bands showed in affinity beads were 
excised separately and subjected to in-gel digestion. In-gel digestion of prominent 
bands and desalting of the samples was performed by the staff of Protein and 
proteomics Centre in NUS, prior to mass analyses. Then mass analyses were 
performed using an ABI Voyager STR (MALDI-Tof-MS) analyzer (Applied 
Biosystems, USA). 
2.11.2 Identification of the binding partners of ISM in mitochondria 
The mitochondrial fractions of intact HEK293T cells and HEK293T cells transient 
transfected by pSecTag-ISM plasmid for 48 h were isolated as above mentioned. 
His-tagged ISM and its binding partners from the mitochondrial fraction of 
pSecTag-ISM plasmid transfected HEK293T cells were pulled down by Epitope Tag 
Protein Isolation Kit with anti-His microbeads (μMACS, Germany). The intact 
mitochondrial fraction was pull-down as the control. Briefly, the mitochondrial pellet 
was dissolved in 100 µl lysis buffer at 4°C for 30 min and centrifuged at 10,000 g for 
10 min to remove the debris. Anti-His microbeads of 50 µl was added into the 
mitochondrial lysate and incubated for 30 min on ice. The μ column was hung at the 
magnetic field of the μMACS separater and equilibrated by 100 µl lysis buffer. The 
lysate with beads was applied into the column. Then the column was washed by 200 
µl wash buffer-1 4 times and 100 µl wash buffer-2 once. After that, 20 µl pre-heated 
95°C elution buffer was added into the column and incubated for 5 min. His-tagged 
ISM and its binding partners were eluted out by 50 µl 95°C elution buffer. The eluants 
were subjected to SDS-PAGE and stained with Coomassie blue. Excised specific bands 
pulled down from the mitochondrial fraction of ISM over-expressed HEK293T cells 




2.12 Immunofluorescent Staining 
HUVECs or HEK293T were grown on 0.2% gelatin coated coverslip and 
transfected with desired plasmid for 48 h or treated by 1 μM His-tagged ISM for 3 h. 
For determining which endocytic pathway ISM went through, HUVECs were 
pre-treated with 25 μg/ml nystatin, 6 μg/ml chlorpromazine or combination of them 
for 30 min and then incubated with 1μM His-tagged ISM for 3 h. Then cells were 
incubated in serum-free medium with 100 nM MitoTracker Red (Invitrogen, USA) for 
30 min. Then cells were washed by acidic PBS (pH 3.5) to remove cell surface 
binding ISM and fixed with 4% PFA in PBS (pH 7.3) at RT for 30 min. After fixation, 
the cells were washed thrice 10 min each by PBST (PBS with 0.1% Triton) and 
permeabilized with 0.3% Triton in PBS at RT for 15 min. Then the cells were again 
washed and blocked with 1% BSA in PBST at RT for 1 h. After blocking, the cells 
were incubated with anti-His primary antibody (Santa Cruz, USA) (1:500 dilution) at 
4°C overnight and washed for 3 times 10 min each with PBST at RT. Then the cells 
were incubated with Alexa Fluor 488 secondary antibody (Invitrogen, USA) (1:500 
dilution) at RT for 1 h. After wash, the cells were counter stained by 1 µg/ml DAPI 
(Chemicon, USA) in PBS to label the nucleus. To mount the stained cells to a glass 
slide, a drop of mounting solution (50% glycerol and 50% PBS) was applied on the 
slide. The coverslip with cells facing the slide was adhered to the slide by the 
mounting solution. The edge of the coverslip was sealed by transparent nail polish. 
Fluorescent images were collected by Zeiss LSM 510 Meta confocal microscope 
(Zeiss, Germany). The co-localization between different fluorescent channels was 
analyzed by Imaris software (Bitplane Inc., USA). 
2.13 In vitro cell-based assays 
2.13.1 EC Tube formation assay 
EC tube formation assay was performed using ECMatrix® in vitro angiogenesis 
assay kit (Chemicon, USA) according to the manufacturers’ instructions. The matrigel 
was prepared in a 4ºC room. The gel solution and diluent buffer were thawed on ice. 
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Then 100 µl of diluent buffer was mixed with 900 µl of gel solution in a sterile 
microcentrifuge tube and mixed well. The gel solution of 10 µl was plated into a 
µ-Slide Angiogenesis chamber (ibidi, Germany) and kept at 37ºC for 1 h to solidify. 
For the internalization study, ECs (1×104 cells) per sample in 50 µl basal medium 
were pre-treated with 25 μg/ml nystatin (Sigma-Aldrich, USA), 6 μg/ml 
chlorpromazine (Sigma-Aldrich, USA) or combination of these two drugs for 15 min 
at 37ºC incubator. For studying the contribution of αvβ3 integrin,αvβ5 integrin and 
GRP78 to the anti-tube formation activity of ISM, HUVECs were pre-transfected by 
siRNAs of β3 integrin subunit, β5 integrin subunit or GRP78 for 48 h or pre-treated 
by neutralizing antibodies of GRP78 (Santa Cruz, USA) for 15 min. Then cells were 
treated with 1μM ISM for additional 30 min before being plated onto the polymerized 
matrigel. The cells were incubated at 37°C incubator with 5% CO2 for 6–8 h before 
documenting the tubular structure formation using Axiovert 200 inverted light 
microscope (Zeiss, Germany). Capillary length from representative fields was 
quantified by NIH ImageJ. 
2.13.2  Apoptosis assay  
Cells (2x104) were seeded in each well of a 96-well plate. For the internalization 
study, HUVECs were pre-treated with 25 μg/ml nystatin, 6 μg/ml chlorpromazine or 
combination of them for 30 min. For studying the contribution of GRP78 to the ECs 
apoptosis induction activity of ISM, HUVECs were pre-transfected by siRNAs of 
GRP78 for 48 h or pre-treated by GRP78 neutralizing antibody for 30 min. Then the 
cells were starved in 2% FBS basal medium for 3 h. After that, HUVECs were treated 
with 1 μM ISM and 15 ng/ml VEGF for 24 h. For non-ECs, such as NIH3T3, 
SWISS3T3, HEK293T, B16F10, 4T1, LS174T, LS-LM6 and O-786 cells, the cells 
were treated with 1μM ISM in 2% FBS basal medium for 24 h after 6 h starvation in 
basal medium. Apoptosis was detected by a Cell Death ELISA kit (Roche, Germany). 
Briefly, the 96-well plate was centrifuged at 200 g for 10 min and the media were 
discarded carefully. The cells were lysed by 200 µl of lysis buffer at RT for 30 min and 
again centrifuged. 20 µl of the supernatant was transferred into the streptavidin coated 
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microplate and 80 µl of immunoreagent containing anti-histone-biotin and anti-DNA 
HRP-conjugated antibody for 2 h at RT with vigorous shaking. The microplate was 
washed thrice with the incubation buffer. Then 100 µl of substrate solution was added 
into the microplate and incubated at RT with shaking for around 20 min till the color 
development was sufficient for a photometric analysis. The reaction was terminated by 
adding 100 µl of stop solution. The absorbance at 405 nm was measured in a microplate 
reader.   
2.13.3 Cell Attachment Assay 
96-well plates were coated with 50 μl of 1 μM ISM at 4°C overnight. Non-specific 
binding sites were blocked with 1% BSA for 2 h at 37°C. HUVECs were either 
pre-treated by GRP78 neutralizing antibody or control IgG for 30 min or transfected 
by siRNA targeting GRP78 for 48 h. Then 2×104 cells were plated into each well and 
allowed to attach for 1 h at 37°C. Attached cells were fixed by 10% formalin and 
stained with 0.2% crystal violet. Absorbed crystal violet was extracted by 10% acetic 
acid and quantified by measuring the absorbance of eluted dye at 595 nm with a 
microplate reader.  
2.13.4 ISM internalization assays 
HUVECs were treated with 1 μM rISM for increasing time period or increasing 
concentrations of ISM for 3 h. For determining which endocytic pathway ISM went 
through, HUVECs were pre-treated with increasing concentrations of nystatin and 
chlorpromazine or combination of them for 30 min and incubated with 1 μM 
His-tagged ISM for 3 h. Then cells were washed by acidic PBS (pH 3.5) to remove 
cell surface binding ISM and examined for internalized ISM by WB using anti-His 
(C-term) antibody (Invitrogen, USA) or immunofluorescent staining by His probe 
(Santa Cruz, USA).  
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2.13.5 Internalized ISM Triton partitioning 
Triton-insoluble and -soluble fractions of HUVEC lysate were prepared as 
previously described (Wickstrom et al, 2003). HUVECs were treated with 1 μM 
His-tagged ISM for 24 h. After thoroughly washed by acidic PBS (pH3.5) to remove 
cell surface associated ISM, the cells were lysed in 1 ml of 1% Triton X-100 in 
2-(N-morpholino)ethanesulfonic acid (MES)-buffered saline (25 mM MES, 0.15 M 
NaCl, 1×protease inhibitor cocktail, pH 6.5) for 30 min on ice. Cell extracts were 
homogenized by a tight-fitting Dounce homogenizer (Wheaton, USA) with 50 strokes 
and adjusted to a final density of 40% by adding OptiPrep density gradient Medium 
(Sigma-Aldrich, USA). Samples were transferred into a centrifuge tube and overlaid 
with discontinuous 30% and 5% OptiPrep density gradient media. Samples were then 
centrifuged at 39,000 rpm for 18 h (Beckman Coulter, USA). After that, fractions from 
top to bottom were collected and analyzed by WB with antibodies against ISM 
(His-probe), integrinβ5 subunit and GRP78. Caveolin-1 and clathrin heavy chain 
(CHC) were used as markers for lipid-raft and non lipid-raft fraction.  
2.13.6 ATP colorimetric assay 
Confluence HUVECs were cultured in 2% FBS basal medium with or without 1 
μM ISM treatment for 24 h in 37°C. The whole cell lysate, mitochondrial and 
cytosolic fractions were obtained as mentioned before. Then ATP concentrations in 
different subcellular fractions were analyzed using the ATP colorimetric assay kit 
(BioVision, USA) following the manufacturer’s protocol. Briefly, 1 mM ATP standard 
was diluted by ATP assay buffer to generate 0, 2, 4, 6, 8, 10 nmol ATP in each well of 
a 96-well plate ATP. The lysates from different subcellular fractions were added into 
the 96-well plate. The volume of both the ATP standard and test samples was adjusted 
to 50 μl by ATP assay buffer. Then 50 μl of reaction mix containing 44 μl ATP assay 
buffer, 2 μl ATP probe, 2 μl ATP converter and 2 μl developer was added into the ATP 
standard and test samples. The reaction was protected from light and incubated at RT 
for 30 min. The absorbance at 570 nm was measured by a microplate reader. The 
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concentration of ATP in each sample was calculated according to the ATP standard 
curve. 
2.13.7 In situ proximity ligation assay (PLA) 
The direct interactions between ISM and GRP78, ISM and integrin αvβ5, GRP78 
and integrin αvβ5 with or without the presence of ISM were detected by in situ PLA 
(Olink Bioscience, Sweden) following the manufacturer’s instructions. Briefly, 
HUVECs grown on coverslips were treated by 2% FBS basal medium with or without 
1 μM ISM for 3 h at 37°C. Then cells were fixed, permeabilized, blocked and 
incubated with primary antibodies following the standard procedure of 
immunofluorescent staining. The primary antibodies against two proteins in each test 
were raised in different species. Appropriate minus and plus PLA probes were diluted 
at the ratio of 1:5 in blocking buffer (1% BSA in PBST) and incubated with samples 
for 1 h at 37°C. After that, the cells were washed twice by buffer A and incubated with 
ligation-ligase solution for 30 min at 37°C. The cells were again washed twice by 
buffer A and incubated with amplification-polymerase solution for 100 min at 37°C. 
Then the cells on coverslips were washed by buffer B, counter stained by DAPI and 
mounted to slides. Fluorescent images were collected by Zeiss LSM 510 Meta 
confocal microscope. The intensities of the red PLA signals representing the direct 
interaction between two proteins of interest were quantified by NIH ImageJ. 
2.14 ELISA binding assay 
To detect the binding affinity between ISM and GRP78, triplicate wells in a 96-well 
plate were coated with 50 µl of 10 nM recombinant GRP78 (StressMarq, Canada) at 
4°C overnight. Non-specific binding sites were blocked with 1% BSA in PBST for 2 h 
at RT. Increasing concentrations of ISM were incubated with immobilized GRP78 for 1 
h at RT. After washing 3 times by PBST, each well was incubated with 50 µl of 
primary anti-ISM antibody (1:1000) at 4°C overnight. Then wells were again washed 
and incubated with secondary HRP-conjugated antibody (1:2000) for 1 h at RT. After 
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washing thrice by PBST, the wells were developed with 100 μl TMB (3,3', 
5,5"-tetramethylbenzidine) peroxidase substrate (Chemicon, USA). After developing 
for 5 min, this reaction was stopped with 100 μl of 1.25 M sulphuric acid. The 
absorbance at 450 nm was measured by a microplate reader (Bio-Rad, USA). 
Dose-response curve was generated and the value for Kd was calculated by GraphPad 
Prism software (GraphPad Software, Inc., USA) 
To detect the binding affinity between ISM and HUVECs, triplicate wells of a 
96-well plate were seeded with a confluent monolayer of HUVECs. The cells were 
treated by 2% FBS basal medium with increasing concentration of ISM for 1 h at 
37°C. After that, the unbound ISM was removed and the cells were fixed by 4% PFA 
in PBS for 20 min at RT. Then the cells were washed 3 times by PBS and blocked 
with 1% BSA in PBS for 2 h at RT. After washing, the amount of bound ISM was 
quantified by standard ELISA as described before. The value for Kd was calculated by 
GraphPad Prism software.  
2.15 Quantification of cell surface GRP78 and integrin αvβ5 molecule 
numbers 
Increased doses of pure recombinant GRP78 (StressMarq, Canada) or integrin αvβ5 
(Merk Millipore, USA) were coated in quadruplicate wells in a 96-well plate to build a 
standard curve of protein level through standard ELISA as above described. Plasma 
membrane fraction isolated from HUVECs also was tested by ELISA. The exact 
number of GRP78 or integrin αvβ5 receptors on each cell was quantified according to 
the standard curve.  
2.16 Co-immunoprecipitation  
Antibodies of ISM candidate binding partners (GRP78 or AACs) of 1 μg were 
pre-immobilized on 20 μl protein A/G agarose beads (Santa Cruz, USA) for 1 h at RT. 
Unbound antibodies were removed by 100 mM Tris-Hcl (pH 8.0). Then 1 μg ISM and 
1 μg GRP78 (or 1 mg membrane fraction protein lysates containing GRP78) or 1 mg 
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mitochondrial lysates containing AACs were incubated with anti-GRP78 or 
anti-AACs antibody mounted beads at 4°C overnight. Anti-GRP78 or anti-AACs 
antibody mounted beads incubated with only 1 μg ISM were used as the control. After 
removing the unbound proteins by 100 mM Tris-Hcl (pH 8.0), precipitates were 
resolved and analyzed for the presence of ISM, GRP78 or AACs by WB. 
2.17 RNAi targeted Gene Silencing  
Several siRNA constructs were generated for knockdown study (Integrated DNA 
Technologies Pte. Ltd, Singapore). For targeting human integrin αvβ5 and integrin 
αvβ3, siRNA targeting human integrin β5 subunit  
(5’-GCUCGCAGGUCUCAACAUA-dTdT-3’) and siRNA targeting human integrin 
β3 subunit (5’-CAAGCCUGUGUCACCAUAC-dTdT-3’) were used. A random 
scramble siRNA (5’-GACGUGGGACUGAAGGGGU-dTdT-3’) was used as the 
control. For targeting human GRP78, two constructs of siRNA were used: 
siRNA1-GRP78 (5’-GGAGCGCAUUGAUACUAGAUU-3’) (Tsutsumi et al, 2006) 
and siRNA2-GRP78 (5’-AGACGCUGGAACUAUUGCUUU-3’) (Su et al, 2010). A 
random scramble siRNA (5’-AAUUCUCCGAACGUGUCACGUUU-3’) was used as 
the control (Tsutsumi et al, 2006). 
2.18 Syngeneic Mouse Tumorigenecity Assay 
Adult 8-week-old female C57BL/6J or BALB/C mice were used in this study. 
Animal care and experimentation was conducted following the institutional guidelines 
issued by the local institutional animal care and use committee (IACUC; protocol 
066/12). For C57BL/6J mouse, 5×105 B16F10 cells were injected subcutaneously into 
the left dorsal flank. Two groups of mice received either PBS or 250 μg rISM by tail 
vein injection on alternative days from day 0 to the end point (day 14) (N=5). 
Similarly, for BALB/C mouse, 1×106 4T1 cells were injected subcutaneously into the 
left dorsal flank. Two groups of mice received either PBS or 250 μg rISM by tail vein 
injection on alternative days from day 0 to the end point (day 22) (N=10).  Health 
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status of the mice was monitored daily and visible tumor size was measured by calipers 
from day 8 until the end point. Tumor volume was calculated using the following 
formula: 0.52 × length × (width)2, where the largest dimension of the tumor is 
considered as the length and the width is the perpendicular dimension. At the end point, 
mice were sacrificed by overdosed CO2 and their dorsal flank was opened and 
photographed to exam the vascularization. Then tumors were excised and weighed 
followed by either fixation in 4% PFA in PBS for sectioning or snap-frozen in liquid 
nitrogen for further analysis. 
2.19 Immunohistochemistry (IHC) 
After fixation with 4% PFA in PBS overnight, tumors were dehydrated by an 
increasing series of ethanol and then infiltrated with the paraffin (Sigma-Aldrich, USA). 
Briefly, tumors cut in equal size were transferred from PFA to 50% ethanol with 
shaking for 6 h at RT. Then tumors were incubated with 70% ethanol at 4°C overnight. 
Next day, tumors were further dehydrated with 90% ethanol for 2 h and 100% ethanol 
for 1 h. The tumors were incubated in histoclear (Sigma-Aldrich, USA) at RT for 3 h 
with a fresh histoclear replacement every hour. Then tumors were incubated with fresh 
histoclear at 4°C overnight with shaking.  Next day, the tumors were submerged in 
melted paraffin (65°C) for 6 h and incubated with fresh paraffin at 65°C overnight. The 
following day, tumors were allowed to solidify in freshly-changed paraffin at RT.  
The embedded solid tumor was stuck to a wooden block and mounted on a 
microtome (Riechert-Jung Inc., Germany). The tumor tissue was sectioned at 5 µM and 
its paraffin sheets were carefully transferred into a 42°C water bath and allowed to 
spread. The sections were adhered to a polysilane coated glass slide 
(Thermo-Scientific, USA) and dried on a 40°C glass slide drier (Riechert, Germany) 
overnight. The slides were stored in a slide box till further use at RT.  
Paraffin-embedded tissue sections were deparaffinized by heating at 60°C for 7 min 
before deparaffinizing in histoclear followed by the rehydration in a decreasing series 
of alcohol (100%, 90%, 80%, and 70% ethanol in ddH2O) and finally 5 min incubation 
 74 
 
in PBS. Antigen was retrieved in a bench-top 2100-Retriever following the instruction 
of the manufacturer (Electron Microscopy Sciences, PA). The sections were blocked 
with 1% BSA in PBS in a humidified chamber at RT for 2 h followed by overnight 
incubation with the anti–CD31 (the marker for vasculature), anti-PCNA (the marker 
for proliferation ), anti-GRP78, or anti-His tag antibody (Santa Cruz Biotechnology, 
USA) (1:500 dilution) at 4°C. After removing the unbound antibody by 3 times wash 
with PBST, the sections were incubated with the appropriate Alexa Fluor 568 or 488 
secondary antibodies (Life Technologies, USA) for 1.5 h at 37°C. Sections were 
washed again by PBST and counter stained by 1 μg/ml DAPI at RT for 10 min.  
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was 
performed on tumor sections for detecting apoptotic cells by an in situ cell death 
detection kit (Roche, Germany). The tumor sections were deparaffinized, 
antigen-retrieved and blocked as described before. Each slide was treated with 50 µl of 
TUNEL reaction mixture containing 5 µl of enzyme solution (Terminal 
deoxynucleotidyl transferase) and 45 µl of label solution (nucleotide mixture) in a dark 
humidified chamber at 37°C for 1 h. The sections were washed with PBST and 
counter stained with DAPI.  
The images of sections were acquired using Zeiss Axiovert 200 or Zeiss LSM 510 
Meta microscope and analyzed by NIH ImageJ. For quantification, three random fields 
were analyzed in each section, three sections were selected from each tumor and two 
tumors were chosen from each group.     
2.20 Statistical analysis  
Data were expressed as standard errors of the mean (±SEM). Statistical significance 





3.1 Investigating the effect of systemically delivered rISM on tumor growth 
3.1.1 Systemically delivered rISM suppresses B16 melanoma in mice 
3.1.1.1 rISM inhibits B16 melanoma growth in mice 
Our lab has previously demonstrated that stable overexpression of ISM in B16F10 
cells suppressed B16 melanoma growth and tumor angiogenesis in mice (Xiang et al, 
2011). To determine if ISM has the potential to be an anticancer drug, the effect of 
systemically delivered ISM on tumor growth was investigated. Subcutaneous tumors 
were generated by injecting half million of B16 melanoma cells into the dorsal flank 
of syngeneic C57BL/6J mice. E. coli produced rISM was then delivered to these mice 
intravenously through tail vein injection once every two days starting from the tumor 
cell inoculation. Control mice received only PBS. Tumor growth was measured daily 
from day 8 post cell inoculation when the tumor nodule became visible.  
Quantification of tumor volume showed a significant reduction in the tumor 
growth rate of the ISM-treated mice compared with the control mice (Fig. 3.1A). 
After the 14th day (when mice started to die), mice were sacrificed and tumors were 
dissected and weighed. There was a marked reduction in the tumor weight of 
ISM-treated mice compared to the control mice (Fig. 3.1B and 3.1C). In addition, an 
obvious reduction in peri-tumoral blood vessels surrounding tumors in ISM-treated 
mice was observed compared to the untreated tumors (Fig. 3.1D). There was limited 
vascular network linked to ISM-treated tumor in contrast to the abundant vascular 
supply of untreated tumor. These results indicate that systemically delivered ISM 






Fig. 3.1 Systemically delivered rISM inhibits B16 melanoma growth: 
A, B16F10 tumor growth curve in mice. X-axis represents the days after 5×105 tumor cells 
inoculation. Control mice received no treatment while treatment mice was given 250 μg rISM 
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through tail vein injection every other day from day 0 (date of inoculation) to 14. B, tumor 
weight at the end of the experiment (day 14). C, tumors at the end of experiment. D, 
representative mouse showing a reduced peri-tumor vascularization in rISM-treated mice. 
3.1.1.2 rISM suppresses B16 melanoma growth by inhibiting tumor angiogenesis, 
tumor cell proliferation and inducing tumor cell apoptosis 
 
 
Fig. 3.2 Systemically delivered rISM suppresses B16 melanoma growth by inhibiting 
tumor angiogenesis, tumor cell proliferation and inducing tumor cell apoptosis: 
A, systemically delivered rISM suppresses B16F10 tumor angiogenesis, tumor cell 
proliferation and induces tumor cell apoptosis. Paraffin sections of B16F10 tumors were probed 
for microvessel density (MVD), tumor cell proliferation and apoptosis through IF staining 
using anti-CD31, anti-PCNA and TUNEL staining respectively. B, quantification of MVD, 
tumor cell proliferation and apoptosis. MVD is the number of microvessels per microscopic 
field. Cell proliferation is presented as the percentage of PCNA positive cells out of the total 
number of cells (DAPI positive cells) in the microscopic field. Apoptosis is quantified as the 
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percentage of TUNEL positive cells out of the total number of cells (DAPI positive cells) in the 
microscopic field. Plots represent the mean of 3 fields per section, 3 sections per tumor and 2 
tumors per group (±SEM). **P<0.01, *P<0.05. 
 
To investigate the potential cellular mechanism responsible for the reduction in 
B16 melanoma growth, tumor angiogenesis, tumor cell proliferation and apoptosis 
were investigated through immunofluorescent staining of the paraffin embedded 
tumor sections. In ISM-treated tumor, a marked reduction of tumor vasculature was 
observed by CD31 staining of ECs (Fig. 3.2A). Quantification of the microvessel 
density showed around 50% reduction in tumors from ISM-treated mice compared 
with that in control mice (Fig. 3.2B). In addition, nuclear PCNA staining revealed a 
significant decrease in cell proliferation in ISM-treated tumors compared with that of 
the untreated tumors (Fig. 3.2A and 3.2B). Furthermore, TUNEL staining of tumor 
sections indicated a dramatic increase in tumor cell apoptosis in ISM-treated mice 
compared to the control mice (Fig. 3.2A and 3.2B). 
3.1.1.3 rISM induces apoptosis in both B16 cancer cells and cancer ECs 
Interestingly, some TUNEL positive cells appeared in tubular structures in tumors 
from ISM-treated mice. This observation indicated apoptotic induction of stromal ECs 
by ISM treatment. To confirm this, double labeling of blood vessels (CD31) and 
apoptotic cells (TUNEL) in tumor section was performed. Overlapping labeling 
between TUNEL and CD31 positive cells in tumors from ISM-treated mice but not 
control mice indicated that systemically delivered ISM induced apoptosis of both 
cancer cells and cancer ECs in B16 melanoma (Fig. 3.3). Therefore, the significant 
induction of cell death coupled with reduced cell proliferation is likely the main 




Fig. 3.3 ISM induces apoptosis of both cancer cells and cancer ECs in B16 melanoma 
Double-staining of ECs and apoptosis using anti-CD31 (red) and TUNEL (green). Nuclei were 
counter stained by DAPI (blue). Representative photos are shown. Apoptotic ECs are indicated 
by white arrow. 
3.1.2 Systemically delivered rISM suppresses 4T1 breast carcinoma in mice  
3.1.2.1 rISM inhibits 4T1 breast carcinoma growth in mice 
To confirm the effect of systemically delivered rISM on tumor growth, we used 
another syngeneic mouse tumorigenesis system, 4T1 breast carcinoma, in BALB/C 
mice. Similarly, subcutaneous tumors were generated by injecting 1 million 4T1 
breast carcinoma cells into the dorsal flank of syngeneic BALB/C mice. E. coli 
produced rISM was then delivered to these mice intravenously through tail vein 
injection on alternative days starting from the same day of tumor cell inoculation. 
Control mice received only PBS. Tumor growth was monitored daily from day 6 post 
cell inoculation when the tumor nodule became visible.  
Consistently, in 4T1 breast carcinoma, tumor growth was significantly reduced in 
ISM-treated mice compared with control mice (Fig. 3.4A). After the 22nd day (when 
mice started to die), mice were sacrificed and tumors were dissected out. Then the 
tumor weight was measured. An obvious reduction of tumor weight was observed in 
ISM-treated mice (Fig. 3.4B and 3.4C). In addition, there was a marked decrease in 
blood vessels surrounding tumors in ISM-treated mice (Fig. 3.4D). These results 
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indicate that systemically delivered ISM functions as an effective anticancer agent for 




Fig. 3.4 ISM inhibits 4T1 breast carcinoma growth in mice when delivered systemically: 
A, 4T1 tumor growth curve in mice. X-axis represents the days after 1×106 tumor cells 
inoculation. Groups consisted of control mice receiving no treatment or 250 μg rISM through 





end of the experiment (day 22). C, dissected tumors at the end of experiment. D, rISM treated 
tumors showed a reduced vascularization compared to untreated control. 
3.1.2.2 rISM suppresses 4T1 breast carcinoma growth by inhibiting tumor 
angiogenesis, tumor cell proliferation and inducing tumor cell apoptosis 
To determine how ISM suppressed tumor growth, tumor angiogenesis, cell 
proliferation and apoptosis were analyzed by immunofluorescent (IF) staining of 
tumor tissue sections. In ISM-treated tumor, there was a marked reduction of tumor 
vasculature by CD31 staining of ECs compared with untreated tumor (Fig. 3.5A). 
Quantification of the microvessel density showed a significant reduction in tumors 
from ISM-treated mice compared with control mice (Fig. 3.5B). In addition, nuclear 
PCNA staining revealed a significant decrease in cell proliferation in ISM-treated 
tumors compared with untreated tumors (Fig. 3.5A and 3.5B). Furthermore, TUNEL 
staining indicated a substantial increase in tumor cell apoptosis of ISM-treated mice 





Fig. 3.5 Systemically delivered rISM suppresses 4T1 breast carcinoma growth by 
inhibiting tumor angiogenesis, tumor cell proliferation and inducing tumor cell 
apoptosis: 
A, systemically delivered rISM suppressed 4T1 tumor angiogenesis, tumor cell proliferation 
and induced tumor cell apoptosis. Paraffin sections of 4T1 tumors from mice groups treated by 
control and rISM were probed for MVD, tumor cell proliferation and apoptosis through IF 
using anti-CD31, anti-PCNA and TUNEL staining respectively. B, quantification of MVD, cell 
proliferation and apoptosis. Plots represent the mean of 3 fields per section, 3 sections per 
tumor and 2 tumors per group (±SEM). **P<0.01. 
3.1.2.3 rISM induces apoptosis in both 4T1 cancer cells and cancer ECs 
Similar to B16 melanoma, the presence of TUNEL positive cells in the tubular 
structure of blood vessels in the tissue sections of ISM-treated 4T1 breast carcinoma 
indicated apoptotic induction of stromal ECs by ISM treatment. Indeed, double 
staining of blood vessels (CD31) and apoptotic cells (TUNEL) indicated that 
systemically delivered ISM induced apoptosis of both cancer cells and cancer ECs in 
4T1 breast carcinoma (Fig. 3.6). Therefore, the significant induction of cell death 
coupled with reduced cell proliferation is likely the main reason for the reduced 4T1 




Fig. 3.6 ISM induces apoptosis of both cancer cells and cancer ECs in 4T1 breast 
carcinoma: 
Double-staining of ECs and apoptosis using anti-CD31 (red) and TUNEL (green). Nuclei were 
counter stained by DAPI (blue). Representative photos are shown. Apoptotic ECs are indicated 
by white arrow. 
3.2 Characterization of the antiangiogenic mechanisms of ISM 
3.2.1 ISM exhibits contrasting functions under different physical conditions 
After its secretion, ISM could potentially exist in different physical status in vivo, 
such as immobilized in the extracellular matrix (ECM) of a tissue or soluble in 
circulation. Indeed, ISM can be detected in the ECM (in matrigel) with the 
concentration of 91.5 nM and also in the mouse blood plasma (98 nM) (Fig. 3.7). 




Fig. 3.7 The concentration of ISM in mouse blood plasma and extra cellular matrix tested 
by ELISA. 
 To test the antiangiogenic function of soluble and immobilized ISM, in vitro tube 
formation assay and apoptosis assay were applied. In tube formation assay, ECs are 
able to form tubular structure on Matrigel. As an angiogenic inhibitor, ISM can 
potently inhibit this process. The function of soluble and immobilized ISM on EC 
tube formation was tested by either applying ISM into the culture medium or 
immobilizing ISM with the Matrigel. Interestingly, when ISM was immobilized in 
Matrigel, it lost the ability to inhibit ECs tube formation. While soluble ISM at the 
concentration of 1 µM in culture medium potently inhibited EC tube formation on 
matrigel, immobilized ISM in Matrigel exerted no effect on tube formation even at the 
concentration as high as 3 µM (Fig. 3.8).  
In addition, as an angiogenic inhibitor, ISM can potently induce EC apoptosis. The 
function of soluble and immobilized ISM on EC apoptosis was studied by either 
applying ISM in the culture medium or immobilized ISM with the matrigel on the 
dish surface. Consistently, while soluble ISM potently stimulated ECs apoptosis in a 
dose-dependent manner, immobilized ISM coated on dish surface lost this apoptotic 
induction activity (Fig. 3.9). Instead, immobilized ISM functions as a cell adhesion 
molecule and supports EC survival. These results confirm that ISM has dual functions 
















Fig. 3.8 Immobilization of ISM by Matrigel abolished its anti-tube formation activity: 
Recombinant ISM was added into culture medium (left) or mixed into Matrigel (right). The 
concentrations of ISM are labeled in the panels. Scale bar represents 200 µm. Control indicates 
culture medium (containing 2% FBS). 
 
 
Fig. 3.9 Immobilization of ISM by Matrigel abolished its pro-apoptotic activity on ECs: 
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Quantification of the apoptosis assay. Plots represent the mean of 3 microscopic fields of 
apoptotic cells in the 96-well plate. *P<0.05, **P<0.01.  
3.2.2 ISM can be internalized into ECs 
As shown above, ISM exerts disparate impacts on EC viability under different 
physical conditions. While soluble ISM induces EC apoptosis, surface-immobilized 
ISM supports EC survival. How a single ligand could induce completely different cell 
signaling pathways when present in soluble or immobilized conditions is still 
unknown. Searching through the literature, one well known angiogenesis inhibitor, 
endostatin, behaves in similar fashion as ISM (Rehn et al, 2001). Only soluble 
endostatin can be internalized into ECs. And this selective internalization is important 
for the antiangiogenic effect of endostatin (Chen et al, 2011). Therefore, one possible 
explanation of this disparate behavior is that only soluble ISM can be internalized into 
ECs via endocytosis to trigger apoptosis.  
To test this hypothesis, internalization assay was carried out. Briefly, rISM was 
either applied in the culture medium of HUVECs or immobilized on the culture dish 
surface. After incubation, the cells were isolated and their surface associated rISM 
was removed by acidic buffer. Subsequently, cells were lysed and internalized rISM 
was examined by Immunoblotting against His-tag. As shown in Figure 3.10A, only 
soluble rISM can be internalized into ECs. In addition, HUVECs were treated with 
increasing doses of rISM for 3 h or 1 μM of rISM for increasing period of time. 
Internalized rISM was detected by WB. The results show that ISM could be 






Fig. 3.10 ISM can be internalized into ECs: 
A, only soluble but not immobilized ISM was internalized into ECs. B, ISM was internalized 
into ECs in a time-dependent manner. C, ISM was internalized into ECs in a dose-dependent 
manner. 
3.2.3 ISM is internalized through clathrin-dependent endocytosis 
In eukaryotic cells, endocytosis is an important cellular process to regulate 
signaling transduction and to internalize various cargo molecules. Clathrin–dependent 
endocytic pathway and clathrin-independent but lipid-raft-mediated route are two 
major vesicular trafficking pathways (Le Roy & Wrana, 2005). To discriminate the 
route for ISM internalization, specific inhibitors were applied to selectively disrupt 
distinct endocytic pathways. HUVECs were separately or combinatorially pre-treated 
with the inhibitor of clathrin-dependent endocytosis - chlorpromazine and the 
inhibitor of lipid-raft-dependent endocytosis inhibitor - nystatin (Ivanov, 2008) at 
increasing doses for 30 min, and then incubated with rISM for 3 h. Internalized rISM 
was analyzed by WB using antibody against His-tag. The internalization of ISM was 
significantly reduced by chlorpromazine but not nystatin in a dose-dependent manner 





Fig. 3.11 ISM is internalized into ECs through clathrin-dependent endocytosis: 
A-B, internalization of ISM was significantly reduced by chlorpromazine but not nystatin in a 
dose-dependent manner. C, IF detection of internalized ISM in normal, nystatin or 
chlorpromazine pre-treated HUVECs. ISM (green) internalization was only suppressed by 
chlorpromazine treatment. Nuclei were stained with DAPI (blue). 
 
In addition, internalized ISM was further examined by IF. HUVECs were either 
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pre-treated by chlorpromazine or nystatin for 30 min and then were incubated with 
rISM for 3 h. Internalized rISM was visualized by IF using antibody against His-tag. 
As shown in Figure 3.11C, internalized ISM mainly located in the cytosol. However, 
upon the treatment of chlorpromazine, the accumulation of ISM in the cytosol was 
blocked and ISM was retained on the cell surface. On the contrary, the treatment of 
nystatin had no effect on ISM internalization. Taken together, these results indicate 
that ISM is internalized into ECs through clathrin-dependent endocytosis.  
3.2.4 Internalization is important for the antiangiogenic function of ISM 
To study whether internalization is important for the antiangiogenic function of 
ISM, the anti-EC tube formation effect of ISM in the presence of endocytosis 
inhibitors was analyzed. HUVECs were pre-treated with chlorpromazine or nystatin 
before been seeded onto Matrigel. rISM was then added to the culture media and 
incubated for 6 h. The result showed that chlorpromazine but not nystatin 
significantly suppressed EC tube formation (Fig. 3.12A). However, chlorpromazine 
and nystatin together did not generate more blockages of ISM’s antiangiogenic 
function than chlorpromazine alone. Therefore, internalization through 





Fig. 3.12 Internalization is critical for the antiangiogenic function of ISM 
A, chlorpromazine but not nystatin effectively reduced the anti-tube formation activity of ISM. 
**P<0.01, n=3. B, chlorpromazine but not nystatin significantly impaired the pro-apoptotic 
function of ISM towards ECs. *P<0.05, n=3.  
 
In the mean time, apoptosis assay was performed to determine the contribution of 
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ISM endocytosis to its pro-apoptotic function. HUVECs were pre-treated by 
chlorpromazine or nystatin for 30 min and then were incubated with rISM for 24 h. 
Only chlorpromazine but not nystatin significantly interfered with ISM-induced EC 
apoptosis (Fig. 3.12B). In addition, chlorpromazine and nystatin together did not 
generate more blockages of ISM’s pro-apoptotic function than chlorpromazine alone. 
Thus, ISM internalization into ECs via clathrin-dependent endocytosis is essential for 
its antiangiogenic function.  
3.2.5 ISM binds to HUVECs with high affinity  
It has been reported that surface-immobilized ISM supports ECs adhesion (Xiang 
et al, 2011). To determine the binding affinity between ISM and ECs, ELISA-based 
binding assay was applied to establish the dissociation constant (Kd) between rISM 
and HUVECs. HUVECs were seeded in a 96-well plate to form a monolayer. The 
cells were incubated with increasing concentration of rISM applied in culture medium. 
After removing unbound rISM by washing, cell associated rISM was detected by 
ELISA using anti-His Ab. The saturation binding curve and Kd value was generated 
by GraphPad Prism Software. The result shows that ISM binds to HUVECs with high 
binding affinity in nM range (Fig. 3.13). 
3.2.6 αvβ5 integrin is a low affinity receptor for ISM 
Since integrin αvβ5 is the only identified cell surface receptor of ISM (Xiang et al, 
2011; Zhang et al, 2011), the binding affinity between ISM and integrin αvβ5 was also 
determined. Recombinant integrin αvβ5 heterodimer was coated onto the surface of a 
96-well plate and incubated with increasing concentration of rISM. Surface bound 
rISM was detected by ELISA. The saturation binding curve and Kd value was 
generated by GraphPad Prism Software. The result shows that ISM binds to integrin 




Fig. 3.13 ISM binds to HUVECs with high affinity 
ISM binds to HUVECs with high affinity (Kd = 37.74 ± 7.9 nM). Dose-response curve was 
generated and analyzed using GraphPad Prism software. N=3. 
 
 
Fig. 3.14 The binding affinity between ISM integrin αvβ5: 
ISM binds to integrin αvβ5 with low affinity (Kd= 0.96±0.33 μM). Dose-response curve was 
generated and analyzed using GraphPad Prism software. N=3. 
3.2.7 Identification of ISM’s binding partners in plasma membrane 
Since ISM binds to EC surface with a Kd in the nM range (Fig. 3.13), but the known 
ISM receptor, αvβ5 integrin, can only bind to ISM with Kd in the µM range (Fig. 3.14), 
there exists unknown high affinity receptor(s) of ISM on EC surface which may play 
important roles in mediating its function. 
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To search for this high-affinity receptor, the plasma membrane protein fraction of 
HUVECs with and without prior incubation with rISM (His-tagged) was isolated and 
pulled down by Ni-NTA beads. After stringent wash, the bound proteins were eluted 
out and analyzed by SDS-PAGE. Specific bands in ISM-treated EC plasma membrane 
fraction were analyzed by MALDI-TOF-TOF mass spectrometry (MS).  
As shown in Figure 3.15A, several potential ISM interacting proteins were 
identified through a search for the tandem mass spectra in the NCBI nr protein 
database using MASCOT. They were myosin heavy chain 9 (MYH9) with a protein 
score as high as 842 (Fig. 3.15B), clathrin heavy chain 1 (CHC1) with a protein score 
as high as 205 (Fig. 3.15C) and glucose-regulated protein of 78 kDa (GRP78) with a 
protein score as high as 353 (Fig. 3.15D). Protein scores greater than 64 were 
considered to be significant.  
MYH9 has been reported to be involved in endosome trafficking (Stasyk et al, 
2007), and might function as the motor protein moving on actin filament to transport 
its cargo-endosome to other subcellular locations. This result indicated that ISM is 
internalized through endocytosis. In addition, clathrin is the key protein mediating 
clathrin-dependent endocytosis (Mousavi et al, 2004). The association between ISM 
and CHC1 supported previous results that ISM is internalized through 
clathrin-dependent endocytosis (Fig. 3.11).  
As introduced before, GRP78 is traditionally regarded as a key endoplasmic 
reticulum (ER) chaperon protein, facilitating protein folding, assembling in ER lumen 
and mediate cellular stress response (Hendershot, 2004; Pfaffenbach & Lee, 2011). It 
has recently emerged that GRP78 is also present on the cell surface to mediate distinct 
cellular functions (Ni et al, 2011). Cell-surface GRP78 has been shown to act as an 
important regulator in tumor progression, metastasis, angiogenesis and resistance to 
cancer therapy (Lee, 2007; Sato et al, 2010; Schwarze & Rangnekar, 2010). 
Identification of GRP78 as a binding partner of ISM in the plasma membrane fraction 























Fig. 3.15 Identified ISM binding partners in plasma membrane fraction 
A, identified ISM binding partners in plasma membrane fraction. B, MS result of myosin 
heavy chain 9 (MYH9). C, MS result of clathrin heavy chain 1 (CHC1). D, MS result of 
glucose-regulated protein of 78 kDa (GRP78). Bold red sequences represent the matched 





3.2.8 GRP78 is a high affinity receptor for ISM 
To confirm the interaction between GRP78 and ISM, co-immunoprecipitation (co-IP) 
experiment was performed by incubating rISM with plasma membrane fraction of 
HUVECs. The protein A/G agarose beads were mounted with anti-GRP78 antibody. 
Then anti-GRP78 antibody mounted agarose beads were incubated with rISM and 
plasma membrane fraction of HUVECs (containing GRP78) or rISM alone as the 
control. Proteins pulled down by the beads were analyzed by WB. The result showed 
that GRP78 from the plasma membrane fraction interacts with ISM (Fig. 3.16A). To 
further confirm the direct interaction between ISM and GRP78, the co-IP experiment 
was repeated using recombinant GRP78 and rISM. The result showed that pure 
recombinant GRP78 can interact with rISM, which suggested that GRP78 can directly 
interact with ISM (Fig. 3.16B). 
Since GRP78 interacts with ISM, the binding affinity between GRP78 and ISM 
was tested by ELISA-based binding assay. Recombinant GRP78 was coated on the 
96-well plate and incubated with increasing concentrations of rISM. The unbound 
rISM was removed by stringent wash. The bound rISM was examined by ELISA. A 
saturated binding curve was generated and the Kd value was calculated accordingly 
by GraphPad Prism. The result showed that the binding affinity between recombinant 
GRP78 and rISM is high with a Kd of 8.58±1.72 nM (Fig. 3.16C). Therefore, GRP78 







Fig. 3.16 GRP78 binds with ISM at high affinity: 
A, GRP78 from the plasma membrane fraction of HUVECs co-immunoprecipitated with ISM. 
B, recombinant GRP78 co-immunoprecipitated with ISM. C, GRP78 binds with ISM at a Kd 
of 8.58±1.72 nM. Saturated binding curve and Kd value were generated by GraphPad Prism. 
N=3.  
3.2.9 GRP78 mediates the antiangiogenic function of ISM 
Since cell surface GRP78 interacts with ISM at high affinity, I hypothesized that 
GRP78 may be the cell surface high affinity receptor mediating the antiangiogenic 
function of ISM. To test this hypothesis, the contribution of GRP78 to the 
antiangiogenic effect of ISM was first determined by antibody blocking in EC 





In the cell attachment assay, rISM was coated on the surface of a 96-well plate. 
HUVECs pre-treated with neutralizing antibodies against GRP78, integrin αvβ5 and 
its individual subunits were applied into ISM-coated plate. After one hour’s 
incubation, attached cells were fixed and colorimetrically quantified upon crystal 
violet staining. The result indicated that GRP78 is important for EC attachment to 
ISM-coated surface. Anti-GRP78 antibody partially compromised the adhesion of ECs 
to ISM-coated surface. Similar effects were observed when HUVECs were pre-treated 
by neutralizing antibodies against integrin αvβ5 and its individual subunits (Fig. 
3.17A). Therefore, GRP78 contributes to the interaction between ISM and ECs. 
In the tube formation assay, HUVECs were pre-treated by increasing 
concentrations of neutralizing antibody against GRP78. Then HUVECs were 
incubated with rISM and applied on matrigel to form tubular structures for 6 h. The 
result showed that anti-GRP78 antibody dose-dependently interrupted ISM’s anti-EC 
tube formation activity (Fig. 3.17B). Thus GRP78 mediates the anti-EC tube 
formation effect of ISM. 
In the apoptosis assay, HUVECs coated on 96-well plate were pre-treated by 
increasing concentrations of neutralizing antibody against GRP78. Then HUVECs 
were incubated with rISM for 24 h in the presence of anti-GRP78 antibody. 
ISM-induced apoptosis was determined by a cell death detection ELISA against DNA 
fragmentation. The result showed that anti-GRP78 antibody dose-dependently 
interrupted ISM’s pro-apoptotic activity (Fig. 3.17C). Hence, GRP78 mediates the 









Fig. 3.17 GRP78 mediates ISM-induced antiangiogenesis: 
A, similar with αvβ5 integrin antibodies, GRP78 antibody partially blocked ISM-mediated ECs 
adhesion. **P<0.01, n=3. B, anti-GRP78 antibody interfered with the anti-tube formation 
action of ISM in a dose-dependent manner. *P<0.05, n=3. C, anti-GRP78 antibody 
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dose-dependently blocked ISM-induced EC apoptosis. *P<0.05, n=3.  
 
To further confirm that GRP78 is the receptor mediating the antiangiogenic 
function of ISM, knockdown of GRP78 expression in HUVECs by two separate 
siRNAs was performed to determine the contribution of GRP78 to ISM-induced 
antiangiogenesis in EC attachment assay, tube formation assay and apoptosis assay 
respectively. The successful knockdown of GRP78 by two constructs of siRNAs was 
confirmed by WB (Fig. 3.18A). 
In the cell attachment assay, rISM was coated on the surface of a 96-well plate. 
HUVECs 48 h post transient transfections of siRNAs against GRP78 expression were 
applied into ISM-coated plate. After 1 h incubation, attached cells were fixed and 
colorimetrically quantified upon crystal violet staining. Similarly, the result indicated 
that GRP78 plays a role in mediating EC attachment to ISM-coated surface. 
Disrupting GRP78 expression by transient transfection of siRNAs partially 
compromised the adhesion of ECs to ISM-coated surface (Fig. 3.18B). This result 
confirmed that GRP78 contributes to the interaction between ISM and ECs. 
In the tube formation assay, HUVECs 48 h post transient transfections of siRNAs 
against GRP78 expression were incubated with rISM and applied on matrigel to form 
tubular structures for 6 h. As shown in Figure 3.18C, disrupting GRP78 expression by 
siRNAs’ transient transfection interrupted ISM’s anti-EC tube formation activity. This 
experiment further confirmed that GRP78 mediates the anti-EC tube formation effect 
of ISM. 
In the apoptosis assay, HUVECs 48 h post of transient transfections of siRNAs 
against GRP78 expression were seeded in a 96-well plate. Then the cells were 
incubated with rISM for 24 h. ISM-induced apoptosis was determined by a cell death 
detection ELISA against DNA fragmentation. Consistently, the result showed that 
disrupting the expression of GRP78 by siRNAs’ transient transfection interrupted 
ISM’s pro-apoptotic activity (Fig. 3.18D). This result suggested that GRP78 mediates 
the apoptotic induction function of ISM.  
Taken together, cell-surface GRP78 is a high-affinity receptor for ISM and 
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Fig. 3.18 ISM inhibits angiogenesis through GRP78: 
A, transient transfection of two different siRNAs effectively knocked down GRP78 expression 
in HUVECs. Equal amount of scramble siRNA was transfected as a control. B, knockdown of 
GRP78 expression by siRNAs diminished ISM-mediated EC adhesion. *P<0.05, n=3. C, 
knockdown of GRP78 expression by siRNAs compromised the anti-tube formation action of 
ISM. *P<0.05, n=3. D, knockdown of GRP78 expression by siRNAs reduced ISM-induced EC 
apoptosis. *P<0.05, n=3.  
3.2.10 GRP78 mediates the internalization of ISM 
Since ISM’s internalization into ECs is critical for its antiangiogenic and 
pro-apoptotic function, the role of cell-surface GRP78 in ISM internalization was 
investigated. Firstly, internalization assay was performed to determine the 
contribution of GRP78 to ISM internalization. HUVECs pre-treated by neutralizing 




surface associated rISM was removed by acidic buffer. The internalized rISM was 
detected by WB using antibody against His-tag. As shown in Figure 3.19A, blocking 
cell-surface GRP78 by anti-GRP78 antibody dose-dependently reduced ISM 
internalization into HUVECs.  
In addition, triton partitioning experiment was conducted to examine the 
distribution of internalized ISM in triton-soluble and triton-insoluble fraction of 
HUVECs post 24 h ISM treatment. As shown in Figure 3.19B, internalized ISM and 
GRP78 are both present in non-lipid raft fraction, sharing similar distribution with 
CHC1 (the marker for clathrin-dependent pathway) but not caveolin (the marker for 
clathrin-independent but lipid raft mediated pathway). The association among ISM, 
GRP78 and CHC1 was consistent with previous MS results and suggested that 
GRP78 is the receptor mediating ISM internalization through clathrin-dependent 
endocytosis. In contrast, the other ISM receptor, integrin αvβ5, is distributed more with 
caveolin-positive lipid raft fraction, distinct from ISM and GRP78.  
To further distinguish which receptor mediates ISM internalization, I constructed 
mammalian expressing plasmids of GRP78, integrin αv subunit and integrin β5 
subunit. Increasing amount of GRP78 expressing plasmid or integrin αv subunit and 
integrin β5 subunit expressing plasmids were transiently transfected into LS174T cells 
(a non-metastatic human colon carcinoma cell line). Forty-eight hours post 
transfection, rISM was added for a 24 h treatment. Cell surface associated rISM were 
removed by washing with acidic buffer. Internalized ISM was detected by WB using 
antibody against His-tag. As shown in Figure 3.19C, transient overexpression of 
GRP78 increased ISM internalization in a dose-dependent manner. However, transient 
overexpression of integrin αvβ5 had no effect on ISM uptake (Fig. 3.19D). 
Simultaneous overexpression of both GRP78 and αvβ5 integrin promoted ISM 
internalization to the same extent as GRP78 overexpression alone, indicating that αvβ5 
integrin is not involved in ISM internalization (Fig. 3.19E).  
Moreover, whether GRP78 is the receptor mediating ISM internalization was 
analyzed by cell imaging. To visualize ISM and GRP78, I built a secretive ISM-GFP 
fusion expressing vector and a mCherry-GRP78 fusion expressing plasmid. Firstly, a 
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batch of HEK293T cells was transient transfected by the secretive ISM-GFP fusion 
expressing vector. Then condition medium containing ISM-GFP fusion protein was 
collected for the later usage. Then another batch of HEK293T cells was transient 
transfected by mCherry-GRP78 fusion expressing plasmid. After 48 h, these cells 
were incubated with previously prepared condition medium containing ISM-GFP 
fusion protein for 24 h. Although ISM-GFP broadly associated with HEK293T cells, it 
only significantly accumulated and internalized in cells expressing mCherry-GRP78 
(Fig. 3.19F). In addition, internalized ISM-GFP shared similar distribution pattern 
with mCherry-GRP78. This experiment also suggested that GRP78 mediates ISM 
internalization. 
Taken together, these results confirmed that ISM is internalized through 
















  Fig. 3.19 GRP78 mediates ISM internalization:  
A, anti-GRP78 antibody reduced ISM internalization into HUVECs in a dose-dependent 






ISM pre-treated HUVECs were washed to remove cell surface associated ISM and lysed in 1% 
Triton X-100 buffer. Triton-insoluble and -soluble fractions of HUVEC plasma membrane 
lysates were prepared by density centrifugation. Immunoblotting with antibodies against ISM, 
αvβ5 integrin subunit β5 and GRP78 was used to analyze each fraction. Caveolin-1 and clathrin 
heavy chain 1 (CHC1) were used as markers for lipid-raft and non lipid-raft fraction. C, 
overexpression of GRP78 increased ISM internalization in LS174T cells. D, overexpression of 
αvβ5 integrin had no effect on ISM internalization in LS174T cells. E, Co-overexpression of 
both GRP78 and αvβ5 integrin promoted ISM internalization to the same extent as GRP78 
overexpression alone. 
3.2.11 ISM selectively induces apoptosis in cells that exhibit high level cell-surface 
GRP78 such as invasive cancer cells and activated ECs 
Since the first report of cell-surface GRP78 on malignant T lymphocytes in 1997, 
accumulating evidences indicate that GRP78 is a cell-surface receptor specifically 
present in cells under stress, in particular cancer cells and activated ECs such as cancer 
ECs (Berger et al, 1997; Ni et al, 2011). Importantly, overexpression of GRP78 has 
been shown to trigger the re-localization of GRP78 to cell surface and is associated 
with advanced stages of tumor progression and invasiveness (Lee, 2007; Zhang et al, 
2010). Thus, cell-surface GRP78 has become a promising target for anticancer therapy. 
Since ISM induces potent apoptosis in activated ECs such as cultured HUVECs which 
express a high level cell-surface GRP78, the relationship between the level of 
cell-surface GRP78 and the susceptibility of the cell to ISM-induced apoptosis was 
investigated.  
The plasma membrane fractions of several cell lines were isolated and analyzed by 
WB to determine their cell surface GRP78 level. As shown in Figure 3.20A, selected 
cell lines express different levels of cell-surface GPR78, including the high expressing 
B16F10 (mouse melanoma), 4T1 (mouse breast cancer), LS-LM6 (highly 
liver-metastatic human colon cancer), 786-O (human renal carcinoma) and HEK293T 
(transformed human embryonic kidney cells). On the other hand, the low metastatic 
colon cancer line LS174T expresses a low level cell-surface GRP78. Fibroblast lines 
NIH3T3 and SWISS3T3 both express negligible level of cell-surface GRP78. In the 
meantime, the apoptotic induction effect of ISM upon these cell lines was tested by 
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apoptosis assay. As shown in Figure 3.20B and 3.20C, ISM did not induce significant 
cell death in NIH3T3 and SWISS3T3 fibroblasts. In comparison, significant apoptosis 
was induced in cells that exhibit high level of cell-surface GRP78 including HUVECs, 
HEK293T, B16F10, 4T1, 786-O and LS-LM6 cells (Fig. 3.20D-I). Notably, ISM did 
not induce significant apoptosis in LS174T which express a low level of cell-surface 
GRP78 (Fig. 3.20J). In contrast, ISM induced potent apoptosis in LS-LM6, a highly 
liver metastatic cell line derived from LS174T which expresses a high level cell-surface 












Fig. 3.20 ISM selectively induces apoptosis in cells that express high level cell-surface 
GRP78 such as invasive cancer cells and activated ECs: 
A, GRP78 level in the cell surface membrane fraction of NIH3T3, SWISS3T3, HUVEC, 
HEK293T, B16F10, 4T1, LS174T, LS-LM6 and 786-O cells. Equal amount of plasma 
membrane fractions were applied in the coomassie blue stained gel as the loading control. B, 
ISM was incompetent in inducing NIH 3T3 cells apoptosis. C, ISM was incompetent in 
inducing SWISS 3T3 cells apoptosis. D, ISM significantly induced apoptosis in HUVECs. E, 
ISM significantly induced apoptosis in HEK293T cells. F, ISM significantly induced 
apoptosis in B16F10 cells. G, ISM significantly induced apoptosis in 4T1 cells. H, ISM 
significantly induced apoptosis in 786-O cells. I, ISM significantly induced apoptosis in 
LS-LM6 cells. J, ISM was incompetent in inducing LS174T cells apoptosis. B16F10 (mouse 
melanoma), 4T1 (mouse breast carcinoma), 786-O (human renal carcinoma), LS-LM6 (highly 
liver metastatic human colon carcinoma) and LS174T (human colon carcinoma). **P<0.01, 
n=3. 
 
As shown above, LS174T cells express low level of cell surface GRP78 and are 
resistant to ISM-induced apoptosis. It has been reported that LS174T cells also 
possess low level of the other receptor of ISM- integrin αvβ5 (Yoshioka et al, 2010). 
Hence, LS174T cell is a good model for gain of function study. To further validate if 
the susceptibility of cells to ISM-induced apoptosis is correlated with increased 
cell-surface GRP78 expression, I artificially increased GRP78 expression in LS174T 
cells by transient transfection of the GRP78 expression construct. As comparison, I 
also overexpressed the ISM’s low affinity receptor integrin αvβ5 by transient 
transfection constructs expressing integrin αv subunit and integrin β5 subunit. Our lab 
has previously discovered that ISM interacts with integrin αvβ5 on EC surface and 
triggers endothelial cell death through integrin-mediated activation of caspase-8 




in dose-dependent increase of ISM-induced LS174T cell apoptosis. Similarly, 
increased expression of integrin αvβ5 also dose-dependently enhanced the 
susceptibility of LS174T cells to ISM-induced apoptosis (Fig. 3.21B). However, 
GRP78 mediated more potent apoptosis than integrin αvβ5. In addition, simultaneous 
GRP78 and integrin αvβ5 overexpression led to more apoptosis than GRP78 or integrin 
αvβ5 alone (Fig. 3.21C). Thus, the presence of high level cell-surface GRP78 triggers 
cells to be susceptible to ISM-induced apoptosis. ISM induces apoptosis either through 
cell-surface GRP78 or integrin αvβ5, with GRP78 as the dominant mediator.  
Taken together, ISM selectively induces apoptosis in cells that exhibit high level of 
cell-surface GRP78 such as invasive cancer cells and activated ECs. The presence of 











Fig. 3.21 Overexpression of GRP78 or αvβ5 integrin conferred the pro-apoptotic 
function of ISM in LS174T cells: 
A, increasing GRP78 expression level sensitized LS174T cells to ISM induced apoptosis 
dose-dependently. B, increasing integrin αvβ5 expression level dose-dependently enhanced the 
effect of ISM in inducing LS174T cells apoptosis. C, simultaneous overexpression of GRP78 
and αvβ5 integrin generated more potent apoptotic response to ISM than overexpression of 
individual receptor in LS174T cells.  
3.2.12 GRP78 is highly expressed by both cancer cells and cancer ECs 
As previously shown, ISM can induce apoptosis in both cancer cells and cancer 
ECs. GRP78 might be the receptor mediating ISM-induced apoptosis in vivo. To 
verify this hypothesis, the expression of GRP78 in tumors obtained from the B16 
melanoma and 4T1 breast carcinoma syngeneic tumorigenesis assays was checked by 
IHC staining. The tumor blood vessels were double stained with GRP78 using CD31 
as the marker. Correspondingly, GRP78 is highly expressed in both cancer cells and 
cancer ECs in B16 melanoma and 4T1 breast carcinoma (Fig. 3.22). This result 
explained why ISM can induce apoptosis in both cancer cells and cancer ECs. 






Fig. 3.22 GRP78 is highly expressed by both cancer cells and cancer ECs: 
GRP78 expression in B16 melanoma and 4T1 breast carcinoma was probed by IF with 
anti-GRP78 (green) and double stained with anti-CD31 (red). Nuclei were counter stained by 
DAPI (blue). Co-localization of GRP78 and CD31 in ECs are indicated by white arrows. 
3.2.13 ISM likely interacts with the N-terminus of GRP78 
As mentioned before, for the cell surface GRP78, a recent study shows that there 
are at least three domains of GRP78 (N, middle and C) exposed on the cell surface 
(Fig. 1.5C) (Zhang et al, 2010). Several natural ligands of cell surface GRP78, 
including Cripto, Kringle 5, T-cadherin and Par-4, interact with the N-terminus of cell 
surface GRP78 (Gray & Vale, 2012). Similarly, previous results showed that using 
antibody against the N-terminus of GRP78 selectively blocked the antiangiogenic 
function of ISM (Fig. 3.17) and ISM internalization (Fig. 3.19). To confirm that ISM 
interacts with the N-terminus of GRP78, antibodies against the N-terminus and 
C-terminus of GRP78 were applied to neutralizing cell surface GRP78 and studying 
which region of GRP78 mediates the antiangiogenic effect of ISM. 
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Firstly, HUVECs pre-treated by either antibody against the N-terminus of GRP78 
or antibody against the C-terminus of GRP78 were incubated with rISM and applied 
on matrigel to form tubular structure for 6 h. The result showed that while GRP78 
N-terminal antibody blocked the function of ISM in inhibiting EC tube formation 
dose-dependently, GRP78 C-terminal antibody had no such effect (Fig. 3.23A).  
In addition, HUVECs pre-treated by either antibody against the N-terminus of 
GRP78 or antibody against the C-terminus of GRP78 were incubated with rISM for 
24 h and examined by cell death detection ELISA. Similarly, the result showed that 
while GRP78 N-terminal antibody dose-dependently hampered the function of ISM in 
inducing EC apoptosis, GRP78 C-terminal antibody had no such effect (Fig. 3.23B).  
The N-terminal antibody used in the above study is a mouse monoclonal antibody 
specific for an epitope mapping between amino acids 19-50 near the N-terminus of 
GRP 78 of human origin. Therefore, ISM likely interacts with the N-terminus of 














Fig. 3.23 ISM interacts with the N-terminus of GRP78: 
A, the N-terminus of GRP78 mediates the anti-EC tube formation effect of ISM. B, the 
N-terminus of GRP78 mediates the apoptotic inducing function of ISM. 
3.2.14 Internalized ISM targets mitochondria 
To visualize the location of internalized ISM, I generated both secretive ISM-GFP 
and secretive GFP expression plasmids and transiently transfected them into HUVECs 
and HEK293T cells. Expressed ISM-GFP fusion protein was secreted into the culture 
media and endocytosed back into cells through binding to cell-surface GRP78. Since 
the clustered pattern of endocytosed ISM resembled mitochondria in previous IF 
results (Fig. 3.11C) and mitochondrion is the key organelle governing apoptotic 
pathways, red MitoTracker was used to label the mitochondria. Surprisingly, 
ISM-GFP and mitochondria showed similar patterns in both HUVECs and HEK293T 
(Fig. 3.24A). There was no ISM-GFP signal inside the nucleus. In contrast, GFP was 
broadly distributed in the whole cell and with distinct pattern compared to 
mitochondria (Fig. 3.24B).  
To quantify the co-localization between ISM and mitochondria, the Coloc function 
in Imaris×64 software was used to analyze the Pearson’s correlation coefficient (Rp) 
(Costes et al, 2004; Manders et al, 1992). Rp ranges between 1 and -1. Value of 1 
represents perfect correlation, 0 means no correlation, and -1 indicates absolute 




mitochondria were 0.822 in HUVECs and 0.941 in HEK293T. Rp values between GFP 
and mitochondria were around 0 in both HUVECs and HEK293T (Fig. 3.24B). It has 
been reported that Rp around 0.91 indicates two images are almost identical (Manders, 
1993) and Rp around 0.75 shows a relatively high degree of co-localization (Will 
Casavan, 2004). Therefore, secretive ISM-GFP was highly co-localized with 
mitochondria. 
In addition, HUVECs were treated with rISM for 24 h. Mitochondria were 
visualized by MitoTraker. The internalized rISM were detected by IF staining using 
antibody against His-tag. Consistently, internalized rISM shared similar pattern with 
mitochondria. The quantification showed internalized rISM was also co-localized 








Fig. 3.24 internalized ISM is co-localized with mitochondria: 
A, IF showing internalized ISM-GFP co-localized with mitochondria in ISM-GFP expression 
plasmid transfected HUVECs and HEK293T cells. B, IF showing internalized GFP shared 
distinct pattern with mitochondria. C, internalized rISM (His-tagged) co-localized with 
mitochondria in HUVECs. Quantitative measurements of Pearson’s correlation coefficient (Rp) 
between red and green fluorescent labeled channels are indicated in the rightmost panel of each 
row. 
 
To further confirm the mitochondria localization of internalized ISM, WB was 
carried out using mitochondrial fraction isolated from both HUVECs and HEK293T 
transfected with a secretive His-tagged ISM expression plasmid. The 
mitochondria-depleted cytosolic fraction was also collected. ISM in both fractions were 
pulled down using equal amount of Ni-NTA beads and used in WB analysis. 
Corresponding with the microscopy imaging results, the majority of internalized ISM 
(detected by anti-His antibody to distinguish from endogenous ISM) is in mitochondria, 
while mitochondria-depleted cytosol contained no or minimum amount of internalized 
ISM (Fig. 3.25A). Similarly, incubation of His-tagged rISM with cultured HUVECs 








Fig. 3.25 Internalized ISM targets mitochondria: 
A, WB showing internalized ISM from ISM expressing plasmid transfection and secretion 
mainly existed in mitochondria of HEK293T cells and HUVECs. B, WB showing internalized 
rISM from rISM incubation with cells mainly located in mitochondria. 
3.2.14 Identification of ISM’s binding partners in mitochondria 
To identify mitochondria proteins that interact with ISM, secretive His-tagged ISM 
expressing plasmid was transiently transfected into HEK293T cells. After 48 h, 
mitochondria were isolated from these cells. After pulling down His-tagged ISM and 
its binding partners by anti-His magnetic microbeads from the mitochondrial lysates, 
the eluents were separated by SDS-PAGE and specific bands present in 
ISM-transfected mitochondrial lysates were identified by MALDI-TOF-TOF MS.  
As shown in Figure 3.26, the identified potential ISM binding partners in 
mitochondria are MYH9, CHC1, GRP78, β-actin, ADP/ATP carrier 2 (AAC2), 


























































Fig. 3.26 Identified potential ISM binding partners in mitochondria: 
A, identified ISM binding partners in mitochondria. B, MS result of myosin heavy chain 9 
(MYH9). C, MS result of clathrin heavy chain 1 (CHC1). D, MS result of glucose-regulated 






ADP/ATP carrier 2 (AAC2). H, MS result of ADP/ATP carrier 3 (AAC3). I, MS result of 
histone H2A. J, MS result of histone H2B. K, MS result of histone H4. Bold red sequences 
represent the matched peptides by MALDI-TOF-TOF MS. Protein scores greater than 64 are 
significant (p<0.05). 
3.2.15 GRP78 co-targets with ISM to mitochondria 
Consistent with previous MS results of ISM binding partners in plasma membrane 
fraction, proteins from mitochondria lysates that bind ISM significantly hit MYH9 
with a protein score of 260 (Fig. 3.26B), CHC1 with a protein score as high as 171 
(Fig.3.26C) and GRP78 with a protein score as high as 233 (Fig.3.26D). These results 
supported that internalized ISM targets mitochondria through GRP78-mediated 
clathrin-dependent endocytosis. Hence, internalized ISM seems to co-target with 
cell-surface GRP78 to mitochondria. Indeed, WB revealed the co-presence of GRP78 
and ISM in mitochondria of cells overexpressing exogenous ISM, but not in control 
cells (Fig. 3.27A). Similarly, upon rISM treatment of HUVECs, GRP78 also became 
translocated into mitochondria together with rISM (Fig. 3.27B). These results revealed 






Fig. 3.27 GRP78 co-targets with ISM to mitochondria: 
A, GRP78 is co-translocated into mitochondria with ISM in ISM-overexpressing HUVECs and 
HEK293T cells. B, GRP78 is co-trafficked into mitochondria together with extracellular rISM 
in HUVECs. VDAC was used the marker for mitochondria.  
3.2.16 ISM interacts with ADP/ATP carriers (AACs) in mitochondria 
The identified mitochondria ISM binding partners also included ADP/ATP carrier 2 
(AAC2) and ADP/ATP carrier 3(AAC3) (Fig. 3.26). AAC, also known as adenine 
nucleotide translocase (ANT) or ADP/ATP translocase, is the major ADP/ATP 
transporter located on the inner membrane of mitochondria, catalyzing the 1 to 1 
exchange of ATP produced in mitochondria matrix against ADP in cytosol (Fiore et al, 
1998). Four AAC isoforms have been identified in human (AAC1, AAC2, AAC3, 
AAC4), each with a different expression pattern (Dolce et al, 2005; Palmieri, 2004). 
AAC1 is specific in heart and skeletal muscles. AAC2 is present in proliferating cells. 
AAC3 is ubiquitous and AAC4 is specific in liver, testis and brain (Dolce et al, 2005). 
Human AAC1, AAC2 and AAC3 are highly identical. They share 88%-92% of 
identical amino acids. AAC4 shares 66%-68% of identical amino acids with AAC1-3 
(Dolce et al, 2005). According to previous reports and comprehensive information 
provided by large-scale analysis of human transcriptome in BioGPS (Su et al, 2002; Su 
et al, 2004; Wu et al, 2009), AAC2 and AAC3 are the dominant AACs in ECs. By 





To verify this hypothesis, I analyzed if ISM interacts with AACs by co-IP. As shown 
in Figure 3.28A, ISM bound with AACs from the mitochondrial fraction of HUVECs. 
To further confirm the interaction between AACs and ISM, I generated a 
mCherry-AAC2 expression plasmid and transfected it into HEK293T cells. After 48 h, 
transfected cells were then treated by conditioned media containing ISM-GFP for 
overnight. The internalized ISM-GFP co-localized with mCherry-AAC2 inside the 
cells (Fig. 3.28B). Thus, internalized ISM is targeted to mitochondria and interacts with 
AACs on the mitochondria inner membrane.  
 
 
Fig. 3.28 ISM interacts with AACs in mitochondria: 
A, ISM co-immunoprecipitated with AACs in mitochondrial fraction of HUVECs. B, 
Internalized ISM-GFP co-localized with AAC2. ISM-GFP expression plasmid was transiently 
transfected into HEK293T cells. Condition media was collected and applied to mCherry-AAC2 
transfected HEK293T cells. ISM (green) co-localized with AAC2 (red) in mCherry-AAC2 





3.2.17 ISM blocks ATP release from mitochondria to cytosol through interaction 
with AACs in mitochondria 
To determine if ISM interferes with the ADP/ATP exchange function of AACs in 
mitochondria, ATP concentrations were measured in whole cell lysates, cytosolic 
fraction (without mitochondria) and mitochondrial fraction of HUVECs pre-treated by 
rISM. The overall ATP level as well as cytosolic ATP level was reduced more than 50% 
upon ISM treatment (Fig. 3.29A and 3.29B). On the other hand, the ATP level in 
mitochondrial was increased about 40% (Fig. 3.29C). These data suggested that ISM 
blocked the exchange of cytosolic ADP against the mitochondria matrix ATP across 
the mitochondrial inner membrane.  
In addition, as the ATP level in the whole cell lysates was also decreased around 50% 
after ISM treatment (Fig. 3.29A), interference of ADP/ATP exchange by ISM also led 
to reduced ATP production. This is not surprising since AACs catalyze the 1:1 
exchange of ADP against ATP, blockage of AAC function would result in ADP (the 
material for ATP synthesis) shortage in mitochondrial matrix, leading to reduction of 
ATP generation. ATP is critical for cell survival and depletion of cellular ATP of 25-70% 
cause apoptosis (Lieberthal et al, 1998).  
Hence, ISM triggers apoptosis through GRP78-mediated mitochondria targeting and 
interference of AAC-mediated ADP/ATP exchange between mitochondria and cytosol. 













A, ISM treatment diminished ATP concentration in whole cell lysates of HUVECs. **P<0.01, 
n=3. B, ISM treatment reduced ATP level in cytosolic fraction of HUVECs. **P<0.01, n=3. C, 
ISM treatment increased ATP level in mitochondrial fraction of HUVECs. *P<0.05, n=3.  
3.2.18 GRP78 and αvβ5 integrin function as independent cell-surface receptors 
for ISM and mediate EC apoptosis through distinct signaling pathways 
3.2.18.1 There was no direct interaction between GRP78 and αvβ5 integrin in 
vitro 
GRP78 and αvβ5 integrin both serve as endothelial cell-surface receptor for ISM and 
mediate the antiangiogenic function of ISM. However, whether these two receptors 
function cooperatively or independently remain unknown. Here I applied proximity 
ligation assay (PLA) to investigate the direct interaction between GRP78 and αvβ5 
integrin. PLA is a method allowing visualization and quantification of specific protein 
interaction events in situ. Red PLA signal represents direct interaction between two 
proteins in their native state and location (Soderberg et al, 2006). The direct interaction 
between GRP78 and αvβ5 integrin were detected by PLA on HUVECs with or 
without ISM pre-treatment. 
As shown in Figure 3.30A, there was no direct interaction between GRP78 and 
αvβ5 integrin in HUVECs in the presence or absence of ISM. In contrast, positive PLA 
signals were evident between ISM and its two receptors respectively. Notably, the 
quantification of PLA signal indicated that the interaction between ISM and GRP78 








Fig. 3.30 GRP78 and αvβ5 integrin do not interact in HUVECs in PLA: 
A, determination of the interaction between GRP78 and αvβ5 integrin, ISM and GRP78, and 
ISM and integrin αvβ5 by Duolink in situ PLA. PLA signals (red) indicate two proteins in close 
proximity (nucleus). GRP78 and αvβ5 integrin do not exist in close proximity in HUVECs in 
the absence (panel 1) or presence (panel 2) of ISM; Panel 3: ISM interacts with GRP78 on the 
cell surface and in the cytoplasm. Panel 4: ISM interacts with αvβ5 integrin in HUVECs. B, 
quantification of PLA signals. PLA signal intensities of 3 microscopic fields from each group 
were calculated by ImageJ and then normalized by cell number. All photos were obtained under 








Fig. 3.31 GRP78 and αvβ5 integrin do not interact in HUVECs in co-IP: 
A, GRP78 and αvβ5 integrin do not bind to each other on the surface of HUVECs with 
or without ISM pre-treatment. B, recombinant GRP78 and αvβ5 integrin do not bind to 
each other with or without the presence of ISM. 
 
To confirm there was no interaction between GRP78 and ISM, I performed 
co-immunoprecipitation (co-IP) experiment using plasma membrane fraction of 
HUVECs. The protein A/G agarose beads were mounted with anti-GRP78 antibody. 
Then anti-GRP78 antibody mounted agarose beads were incubated with plasma 
membrane fraction of HUVECs with or without rISM pre-treatment (containing 
GRP78). Proteins pulled down by the beads were analyzed by WB. The result showed 
that GRP78 from the plasma membrane fraction does not interact with αvβ5 integrin 
(Fig. 3.31A). However, GRP78 from the plasma membrane fraction interacts with 
rISM. In addition, the co-IP experiment was repeated using pure recombinant GRP78 
and αvβ5 integrin heterodimer. Similarly, the protein A/G agarose beads were 
mounted with anti-GRP78 antibody. Then anti-GRP78 antibody mounted agarose 
beads were incubated with recombinant GRP78 and αvβ5 integrin with or without the 
presence of rISM. Proteins pulled down by the beads were analyzed by WB. The 
result further confirmed that the pure recombinant GRP78 does not interact with αvβ5 
integrin (Fig. 3.31B). Similarly, recombinant GRP78 can pull down rISM. Therefore, 





3.2.18.2 The discrepancy of cell surface GRP78 and αvβ5 integrin numbers on 
HUVECs 
The number of cell surface GRP78 and αvβ5 integrin molecules in HUVECs were 
also determined using ELISA. Increasing concentrations of pure recombinant GRP78 
and αvβ5 integrin were coated on the surface of 96-well plate respectively. Standard 
curves of protein concentration were generated by ELISA. In the meantime, plasma 
membrane fractions of HUVECs were isolated and coated on the surface of 96-well 
plate. After ELISA, the molecule number of GRP78 and αvβ5 integrin on each 
HUVEC was calculated according to pre-established standard curve. As shown in 
Figure 3.32, there were around 8× more cell-surface GRP78 molecules on each 
HUVEC than αvβ5 integrin molecules. Given previous results that the binding affinity 
between ISM and GRP78 (Fig. 3.16) are 100× higher than the binding affinity 
between ISM and αvβ5 integrin (Fig. 3.14), it was not surprising to observe that the 
PLA signal between ISM and GRP78 was 12-fold stronger than that between ISM and 
αvβ5 integrin (Fig. 3.30). Therefore, GRP78 is the dominant receptor of ISM on ECs.  
 
Fig. 3.32 Quantification of the number of ISM receptors on HUVEC 
Pure recombinant GRP78 and αvβ5 integrin were used to build a standard curve through 
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ELISA. HUVEC plasma membrane fractions were analyzed by ELISA. The number of GRP78 
or αvβ5 integrin receptors on each cell was quantified according to the standard curve. *P<0.05, 
n=4. 
3.2.18.3 GRP78 and αvβ5 integrin distribute distinctly in vivo 
To illustrate whether GRP78 and αvβ5 integrin interact with each other in vivo, I 
further probed the distribution of GRP78 and αvβ5 integrin in tumors after systemic 
ISM treatment by double IHC staining using antibodies against both GRP78 and αvβ5 
integrin. As shown in Figure 3.33, in both ISM-treated and control B16 melanoma and 
4T1 breast carcinoma, GRP78 and αvβ5 integrin presented distinct distribution patterns. 
The quantification showed that there was no significant co-localization between 
GRP78 and αvβ5 integrin in both B16 melanoma and 4T1 breast carcinoma.  
 
Fig. 3.33 GRP78 and αvβ5 integrin present distinct distribution patterns in both B16 
melanoma and 4T1 breast carcinoma: 
Paraffin sections of B16F10 and 4T1 tumors from ISM-treated and control groups were 
double-stained for both GRP78 and αvβ5 integrin through IF using anti-GRP78 (red) and 
anti-αvβ5 integrin (green). Nuclei were counter stained by DAPI (blue). Representative photos 
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are shown. Quantitative measurements of Pearson’s correlation coefficient (Rp) between red 
and green fluorescent labeled channels were indicated in the far-right.  
 
Interestingly, systemically delivered ISM also was detected to be internalized into 
both B16 melanoma and 4T1 breast carcinoma tumor cells (Fig.3.34). And its 
distribution pattern was similar with GRP78 but not αvβ5 integrin. The quantification 
showed systemically delivered ISM co-localized with GRP78 but not αvβ5 integrin 
(Fig.3.34). Taken together, these results indicated that GRP78 and αvβ5 integrin 
function as independent receptors for ISM and each mediates cell death through 
separate signaling pathways with GRP78 serving as the main mediator of ISM-induced 




Fig. 3.34 systemically delivered ISM is co-localized with GRP78, but not with αvβ5 






A, systemically delivered ISM is co-localized with GRP78 in both B16 melanoma and 4T1 
breast carcinoma. B, systemically delivered ISM distributes distinctly with αvβ5 integrin in 
both B16 melanoma and 4T1 breast carcinoma. Paraffin sections of ISM-treated B16 
melanoma or 4T1 breast carcinoma were probed for both GRP78/αvβ5 integrin and ISM 
through IF using anti-His (red) and anti-GRP78 or αvβ5 integrin (green) double staining. 
Nuclei were counter stained by DAPI (blue). Representative photos are shown. Quantitative 
measurements of Pearson’s correlation coefficient (Rp) between red and green fluorescent 





4.1 The prospect of ISM as a therapeutic agent in cancer treatment 
Cancer is a complex and multi-step process. It is the second most common cause of 
death in developed countries and many developing countries. During the process of 
carcinogenesis, cancer cells require neo-vascularization to make rapid tumor growth 
possible by supplying oxygen, nutrients, route for metastasis and removing wastes 
(Carmeliet & Jain, 2000). Hence, tumor angiogenesis is one of the limiting steps in 
tumor progression and metastasis. Selectively inhibiting angiogenesis has become a 
promising strategy in cancer therapy. Comparing to conventional cancer therapies, 
such as chemo-therapy and radiation-therapy, antiangiogenic cancer therapy 
specifically targeting tumor ECs offers the advantage of lower toxicity.  
One of the future directions in antiangiogenic therapy is to identify novel 
therapeutic agents that can selectively target pathogenic angiogenesis without 
influencing quiescent vessels that are essential for tissue maintenance. Endogenous 
angiogenesis inhibitors are capable to inhibit pathological neo-vascularization with no 
adverse impact on the established ones in healthy organs (Noh et al, 2003; Volpert et 
al, 1998). These proteins provide a convenient source to design and develop novel 
antiangiogenic agents with minimal vascular side effects. Therefore, as a recently 
characterized endogenous angiogenic inhibitor, ISM is predicted to be a safe alternate 
antiangiogenic drug for cancer treatment. In addition, the fact that ISM could inhibit 
angiogenesis in the presence of multiple growth factors, including the most dominant 
angiogenic stimulators VEGF and bFGF, strongly suggests that ISM can serve as a 
prototype for developing novel antiangiogenic drugs (Xiang et al, 2011). 
Previous work in our lab has demonstrated that stable overexpression of ISM in 
B16F10 cells suppressed B16 melanoma growth and tumor angiogenesis in mice 
(Xiang et al, 2011). Since genetic overexpression is not applicable in patients with 
advanced cancer, I performed tumor studies with systemic delivery by intravenous 
injection that can be adopted in human clinical settings.  
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In this work, I demonstrated for the first time that systemically delivered 
recombinant ISM is a potent anti-tumor growth agent in both B16 melanoma and 4T1 
breast carcinoma. I showed that systemically delivered rISM significantly suppresses 
tumor vascularization, proliferation and induces apoptosis. Interestingly, systemically 
delivered rISM induces apoptosis of both cancer cells and cancer endothelial cells. 
These results strongly support the therapeutic potential of ISM in cancer therapy. 
4.2 The functional disparity between soluble and immobilized ISM 
In this work, ISM was found to induce different responses from adherent ECs under 
different physical conditions (Zhang et al, 2011). Immobilized ISM can provide 
positive signals that promote HUVECs survival. On the other hand, soluble ISM 
induces HUVECs apoptosis. 
This kind of disparate behavior between soluble and immobilized form of ISM is 
shared among several angiogenesis inhibitors such as endostatin (Rehn et al, 2001) 
and thrombospondin-1 (TSP-1) (Chandrasekaran et al, 2000). While anchored 
endostatin supports EC adhesion and promotes survival, soluble endostatin suppresses 
EC migration and induces apoptosis (Rehn et al, 2001). In the case of TSP-1, the 
soluble form suppresses EC proliferation, migration and inducing apoptosis. In contrast, 
immobilized TSP-1 supports EC adhesion and promotes EC proliferation and 
migration, therefore promoting angiogenesis (Chandrasekaran et al, 2000). However, 
the mechanisms of apoptosis induction may not be the same amongst the different 
proteins.  
How does the same ligand induce opposite signaling pathways in adherent cells 
under different physical conditions? In vivo, both ISM and other angiogenesis 
inhibitors are in immobilized condition in the extracellular matrix in tissues, but in 
soluble condition in the circulation. Although the mechanisms of apoptosis induction 
may be different amongst these angiogenic inhibitors, understanding the mechanisms 
of the differential signal transductions is important not only for fundamental cell 
biology but also how these proteins function as antiangiogenic molecules in vivo. 
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Hence, ISM can serve as a model to study the functional disparity of proteins under 
different physical conditions. 
4.3 Internalization is critical for the antiangiogenic effect of ISM  
The disparate functions of ISM on ECs under different physical conditions may be 
due to one or multiple reasons. One possibility is that only the soluble but not the 
immobilized ISM can be internalized into cells, and only internalized protein can 
induce apoptosis. Indeed, this work demonstrated that only soluble ISM but not the 
immobilized ISM can be endocytosed into cells. Endocytosis is an important cellular 
process to regulate signal transduction and to internalize various cargo molecules, 
which can be roughly classified into clathrin–dependent endocytic pathway and 
clathrin-independent but lipid-raft-mediated route (Le Roy & Wrana, 2005). Using 
specific chemical inhibitors that disrupt distinct endocytic pathways, this work 
showed that soluble ISM can be selectively endocytosed through clathrin-dependent 
pathway. Importantly, this endocytosis is important for the antiangiogenic effect of 
ISM. Once the internalization of ISM was inhibited, the functions of ISM in inhibiting 
EC tube formation and inducing EC apoptosis were hampered.  
These observations effectively explained why soluble and immobilized ISM 
exerted death-promoting and pro-survival effects on EC separately. As a matricellular 
angiogenic inhibitor, this is the first time that ISM is shown to function directly inside 
cells. However, this is not the first report of extracellular angiogenic inhibitor 
functioning through internalization. Besides ISM, endostatin (Chen et al, 2011), 
angiostatin (Lee et al, 2009), thrombospondin-1 (TSP-1) (Mikhailenko et al, 1997; 
Oganesian et al, 2008), RGD peptides (Aguzzi et al, 2004) and P11-a hexapeptide 
(HSDVHK) containing a novel integrin-binding motif SDV (Chen et al, 2011) are all 
efficient angiogenesis inhibitors functioning through endocytosis. For example, 
endostatin is endocytosed through both clathrin-dependent and cavaolae/lipid raft 
dependent pathways (Chen et al, 2011). Enhancement of endostatin uptake into ECs 
increased its antiangiogenic activity. It is not clear where the internalized endostatin is 
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targeted to inside the cell. In addition, another well-known angiogenic inhibitor, 
angiostatin, has been shown to be internalized into ECs and targeted to mitochondria 
where it interacts with ATP synthase and malate dehydrogenase (MDH2), suppressing 
ATP production to induce apoptosis (Lee et al, 2009). Interestingly, angiostatin also 
interacts with cell-surface ATP synthase and the cell-surface ATP synthase partially 
mediates its internalization to mitochondria. 
In combination of all these factors, it seems that specific internalization might be a 
general fundamental process for the antiangiogenic function of angiogenesis 
inhibitors. This work presented new insights on the functional mechanism research of 
novel angiogenesis inhibitors, especially those exerting different action under soluble 
and immobilized status. 
4.4 GRP78: a novel cell surface receptor of ISM 
The ER stress response protein GRP78 has recently emerged as a promising target 
for anticancer therapeutics due to its restricted presence on the cell-surface in stressed 
cancer cells (invasive/metastatic cancers) and proliferating ECs but not in normal cells 
(Ni et al, 2011; Sato et al, 2010; Schwarze & Rangnekar, 2010). This work reported 
that ISM is a novel extracellular ligand of cell-surface GRP78 and ISM-GRP78 
interaction triggers apoptosis in vitro. In addition, the IHC staining of both B16 
melanoma and 4T1 breast carcinoma tumor sections showed that GRP78 is highly 
expressed by both cancer cells and cancer ECs. In the meantime, ISM significantly 
induces apoptosis of both cancer cells and cancer ECs. Hence, ISM-GRP78 
interaction also triggers apoptosis in vivo. The anti-cancer effect of ISM functions 
through two modes of actions: one is through targeting tumor angiogenesis; the other 
one is through directly targeting tumor cells. Therefore, the selective expression of 
cell surface GRP78 makes ISM a unique tumor-specific and dual targeting anticancer 
protein.  
This work also demonstrated that cell-surface GRP78 binds ISM with high affinity 
and mediates ISM internalization into ECs through clathrin-dependent endocytosis in 
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vitro. Consistently, internalized ISM also has been observed in both B16 melanoma 
and 4T1 breast carcinoma tumor sections, which shares similar pattern with GRP78. 
This observation provided in vivo evidence that GRP78 mediates ISM internalization.  
Significantly, the expression level of cell-surface GRP78 determines whether a cell 
is susceptible to ISM-induced apoptosis. Cells that harbor a high level of cell-surface 
GRP78 are susceptible to ISM-induced apoptosis while lack of sufficient cell-surface 
GRP78 renders the cells resistant to ISM-induced apoptosis. While the highly 
metastatic LS-LM6 expresses a high level of cell-surface GRP78 and is very sensitive 
to ISM-induced apoptosis, its non-metastatic parental line LS174T is relatively 
resistant, correlating with its low level of cell-surface GRP78. It is noted that LS-LM6 
cells also express a higher level of αvβ5 integrin, the low-affinity receptor of ISM 
(Yoshioka et al, 2010). αvβ5 integrin may also contribute to its high susceptibility to 
ISM-induced apoptosis.  
4.5 Mitochondrion: the subcellular localization of internalized ISM 
To study the intracellular pathway triggered by ISM internalization, 
immunocytochemistry was used to visualize the subcellular location of endocytosed 
ISM. Interestingly, internalized ISM localizes to mitochondria. In addition, GRP78 
co-targets with ISM to mitochondria, suggesting that GRP78 is the receptor mediating 
ISM translocation from extracellular matrix into intracellular mitochondria.  
Mitochondria play central roles in activating apoptosis in mammalian cells. 
Understanding the downstream events triggered by ISM in mitochondria could shed 
light on the pro-apoptotic mechanism of internalized ISM. To achieve that, the 
binding partners of ISM in mitochondria fraction were pulled down and identified by 
MS. The identified ISM binding partners in mitochondria include conventional 
mitochondrial proteins, such as AAC2 and AAC3, and also unconventional 
mitochondrial proteins such as MYH9, CHC1, GRP78, β-actin, histone H2A, histone 
H2B, and histone H4. 
Interestingly, the MS results of ISM binding partners in the plasma membrane 
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fraction also include MYH9, CHC1 and GRP78. These data further supported that 
GRP78 on the endothelial cell surface associated with CHC1 mediates ISM 
internalization through clathrin-dependent endocytosis and concurrently translocates 
into mitochondria. MYH9, as has been reported involved in endosome trafficking 
(Stasyk et al, 2007), might function as the motor protein moving on actin filament to 
transport its cargo-endosome toward mitochondria.  
In addition, the MS results indicated that ISM may interact with AACs in 
mitochondria. Through co-IP and immunocytochemistry, this work showed that ISM 
indeed interacts with AACs.  
 Mitochondrion is enclosed within two membranes- the outer membrane and the 
inner membrane (Alberts Bruce, 1994). The outer membrane is smooth and allows 
molecules of 5 kDa or less to freely pass through. So the outer membrane is 
completely permeable to ions, nutrient molecules, ADP and ATP. On the contrary, the 
inner membrane is more complex as it contains the ATP synthase complex and the 
complexes of electron transport chain. The inner membrane is only permeable to 
oxygen, carbon dioxide and H2O. As mentioned before, AAC is the major ADP/ATP 
transporter located on the inner membrane of mitochondria catalyzing the exchange of 
ATP produced in the mitochondrial matrix by ATP-synthase against ADP generated by 
energy consuming reactions in cytosol (Fiore et al, 1998). Based on the subcellular 
location of AACs, internalized ISM is not simply associated with mitochondria on the 
outer surface. Instead, ISM is secondarily internalized into mitochondria and at least 
located in the inter-membrane space of mitochondria in order to interact with AACs. 
As a 60 kDa protein, ISM is unable to freely pass through the outer membrane of 
mitochondria. The mechanism of the secondary internalization of ISM into 
mitochondria remains unknown.  
It is interesting that histone family proteins, histone H2A, histone H2B and histone 
H4, are identified as potential binding partners of ISM in mitochondria. Human 
histone family includes 5 members, namely H1, H2A, H2B, H3 and H4 (Bhasin et al, 
2006). They are traditionally regarded as proteins located in nuclei and functioning as 
constructers of nucleosomes, packaging and ordering the DNA into structural units. 
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Histone H2A, H2B, H3 and H4 are the core histones, while histone H1 is known as 
the linker histones. They are the dominant protein components of chromatin, 
functioning as spools around which DNA winds, and contribute to gene 
regulation. However, a recent study has found that histone family members of H1, 
H2A, H2B, H3 and H4 are present in mitochondria (Choi et al, 2011). In particular, 
histones H2A and H2B were found to locate in the mitochondrial outer membrane as 
integral membrane proteins protruding towards the cytoplasm. Histones H1, H3 and 
H4 are associated with the outer mitochondrial membrane. Localization of histones in 
mitochondria is difficult to explain. Until now, their biological functions in 
mitochondria remain unclear. Hence, ISM is the first identified endogenous protein 
interacting with histone H2A, H2B, H4 inside mitochondria.  
4.6 ISM blocks ADP/ATP exchange through interaction with AACs inside 
mitochondria 
We demonstrated in this work that inside mitochondria, ISM at least interacts with 
AACs. Given that AAC is the dominant ADP/ATP exchange gate located on the inner 
membrane of mitochondria (Fiore et al, 1998), internalized ISM was speculated to 
interfere with ADP/ATP transport inside mitochondria. Indeed, cytosolic ATP level 
was reduced more than 50% upon ISM treatment. In contrast, the ATP level in 
mitochondria was increased about 40%. These data suggested that the transport of ATP 
from mitochondrial matrix to cytosol was blocked. In addition, the whole cell ATP 
level also decreased around 60%. Since the ATP synthases need the ADP from the 
cytosol as the material to produce new ATP, blocking the ADP/ATP transport also 
indirectly blocks the ATP synthesis. So there is a remarkable reduction in the whole cell 
ATP level.  
Taken together, inside mitochondria, ISM suppresses cytoplasmic ATP level mainly 
through interacting with AACs and blocking ADP/ATP exchange. ATP production is 
indirectly suppressed due to blockage of ADP import into the mitochondria matrix. 
Given that ATP is critical for cell survival and depletion of them can cause apoptosis 
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(Lieberthal et al, 1998), ISM induced apoptosis may be caused by mitochondrial 
dysfunction. 
4.7 GRP78 and αvβ5 are two independent receptors of ISM 
Previous mechanism study of our lab has shown that ISM selectively binds to 
integrin αvβ5 on the ECs surface (Xiang et al, 2011). Through the interaction with 
integrin αvβ5, ISM induces EC apoptosis through integrin mediated death (IMD) by 
direct recruitment and activation of caspase-8 without generating anoikis (Fig. 4.1) 
(Xiang et al, 2011). In this work, GRP78 was identified as a novel cell surface 
high-affinity receptor of ISM, mediating the internalization of ISM through 
clathrin-dependent endocytosis and concurrently targeting with ISM into 
mitochondria, where ISM interacts with AACs and blocks ADP/ATP transport, thus 




Fig. 4.1 Schematic illustration of the integrin αvβ5 mediated pro-apoptotic function of 
ISM: 
Soluble ISM induces ECs apoptosis through integrin-mediated death (IMD), which directly 
activates caspase-8. Then caspase-8 promotes the activation of caspase-3. ‘?’ represents the 
unresolved question if additional molecules participate in the integrin–caspase-8 complex 
formation. (Adapted from (Xiang et al, 2011)) 
 
So far, at least two cell surface receptors have been identified for ISM: GRP78 and 
αvβ5 integrin. Both mediate the antiangiogenic function of ISM. However, whether 
these two receptors function cooperatively or independently remained unknown. To 
solve this puzzle, the PLA was performed to investigate the direct interaction between 
GRP78 and αvβ5 integrin. As mentioned before, PLA is a powerful method allowing 
visualization of protein-protein interactions in their native state, detection of weak and 




2006). The result showed that there is no detectable interaction between GRP78 and 
αvβ5 integrin, which was further confirmed by co-IP. On the contrary, positive PLA 
signals were evident between ISM and its two receptors respectively. Notably, the 
quantification of PLA signal between ISM and GRP78 was 12-fold stronger than that 
between ISM and αvβ5 integrin. This reflects the presence of 8× more cell-surface 
GRP78 molecules on each HUVEC than αvβ5 integrin molecules plus the 100× higher 
binding affinity between ISM and GRP78 than that between ISM and αvβ5 integrin.  
In addition, the IHC staining of both B16 melanoma and 4T1 breast carcinoma 
tumor section showed that the distribution patterns of GRP78 and αvβ5 integrin were 
distinct. Moreover, internalized ISM was also observed in tumor sections. And it only 
co-localized with GRP78 but not αvβ5 integrin. Furthermore, the triton-partitioning 
experiment showed that the internalized ISM mainly associated with GRP78/CHC1 
but not αvβ5 integrin. Consistently, only overexpression of GRP78 but not αvβ5 
integrin dose-dependently increased the uptake of ISM into cells. Although 
overexpression of GRP78 or αvβ5 integrin both sensitized LS174T cells to 
ISM-induced apoptosis, overexpressed GRP78 were more potent than αvβ5 integrin in 
lanching the apoptotic induction function of ISM.  
Taken together, αvβ5 integrin and GRP78 are two independent receptors mediating 
the antiangiogenic functions of ISM. As an angiogenic inhibitor, ISM induces 
apoptosis at least through two modes of actions. One is through αvβ5 integrin 
mediated cell death. The other one is through GRP78-mediated internalization. 
According to the binding affinity and available receptor number, GRP78 is the 
dominant receptor of ISM on HUVECs.  
Nevertheless, there are still several unknown aspects regarding these two ISM 
functioning pathways. For example, although GRP78 does not directly interact with 
αvβ5 integrin on cell surface, whether their downstream signals cross talk or whether 
one receptor indirectly influences the function of the other one remains unclear. In 
addition, ISM may be involved in additional unknown signaling pathways besides 
αvβ5 integrin-mediated cell death and GRP78-mediated internalization. Future 




 In summary, this work demonstrated a novel ISM-GRP78 ligand-receptor 
signaling pathway that triggers apoptosis specifically in cancer cells and cancer 
ECs by inducing mitochondrial dysfunction (Fig. 4.2). ISM thus has tremendous 
potential as a cancer-specific and dual targeting anticancer agent without 
affecting normal cells.  
 Full-length rISM inhibits B16 melanoma and 4T1 breast carcinoma growth in 
syngeneic mice when delivered systemically. This anti-tumorigenic effect is 
correlated with reduced peri-tumoral vascularization and intra-tumoral 
angiogenesis, decreased tumor cell proliferation and increased tumor cell 
apoptosis. In addition, systemically delivered ISM induces apoptosis of both 
tumor cells and tumor-associated ECs.  
 ISM possesses opposite functions under different physical conditions. While 
soluble ISM induces ECs apoptosis, immobilized ISM provides positive signals 
for cell survival. In vivo, ISM presents in both immobilized condition in the 
extracellular matrix in tissues, and soluble condition in the circulation. 
 Disparate internalization is the reason for the functional disparity between soluble 
and immobilized ISM. Only soluble but not immobilized ISM can be internalized 
into cells through clathrin-dependent endocytosis. And this selective 
internalization is important for the antiangiogenic functions of ISM. 
 GRP78 is identified as a novel high-affinity receptor for ISM (Kd = 8.6 nM), 
mediating ISM internalization into ECs through clathrin-dependent endocytosis. 
 ISM-GRP78 interaction only triggers apoptosis in cultured cells exhibiting high 
level of cell-surface GRP78 such as metastatic/invasive cancer cells and activated 
ECs but not in normal/non-cancer cells which display minimum cell-surface 
GRP78. As cell-surface GRP78 is limited on stressed cells, such as cancer cells 
and cancer ECs, ISM is thus a novel tumor-specific and dual targeting anticancer 
agent. 
 Once inside the cell, ISM co-targets with GRP78 to mitochondria where it 
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interacts with ADP/ATP carriers on the inner membrane and blocks ATP transport 
from mitochondria to cytosol therefore causing apoptosis. Hence, the observed 
ISM-induced apoptosis is through mitochondrial dysfunction. 
 GRP78 and αvβ5 integrin function as independent cell-surface receptors for ISM 
and mediate EC apoptosis through distinct signaling pathways. 
 
 
Fig. 4.2 The functional model of ISM through GRP78-mediated internalization: 
As a secreted protein, ISM interacts with the cell surface receptor- GRP78 and internalized 
through clathrin-dependent endocytosis. Then, the internalized ISM co-targets with GRP78 to 
mitochondria. Inside mitochondria, ISM interacts with AAC and blocks ATP transport from the 
mitochondrial matrix to cytosol, which will eventually lead to apoptosis. However, how ISM 
translocates from endosome into mitochondria remains unclear.  
4.9 Future directions 
This work identified the importance of cell-surface GRP78 as a receptor mediating 
the antiangiogenic and anti-cancer function of ISM. It also opened up the therapeutic 
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potential of ISM as an anticancer drug. The following sections are some of the 
unresolved issues demanding future studies. 
4.9.1 Exploring the therapeutic potential of ISM in cancer therapy 
The potential of ISM to be used as an anticancer drug was demonstrated for the 
first time in this work. Systemically delivered rISM is a potent anti-tumor growth 
agent in both B16 melanoma and 4T1 breast carcinoma. Systemically delivered rISM 
significantly suppresses tumor vascularization, proliferation and induces apoptosis. 
Interestingly, rISM induces apoptosis of both cancer cells and cancer endothelial cells. 
However, in these experiments, rISM was applied at the same day of tumor cells 
inoculation. This is different from the clinical reality that most cancer patients are 
only given anticancer drugs after cancer is diagnosed and are already well formed. To 
better evaluate the anti-cancer growth effect of ISM, these experiments need to be 
repeated by applying rISM systemically through tail vein injection when tumor 
nodules are pre-established.  
In addition, the anti-cancer growth effect of systemically delivered rISM has only 
been investigated in B16 melanoma and 4T1 breast carcinoma. Given that tumors are 
highly heterogeneous and the mechanisms for tumor growth are variable in tumors 
from different tissue origins, other tumor types should also be tested to determine the 
therapeutic potential of ISM in cancer treatment.  
Moreover, although full length ISM functions as a potent anti-cancer protein when 
delivered systemically, based on the molecular size of 60 kDa, to make ISM protein 
into a drug will be expensive. Future investigation is required to narrow down the 
functioning domains of ISM important for anti-angiogenesis and anti-tumorigenesis. 
Based on the functional domains, cost-effective ISM-derived functional peptide for 
anticancer therapy can be developed.  
4.9.2 Utilizing ISM for GRP78 targeting 
This work also demonstrated that ISM targets cell-surface GRP78 with high affinity 
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both in vitro and in vivo. Significantly, the level of cell-surface GRP78 determines 
whether a cell is susceptible to ISM-induced apoptosis. Cells that possess a high level 
of cell-surface GRP78 are sensitive to ISM-induced apoptosis while lack of sufficient 
cell-surface GRP78 renders the cells insusceptible to ISM-induced apoptosis. Given 
that cell surface GRP78 is restricted to presence in stressed cancer cells 
(invasive/metastatic cancers) and proliferating ECs but not in normal cells (Ni et al, 
2011; Sato et al, 2010; Schwarze & Rangnekar, 2010), GRP78 is an appealing target 
for cancer therapy. Therefore, ISM serves as a unique tumor-specific protein through 
targeting tumor cell surface GRP78.  
In the future, a comprehensive study of the expression level of GRP78 on the 
surface of different cancer cells can be carried out. The identified tumors which 
possess high level of cell surface GRP78 may be sensitive to ISM-induced apoptosis. 
We can test the anticancer therapeutic potential of ISM in these tumor types.  
Meanwhile, the binding site of GRP78 on ISM remains unknown. In the future, 
through domain deletion and site-directed mutation, we can narrow down the binding 
region of GRP78 on ISM, which will provide important information for designing 
functioning peptides of ISM. These peptides may possess therapeutic potentials, such 
as serving as GRP78-targeting peptides and functioning as antiangiogenic or 
anti-tumorigenic molecules.  
Cell-surface GRP78 serves as a receptor for several extracellular ligands including 
Par-4, Kringle 5 of human plasminogen, and activated α2-macroglobulin (α2M*). 
While Par-4 and Kringle 5 (K5) both trigger apoptosis through GRP78, α2M*-GRP78 
interaction leads to enhancement of cell survival and promotion of cell proliferation (Ni 
et al, 2011). Similar to ISM, K5 also induced apoptosis in both ECs and cancer cells that 
present a high level of cell-surface GRP78 (Davidson et al, 2005). However, while K5 
only induced significant apoptosis in cultured cancer cells such as B16F10 under 
hypoxia, ISM induced cancer cell apoptosis under normaxia. In the case of Par-4, it 
induces apoptosis both intracellularly and extracellularly. Extracellular Par-4 binds to 
cell-surface GRP78 and induces apoptosis via TRAIL (Burikhanov et al, 2009). Similar 
to K5 and Par-4, antibody targeting the N-terminal but not C-terminal region of GRP78 
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blocked ISM’s antiangiogenic/proapoptotic function (Burikhanov et al, 2009; 
Davidson et al, 2005). It seems that these three extracellular pro-apoptotic factors all 
function through interacting with N-terminal region of GRP78. Therefore, the 
N-terminal region of GRP78 could be an appealing target for developing novel cancer 
targeting agents.  
In future, the N-terminal region of GRP78 can served as a bait to screen candidate 
chemical compounds, peptides and proteins for pharmaceutical development of novel 
anti-cancer drugs.  
In addition, as GRP78 is one of the reasons conferring cancer resistance to 
anti-cancer treatment (Dong et al, 2005; Li & Lee, 2006), in future, combinatorial 
strategies including both ISM or ISM-derived functional peptides as the compounds 
against GRP78, plus traditional anti-cancer chemotherapy drugs can be used to 
eradicate tumors. These treatments will possess enhanced efficacy through 
eliminating drug resistance and reducing toxicity. 
4.9.3 How is ISM targeted to mitochondrion? 
This work showed that cell surface GRP78 mediates the internalization of ISM and 
co-targets with ISM to mitochondria. However, further investigations are required to 
deduce the mechanisms involved in this process. ISM is not the first extracellular 
protein that has been reported to be targeted to mitochondria. Angiostatin can also be 
internalized into cells and translocated into mitochondria (Lee et al, 2009). But how 
these proteins are translocated from endosome into mitochondria is still a biological 
puzzle. In the future, ISM may serve as a model to study this endosome to 
mitochondrion pathway.  
Inside mitochondria, ISM interacts with AACs. Based on the subcellular location 
of AACs, internalized ISM is secondarily internalized into mitochondria and at least 
located in the inter-membrane space of mitochondria. Mitochondrion is a double 
membrane organelle, with its outer membrane prohibit freely transport of molecules 
greater than 5 kDa.  How ISM gets into mitochondria remains unknown. In addition, 
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ISM may interact with histone H2A, histone H2B and histone H4 in mitochondria, 
which were recently reported to be in mitochondrion (Choi et al, 2011).  
Interestingly, Elana Hariton-Gazal and her colleagues have shown that histones are 
able to directly transverse cell plasma membranes using an energy- or endocytosis- 
independent process, and mediate internalization of macromolecules covalently 
attached to them (Hariton-Gazal et al, 2003). Among different histones, H2A and H4 
have the strongest ability to penetrate cell plasma membrane. They have also 
proposed the possibility of using histones as carriers of a delivery system.  
In addition, histones are rich in basic amino acids and are relatively small proteins 
(less than 14 kDa), sharing similar features with signal sequences of mitochondrial 
proteins. Moreover, just like histones, amphiphilic mitochondrial signal peptides 
translocate without consuming energy and reside in the inner membrane or contact 
site between outer and inner membranes (Pak & Weiner, 1990).  
Whether histones H2A, H2B and H4 play any roles in mediating the penetration of 
ISM into mitochondria need to be investigated. In the meantime, as the first identified 
endogenous protein interacting with histone H2A, H2B and H4 in mitochondria, ISM 
may also serve as a key tool to unravel the biological functions of histones in 
mitochondria.  
4.9.4 Does ISM influence other functions in mitochondria? 
This work demonstrated that, inside mitochondria, ISM blocks ATP release from 
mitochondrial matrix to cytosol. Given that ATP is critical for cell survival and 
depletion of them can cause apoptosis (Lieberthal et al, 1998), ISM induced apoptosis 
may be caused by mitochondrial dysfunction. 
However, although AAC mediates the 1 to 1 exchange of cytosolic produced ADP 
against ATP generated in mitochondrial matrix (Fiore et al, 1998), this work only 
tested the ATP level in different cellular fractions. To further confirm the function of 
ISM in blocking ADP/ATP transport through interacting with AACs, future 
experiment is required to determine the ADP level in whole cell lysate, cytosolic 
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fraction with mitochondria removed and mitochondrial fraction of ISM-treated 
HUVECs and in those of control HUVECs. 
In addition, blocking ADP/ATP exchange may not be the sole mechanism of 
ISM-induced apoptosis in mitochondria. Apoptosis is mainly triggered through two 
signalling pathways: the intrinsic pathway and the extrinsic pathway (Fig. 4.3) 
(Chalah & Khosravi-Far, 2008). As its name suggests, the intrinsic pathway, also 
known as the mitochondrial pathway owing to its essential involvement of 
mitochondria, is initiated within the cells. This process responds to signals resulting 
from severe cellular stresses, such as DNA damage, UV radiation, the action of some 
tumor suppressor genes and most chemotherapeutic drugs (Kroemer, 2003). These 
signals are transduced into mitochondria and lead to alterations of Bcl-2 family 
members, which regulate apoptosis by controlling mitochondrial permeability in the 
mitochondrial outer membrane (Esposti et al, 2003; Green & Kroemer, 2004; 
Zamzami & Kroemer, 2001). These changes ultimately increase the permeability of 
the mitochondrial outer membrane, which enables the pro-apoptotic factors residing 
inside mitochondria to escape and diffuse into the cytosol (Chalah & Khosravi-Far, 
2008). One of those pro-apoptotic factors, cytochrome C, is regarded as a key 
regulator of apoptosis. Once it is released from mitochondrial inter-membrane space 
into cytosol, the cell is irreversibly committed to cell death (Green & Evan, 2002; 
Zhivotovsky et al, 1998). In cytosol, released cytochrome C activates apoptosis 
protease activating factor-1 (Apaf-1) and initiates subsequent formation of 
apoptosome (Arnoult et al, 2003). Then apoptosome recruits and facilitates the 
autocatalytic activation of procaspase-9. The activated caspase-9 leads to the 
activation of the effector caspases (i.e., caspase-3), which will eventually terminate 
the cell.  
The extrinsic pathway is initiated through death receptor activation by 
pro-apoptotic ligands (Adams, 2003). Then the activated receptors lead to the 
activation of caspase-8, which in turn activates caspase-3. In the meantime, activated 
caspase-8 also can promote the cleavage of Bid, which induces changes in the 
mitochondrial outer membrane and leads to the release of apoptogenic factors, thus 
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switching on the mitochondrial pathway (Chalah & Khosravi-Far, 2008). Therefore, 
the mitochondrial pathway of apoptosis can also be triggered by extracellular 
pro-apoptotic ligands. 
 
Fig. 4.3 Schematic representation of the intrinsic and extrinsic pathways of apoptosis. 
(Adopted from (MacFarlane & Williams, 2004)) 
 
This work showed that ISM is a pro-apoptotic ligand, which promotes apoptosis 
through cell surface receptor GRP78. So ISM might induce apoptosis through the 
extrinsic pathway. Indeed, previous work in our lab has shown that ISM promotes the 
activation of caspase-8 and caspase-3 (Zhang et al, 2011). In addition, this work also 
indicated that mitochondria are involved in the ISM-induced apoptosis. Therefore, 
ISM may also induce apoptosis through the mitochondrial pathway. However, in this 
work, I only tested the influence of ISM on the ADP/ATP transport. The effect of ISM 
on the traditionally mitochondrial pathway remains unclear. Future work can involve 
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the determination of the influence of ISM on the mitochondrial apoptosis pathway 
such as the cleaved form of Bid, the potential and permeability of the mitochondrial 
outer membrane and the release of cytochrome C from the inter-membrane space of 
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